

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

A patient-derived T cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

This is the author's manuscript

Original Citation:

Availability:

This version is available <http://hdl.handle.net/2318/2078433> since 2025-06-03T11:46:37Z

Published version:

DOI:10.1016/j.xcrm.2025.102029

Terms of use:

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Cell Reports Medicine

A patient-derived T-cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities

--Manuscript Draft--

Manuscript Number:	CR-MEDICINE-D-24-02688R4
Full Title:	A patient-derived T-cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities
Article Type:	Research Article
Keywords:	T-cell lymphoma, Patient-derived-Tumor-Xenografts, clonal evolution, stratification, microenvironment, repository
Corresponding Author:	Giorgio G. A. Inghirami Weill Cornell Medicine New y, UNITED STATES
First Author:	Giorgio G. A. Inghirami
Order of Authors:	Giorgio G. A. Inghirami
	Danilo Fiore
	Luca Vincenzo Cappelli
	Liu Zhaoqi
	Nikita Kotlov
	Maria Sorokina
	Jude Phillip
	Paul Zumbo
	Liron Yoffe
	Paola Ghione
	Anqi Wang
	Xueshuai Han
	Abigail Taylor
	William Chiu
	Valentina Fragliasso
	Fabrizio Tabbo
	Nahuel Zamponi
	Nicolás Di Siervi
	Clarisse Kayembe
	Giovanni Medico
	Ruchi P Patel
	Marcello Gaudiano
	Rodolfo Machiorlatti
	Giuseppina Astone
	Maria Teresa Cacciapuoti
	Giorgia Zanetti
	Claudia Pignataro

Ruiz Arvin Eric
Sanjay Patel
Francesca Zammarchi
Claudio Zanettini
Lucio Queiroz
Anastasia Nikitina
Olga Kudryashova
Anton Karelin
Daniil Nikitin
Dmitry Tychinin
Ekaterina Postovalova
Alexander Bagaev
Viktor Svekolkina
Ekaterina Belova
Katerina Tikhonova
Sandrine Degryse
Chengqi Xu
Domenico Novero
Maurilio Ponzoni
Enrico Tiacchi
Brunangelo Falini
Joo Song
Inna Khodos
Elisa De Stanchina
Gabriele Macari
Luciana Cafforio
Simone Gardini
Roberto Piva
Enzo Medico
Samuel Y Ng
Allison Moskowitz
Zachary Epstein
Andrew Intlekofer
Dogan Ahmed
Wing C. Chan
Peter Martin
Jia Ruan
Francesco Bertoni
Robin Foà
Joshua D. Brody
David M. Weinstock

	Jaspreet Osan
	Laura Santambrogio
	Oliver Elemento
	Doron Betel
	Wayne Tam
	Marco Ruella
	Leandro Cerchietti
	Raul Rabadan
	Steven Horwitz
Abstract:	Peripheral T-cell lymphomas (PTCL) comprise heterogeneous malignancies with limited therapeutic options. To uncover targetable vulnerabilities, we generate a collection of PTCL patient-derived-tumor-xenografts (PDX) retaining histomorphology and molecular donor-tumor features over serial xeno-grafting. PDX demonstrates remarkable heterogeneity, complex intra-tumor architecture, and stepwise trajectories mimicking primary evolutions. Combining functional transcriptional stratification and multiparametric imaging, we identify four distinct PTCL microenvironment subtypes with prognostic value. Mechanistically, we discover a subset of PTCL expressing Epstein-Barr Virus-specific T-cell receptors and uncover the capacity of cancer-associated fibroblasts of counteracting treatments. PDX' pre-clinical testing captures individual vulnerabilities, mirrors donor patients' clinical responses, and defines effective patient-tailored treatments. Ultimately, we assess the efficacy of CD5KO-CART and CD30-CART, demonstrating their therapeutic potential and the synergistic role of immune checkpoint inhibitors for PTCL treatment. This repository represents a resource for discovering and validating intrinsic and extrinsic factors and improving the selection of drugs/combinations and immune-based therapies.
Suggested Reviewers:	Philippe Gaulard philippe.gaulard@aphp.fr Salvia Jain Salvia.Jain@mgh.harvard.edu Larry Kwak lkwak@coh.org
Opposed Reviewers:	Roberto Chiarle roberto.chiarle@childrens.harvard.edu There is conflict of interest Wei-Li Zhao zhaoweili@fudan.edu.cn There is conflict of interest Francisco Vega Vazquez FVega@mdanderson.org There is conflict of interest
Additional Information:	
Question	Response
Clinical trials Does your manuscript report clinical trial results?	No
Standardized datasets A list of datatypes considered standardized under Cell Press policy is available here . Does this manuscript	Yes

report new standardized datasets?	
Original code Does this manuscript report original computer code, algorithms, or computational models?	Yes
Reviewers must have free and anonymous access to these standardized datasets. Please provide dataset locations and instructions for access here. If applicable, include accession numbers and reviewer tokens. If you don't specify access information, your manuscript will not be sent to reviewers. Please consult these guides for more information: " Standardized datatypes, datatype-specific repositories, and general-purpose repositories recommended by Cell Press " and " How standardized datasets and original code accompany Cell Press manuscripts from submission through publication ." Email us at cr-medicine@cell.com if you have any questions. as follow-up to " Standardized datasets A list of datatypes considered standardized under Cell Press policy is available here . Does this manuscript report new standardized datasets? "	Raw Data Files from RNA-seq - SRA: PRJNA1214670 Raw Data Files from WES - SRA: PRJNA1198080 Raw Data Files from scRNASeq - SRA: PRJNA1218277
Reviewers must have free and anonymous access to original code, algorithms, and computational models that underlie this work. Please provide a code location and instructions for access below. Without access information, your manuscript cannot be sent to reviewers. Access must not require that users provide any personal information, including personal logins or passwords. Please consult this guide for more information: " How standardized datasets and original code accompany Cell Press manuscripts from submission through publication ." Email us at cr-medicine@cell.com if you have any questions. as follow-up to " Original code	https://doi.org/10.5281/zenodo.14847458 https://doi.org/10.5281/zenodo.14845644

Does this manuscript report original
computer code, algorithms, or
computational models?
"



Weill Cornell
Medicine

NewYork-Presbyterian
The University Hospital of Columbia and Cornell

New York, February 16th, 2025

Ms Subhasri T S
Acceptance Coordinator
Cell Reports Medicine
London, UK

Dr. Elisa Panada
Scientific Editor
Cell Reports Medicine
London, UK

Dear Ms Subhasri & Dr. Panada,

This is to introduce the resubmission after pre-acceptance of our paper entitled "A patient-derived T-cell lymphoma biorepository uncovers new pathogenetic mechanisms and host-related therapeutic vulnerabilities", as an original article to Cell Reports Medicine.

In the current version, we modified the draft to follow the recommendations included in your last email.

Thank you for this opportunity.

Respectfully yours,

A handwritten signature in black ink, appearing to read "G. Inghirami".

Giorgio Inghirami, M.D.



**Weill Cornell
Medicine**

NewYork-Presbyterian
The University Hospital of Columbia and Cornell

New York, February 12th, 2025

Ms Subhasri T S
Acceptance Coordinator
Cell Reports Medicine
London, UK

Dr. Elisa Panada
Scientific Editor
Cell Reports Medicine
London, UK

Dear Ms Subhasri & Dr. Panada,

This is to introduce the resubmission after pre-acceptance of our paper entitled “A patient-derived T-cell lymphoma biorepository uncovers new pathogenetic mechanisms and host-related therapeutic vulnerabilities”, as an original article to Cell Reports Medicine.

In the current version, we modified the draft to follow the recommendations included in your last email I received on January 31st, 2025.

In detail, here below the list of the main changes:

- **Cover Submissions:** we are still working with art department.
- **Publication Requirements:** we added email for the Lead Contact on the title page and removed the Highlights from the main text file. We uploaded it as a separate word file.
- **Length restriction:** the revised version of the manuscript is 8094 words. We worked hard to meet the goal, as we strongly reduced the text count of more than 2000 words. We wonder if the little excess can be justified by the long list of co-authors and relative affiliations (accounting for 814 words in total).
- **Data and Code Availability paragraph:** it is now structured and filled with the info requested. All the sequencing data (SRA: PRJNA1214670, PRJNA1198080, PRJNA1218277) and code (<https://doi.org/10.5281/zenodo.14847458>, <https://doi.org/10.5281/zenodo.14845644>) are publicly available and referenced in the KRT.
- **KRT:** only one version within the manuscript file.
- **Inclusion and diversity statement and form:** removed.
- **About the EGAS00001001296:** data is available at the link: <https://ega-archive.org/datasets/EGAD00001001411> upon request.
- **Minor changes** have been implemented as requested (please see manuscript).

Thank you for this opportunity.

Respectfully yours,

Giorgio Inghirami, M.D.



**Weill Cornell
Medicine**

NewYork-Presbyterian
The University Hospital of Columbia and Cornell

New York, January 24th, 2025

Dr. Elisa Panada
Scientific Editor
Cell Reports Medicine
London, UK

Dear Dr. Elisa Panada,

This is to introduce the resubmission after pre-acceptance of our paper entitled “A patient-derived T-cell lymphoma biorepository uncovers new pathogenetic mechanisms and host-related therapeutic vulnerabilities”, as an original article to Cell Reports Medicine.

We would like to thank you for this opportunity and for providing us with extended revision time. We apologize for the delay in finalizing the resubmission, but we faced multiple issues in uploading raw sequencing data on publicly databases that required long time to be solved.

Thank you again for this opportunity.

Respectfully yours,

A handwritten signature in black ink, appearing to read "G. Inghirami".

Giorgio Inghirami, M.D.

Reviewers' Comments:

Reviewer #1:

Thank you for your detailed response to the my comments. I appreciate the extensive work and significant effort that has gone into enhancing your manuscript, and this response has addressed some of my previous concerns. Although the use of PDX in the article is still far from clinical translation, the paper nevertheless provides us with guidance.

We thank the reviewer for appreciating the last revised version of the manuscript. We recognize that the PDX usage we described is still far from clinical translation as now stated in the "Limitations" section of the manuscript.

Reviewer #2:

The authors have addressed my previous questions, and no further revisions are needed. However, the relevance of immunotherapy in human and PDX models should be further investigated. While this may not be essential for the current paper, it is worth considering.

Editors: please, address these concerns in the "Limitations of the study".

We thank the reviewer for providing positive feedback on the last version of our manuscript. Nevertheless, we share the needs of further study immunotherapy in human and PDX models as now indicated in the "Limitations" section of the manuscript (following the Editors suggestion). We are currently exploring the potential of alternative mouse models, including humanized animals to better dissect the interactions between the immune environment and lymphoma cells. We hope that this data will be submitted shortly as a dedicated study.

We are sorry for the delay in submitting the revised manuscript. We unfortunately experienced significant difficulties in depositing our raw sequencing data on publicly available databases.

A patient-derived T-cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

Danilo Fiore^{1,2,3,44}, Luca Vincenzo Cappelli^{1,4,44}, Liu Zhaoqi^{5,6,7}, Nikita Kotlov⁸, Maria Sorokina⁸, Jude Phillip^{9,10}, Paul Zumbo^{11,12}, Liron Yoffe^{1,13}, Paola Ghione¹⁴, Anqi Wang⁵, Xueshuai Han^{5,6,7}, Abigail Taylor¹, William Chiu¹, Valentina Fragliasso^{1,15}, Fabrizio Tabbo^{1,16}, Nahuel Zamponi⁹, Nicolás Di Siervi⁹, Clarisse Kayembe¹, Giovanni Medico¹, Ruchi P Patel^{17,18}, Marcello Gaudiano¹, Rodolfo Marchioratti¹⁹, Giuseppina Astone¹, Maria Teresa Cacciapuoti¹, Giorgia Zanetti¹, Claudia Pignataro², Ruiz Arvin Eric¹, Sanjay Patel¹, Francesca Zammarchi²⁰, Claudio Zanettini¹, Lucio Queiroz¹, Anastasia Nikitina⁸, Olga Kudryashova⁸, Anton Karelin⁸, Daniil Nikitin⁸, Dmitry Tychinin⁸, Ekaterina Postovalova⁸, Alexander Bagaev⁸, Viktor Svekolkina⁸, Ekaterina Belova⁸, Katerina Tikhonova⁸, Sandrine Degryse⁸, Chengqi Xu¹³, Domenico Novero²¹, Maurilio Ponzoni²², Enrico Tiacci²³, Brunangelo Falini²³, Joo Song²⁴, Inna Khodos²⁵, Elisa De Stanchina²⁵, Gabriele Macari²⁶, Luciana Cafforio²⁶, Simone Gardini²⁶, Roberto Piva^{27,28}, Enzo Medico²⁹, Samuel Y Ng^{30,31}, Allison Moskowitz¹⁴, Zachary Epstein¹⁴, Andrew Intlekofer¹⁴, Dogan Ahmed³³, Wing C. Chan²⁴, Peter Martin³³, Jia Ruan³³, Francesco Bertoni^{34,35}, Robin Foà⁴, Joshua D. Brody^{36,37,38,39}, David M. Weinstock⁴⁰, Jaspreet Osan⁴¹, Laura Santambrogio⁴¹, Oliver Elemento¹³, Doron Betel^{9,11,12}, Wayne Tam^{1,42}, Marco Ruella^{17,18,43}, Leandro Cerchietti⁹, Raul Rabadan⁵, Steven Horwitz¹⁴, Giorgio Inghirami^{1*}

¹Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA.

²Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.

³Institute for Experimental Endocrinology and Oncology, "G.Salvatore" IEOS, Consiglio Nazionale delle Ricerche (CNR), 80131 Naples, Italy.

⁴Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

⁵Program for Mathematical Genomics, Department of Systems Biology, Department of Biomedical Informatics, Columbia University, New York, NY 10027 USA.

⁶Chinese Academy of Sciences Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.

⁷University of Chinese Academy of Sciences, Beijing 100049, China.

⁸BostonGene Corporation, Waltham, Massachusetts, 02453, USA.

⁹Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, 10065 US.

¹⁰Chemical and Biomolecular Engineering, Oncology, Sidney Kimmel Comprehensive Cancer Center, Core Member, Institute for Nanobiotechnology (INBT), Whiting School of Engineering, Johns Hopkins University, MD 21218, USA.

¹¹Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, 10065, USA.

¹²Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, 10065, US.

¹³Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA.

¹⁴Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

¹⁵Laboratory of translational research, Azienda USL – IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

- ¹⁶SC Oncologia ASL CN2 Alba Bra Ospedale Michele e Pietro Ferrero - 12060 Verduno (CN), Italy.
- ¹⁷Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA 19104, USA.
- ¹⁸Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.
- ¹⁹Department of Pathology, Center for Experimental Research and Medical Studies, University of Torino, 10126 Torino, Italy.
- ²⁰ADC Therapeutics (UK) Limited, London, W12 0BZ United Kingdom.
- ²¹Division of Pathological Anatomy, Quality and Safety of Diagnosis and Treatment, Città della Salute e della Scienza, 10126 Turin, Italy.
- ²²Pathology Unit, San Raffaele Scientific Institute, Milan, Italy; Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, 20132, Milan, Italy.
- ²³Institute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, 06156 Italy.
- ²⁴Department of Pathology, City of Hope Medical Center, Duarte CA, 91010, US.
- ²⁵Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, US.
- ²⁶GenomeUp S.r.l., 00144 Rome RM, Italy.
- ²⁷Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy.
- ²⁸Medical Genetics Unit, Città della Salute e della Scienza University Hospital, 10126 Turin, Italy.
- ²⁹Department of Oncology, University of Torino, Candiolo, TO, Italy; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, TO, Italy.
- ³⁰Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
- ³¹National Cancer Institute, Bethesda, MD 20892, USA.
- ³²Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
- ³³Lymphoma Service, Weill Cornell Medical Center, New York, NY 10065, USA.
- ³⁴Lymphoma Genomics, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland.
- ³⁵Oncology Institute of Southern Switzerland, EOC, 6500 Bellinzona, Switzerland.
- ³⁶Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, US.
- ³⁷Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- ³⁸Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- ³⁹Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- ⁴⁰Merck Research Laboratories, Boston, MA 02115, USA.
- ⁴¹Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
- ⁴²Division of Hematopathology, Northwell Health, New York, NY 11740, USA.
- ⁴³Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.

⁴⁴D. Fiore and L.V. Cappelli contributed equally to this article.

*Corresponding Author: ggi9001@med.cornell.edu

Lead contact: ggi9001@med.cornell.edu

Keywords

T-cell lymphoma, Patient-derived-Tumor-Xenografts, clonal evolution, stratification, microenvironment, repository

Summary

Peripheral T-cell lymphomas (PTCL) comprise heterogeneous malignancies with limited therapeutic options. To uncover targetable vulnerabilities, we generate a collection of PTCL patient-derived-tumor-xenografts (PDX) retaining histomorphology and molecular donor-tumor features over serial xeno-grafting. PDX demonstrates remarkable heterogeneity, complex intra-tumor architecture, and stepwise trajectories mimicking primary evolutions. Combining functional transcriptional stratification and multiparametric imaging, we identify four distinct PTCL microenvironment subtypes with prognostic value. Mechanistically, we discover a subset of PTCL expressing Epstein-Barr Virus-specific T-cell receptors and uncover the capacity of cancer-associated fibroblasts of counteracting treatments. PDX' pre-clinical testing captures individual vulnerabilities, mirrors donor patients' clinical responses, and defines effective patient-tailored treatments. Ultimately, we assess the efficacy of CD5KO-CART and CD30-CART, demonstrating their therapeutic potential and the synergistic role of immune checkpoint inhibitors for PTCL treatment. This repository represents a resource for discovering and validating intrinsic and extrinsic factors and improving the selection of drugs/combinations and immune-based therapies.

Introduction

In 2023, a total of 80,550 cases of lymphomas were diagnosed in the USA, with a staggering number of 20,180 deaths (<https://seer.cancer.gov/statfacts/html/nhl.html>). Peripheral T-cell lymphomas (PTCL), represent ~15% of all lymphomas and comprise >30 different entities^{1,2}. PTCL patients display a remarkable clinical heterogeneity, with a 5-year overall survival (OS) ranging from 14% [(Adult T-cell Leukemia-Lymphoma (ATLL)] to 70% [(ALK⁺ Anaplastic Large Cell Lymphoma (ALCL)]³. Regrettably, chemotherapies (including anthracycline-containing regimens) have limited efficacy, and relapsed/refractory PTCL experience a short overall survival (~6 months)⁴, calling for effective agents and/or combinations⁵. Improvements in PTCL classification, predictive biomarkers identification, and targeted agent development remain unmet medical needs⁶.

In recent years, multiple drugs were approved, and several are in clinical trials. Nevertheless, response rates remain disappointing (25-29%), with progression-free survival (PFS) <4 months⁶⁻⁸.

This is mainly due to PTCL heterogeneity and rarity, as well as to the lack of informative models (only a few PTCL cell lines mainly corresponding to ATLL and ALCL subsets). Cell lines are unable to fully recapitulate the biology and therapeutic responsiveness of human cancers⁹⁻¹¹. Many of these limitations are shared by transgenic mice, including a few PTCL models¹²⁻¹⁶.

Patient-derived tumor xenografts (PDX) can provide critical insight into overcoming treatment resistance, identifying targetable liabilities¹⁷⁻²² and microenvironment stimuli²³⁻²⁵ and enabling pre-clinical trials^{26,27}. Despite limitations²⁸⁻³¹, PDX are considered among the most informative tools to model human cancers^{26,27,32,33}. However, lymphoma PDX remain poorly represented^{17,34-37}.

Here, we describe an extensive library of PDX corresponding to different PTCL entities. We show that these models (i) faithfully recapitulate the biological features and driver defects of their matched donor neoplasms; (ii) allow the recognition of causative genetic defects and suitable dependencies; (iii) underline the lymphoma-host dependencies and host-related refractory mechanisms, and (iv) represent informative platforms to test established/innovative and cell-based therapeutic strategies. This repository will foster scientific discoveries and the development of therapeutic regimens tailored to molecularly defined subgroups, advancing personalized approaches for PTCL patients.

Results

Establishing a living PTCL PDX biorepository

We implanted 308 PTCL from fresh or cryopreserved samples, yielding 102 patient-derived tumor models comprising 88 PDX and 14 PDX-Derived lines (PDX-Dlines; Figure 1A-1B, Table S1) and 3,283 PDX cryopreserved seed samples (median passage: T4).

The biorepository represents the most common PTCL subtypes (Figure 1A). Higher engraftment rates were seen in relapsed/refractory PTCL (r/r - 62%, naïve – 38%), with a 36% engraftment rate on average for the most common T/NK entities (PTCL-NOS, AITL, ALCL). Also, rates were not linked to other parameters (Table S1). Rare entities engrafted less efficiently (Table S1, <15%) except MEITL (Figure 1C-D). We also generated six PDX from two longitudinal samples of the same patient. The engraftment time ranged from 3 weeks to 10 months (Figures 1E and S1A-H), remaining relatively stable along serial passages, except for AITL, which displayed progressively longer times over serial transfers (Figure S1B). Tumors implanted subcutaneously seldom homed to distant tissues (lungs, liver, and/or spleen), sometimes without a concomitant expansion at the implantation site (Figure 1F-G, and S1I). Seventy-three of 88 models propagated ≥ 2 serial passages without EBV+ lymphoblastoid CD19+ B-cells (EBV-LCLs). Some EBV+ LCLs (1 to 90%) were detected (30 cases), primarily angioimmunoblastic T-cell lymphoma (AITL, n=10) (Table S1), and prominent expansions (>90%) were also seen (18 samples, 17% of all engraftments). EBV+ LCLs were present intratumorally, in visceral tissues (i.e., kidney, spleen, liver, and lung) and, in most cases, expanded over serial passages (Figure 1H and Figure S1J). EBV+ PDX and samples with no lymphoma expansion (6-9 months from injection) were failures (Figure S1J). Aiming to eradicate EBV+ LCLs, we treated six EBV+ PDX with the anti-CD19 drug-conjugated loncastuximab tesirine (ADCT-402)³⁸. The antibody successfully eradicated B-cells, but only one PDX was established and serially propagated (IL129A AITL PDX, Figure 1H, and Figure S1K-L). Similar data were obtained by treating EBV+ PDX in complement-proficient (Hc1) mice with rituximab (data not shown).

Lastly, we established fourteen continuous PDX-Dlines using cytokine-supplemented media (with/without IL2 and IL15) or murine cancer-associated fibroblasts (CAFs; Figure 1I, Table S1).

PDX maintain the immunophenotypic and TCR clonotype profiles of primary PTCLs

PTCL PDX histologically/cytologically resembled their matched donor samples (Figure 2A and S2A). In 29 cases, mostly AITL PDX, normal T- and B-cells (or EBV+ LCLs) were co-mingled with neoplastic elements, particularly in early passages (Figure 2B-C). PDX lineage fidelity and individual phenotypes were preserved, as demonstrated by immunohistochemistry and immunophenotyping (Figure 2D and S2B). Gene rearrangement analysis demonstrated that PDX and matched primaries share identical TCR DNA rearrangements (Table S1, S2; Figure 2E and S2C-D). By total RNAseq, primary and PDX displayed a rich TCR clonotype representation (Figure S2E-F). Explicit α and/or β TCR lymphoma clonotypes (>5% of the TCR) were documented in ~50% of primary samples, with a higher clonal representation in PDX (Figure 2E and S2E-G).

Since antigen-driven TCR engagement facilitates cell growth and treatment resistance³⁹, we assessed the TCR usage and antigen specificity (<https://vdjdb.cdr3.net/>). We observed a relative overrepresentation of selected VDJ (TRA-V29DV5, V9-2, and V13-1), particularly in EBV+ AITL (Figure S2H). Notably, EBV transcripts were identified (Figure 2F), corresponding to both lytic and latent

genes (Figure S2I) and, seldom, to HTLV-1 and HHV6 transcripts (Figure S2J)⁴⁰. Remarkably, individual primary/PDX displayed dominant TCR clones expressing canonical or mismatched TCR CDR3 motifs known to bind EBV peptides (Figure 2G, Figure S2K-L, Table S2). To extend this prediction, we estimated the MHC-II binding for multiple EBV peptides (Figure 2H). Next, we executed a competitive *in-vitro* binding assay showing a high binding affinity of EBNA-3B/4 peptides (IC₅₀: 0.08μM) to recombinant DRB1 (IL36, Figure 2I).

Lastly, we detected explicit IgH clones, at very low frequency in primary tumors (Figure S2M). Exceptions included rare primary AITL and EBV+ PDX (Figure S2N).

PDX preserve the transcriptomic landscape of primary lymphomas

We first compared the transcriptomic profiles of primary (n=79) and matched PDX (n=140; Table S2) by principal component analysis (PCA), demonstrating a partial overlap (Figure S3A), likely due to the tumor content (Figure S3B-C) and host human cells (Figure S3C-E). Hence, we performed a surrogate variable analysis (see Methods) and established distinct clusters corresponding to ALK⁺ ALCL, ALK⁻ ALCL, and PTCL-NOS/AITL, demonstrating a close correspondence of primary and PDX (Figure 3A-B and S3F). PTCL-NOS and AITL were stratified using GO-enrichment, differential expression, pathway analyses, and publicly available signatures (Figure 3C and S3G-I), confirming known transcripts in different subtypes (Figure S3H). As selected biomarkers distinguish PTCL subtypes^{41,42}, we established PDX classifiers for each subgroup enriched by known differentially expressed genes (Figure S3J). The PDX-Dlines also showed close transcriptional signatures to matched donor PDX (Figure S3K).

By single-cell RNA sequencing (scRNASeq) (5 PDX, Table S2), models were individually segregated at cluster resolution, even within the same entity (i.e., ALK⁺ ALCL, Figure 3DE). Tumor clusters were common between primary and PDX (#1 and #2) (Figure 3F-G), and normal human stromal cells were depleted in PDX (#6 and #8, populated by normal CD8⁺ T-cells and monocytes, respectively) (Figure 3F and Figure S3L).

Fusion transcripts are common in PTCL and typical to histologic subtypes². We thus searched for chimeric transcripts (see Methods; Table S3) and identified 4022 gene fusions across 206 samples. Previously identified fusions were annotated^{43,44,45}, as well as unknown putative tumorigenic fusions involving a variety of T-cell genes (*ACADVL-VAV1*, *MAZ-NF1*, *VASP-PPP2R1A*, *TET3-IMMT*, *MYL3-SETD2*, *TOX-MYBL1*, *IL17RA-RP11-363L24.3*, and *SMG1-NFATC3*) (Table S3 and Figure 3H). In the *ACADVL-VAV1*, the *ACADVL* was fused in-frame, while *VAV1* translated to a truncated protein lacking its negative regulatory domain (Figure S3M), reminiscent of other oncogenic *VAV1* fusion proteins^{46,47}. Since Ras signaling can contribute to PTCL pathogenesis⁴⁸⁻⁵¹, we validated the *MAZ-NF1* fusion of an ALK⁻ ALCL PDX. The predicted outcome was a truncated NF1 protein lacking activity (Figure S3N-S3P). Meanwhile, primary and PDX lost the second *NF1* allele (Figure S3P), leading to the deregulated activation of Ras. Of note, we observed the loss of ERK1/2 phosphorylation (Figure S3Q), and the improved PDX outcome *in-vivo* (Figure 3I) upon selumetinib treatment (AZD-6244, a MEK inhibitor); a compound with limited activity in other PDX-Dlines (Figure S3R).

Since fusion transcripts are informative biomarkers of disease identity^{52,53} and serve as surrogates for tracing clonal evolution⁵³, we explored their landscape in two models (IL2 and IL19), derived from the same donor at different time points (Figure 3J and S3S-T). PDX displayed several undetectable fusions in primary samples (IL2, n=62, and IL19, n=68), some co-shared (n=36). By qRT-PCR (n=9) and Sanger sequencing (n=3 – Figure S3U-V), we confirmed selected fusions in PDX and primary

samples (Figure S3V). Remarkably, emerging fusions in the relapsed sample (primary IL19) and corresponding PDX suggested the occurrence of clonal trajectories in part shared and maintained along the diagnostic, PDX samples, and even PDX-Dlines (Figure S3U-V).

PTCL PDX retain pathogenetic drivers and inter- and intra-tumoral heterogeneity

We performed whole-exome sequencing (WES) in 223 samples (34 primary, 29 normal, and 160 PDX and PDX-Dlines), derived from 49 different models (Table S2). Having assessed the contribution of human and mouse reads (Figure S4A), copy number alteration (CNA) demonstrated significant overlaps between primary and corresponding PDX (Table S4, Figure 4A, and S4B). Globally, PTCL-NOS and ALK⁻ ALCL displayed a higher degree of DNA structural alterations (Figure 4B), including known abnormalities (e.g., 6q21 and 1q+ or 3q31.3+ in ALK⁻ ALCL) and defects associated with pathogenic alterations (e.g., *PRDM1* and *MIR17HG*) than other histology^{54,55}. ALCL displayed specific gains at 1p36.22 and 19q13.42, occurring in regions harboring pathogenetic *TNFRSF8* (CD30) and *KIR2FDL1/KIR3DL2* genes⁵⁶⁻⁵⁸.

We found a high concordance of single-nucleotide variants (SNVs) and indels between primary tumors and matched PDX (Figure S4C-D, Table S5) with a higher median variant allele frequency (VAF) in PDX (50% vs 40%, respectively, $p < 2.2 \times 10^{-16}$, t-test; Figure S4E). Globally, 3,430 non-synonymous somatic variants were recognized (Table S5), mostly missense (77%), 11% splice-site, 4% stop-gain, 4% in-frame, and 4% frameshift. A total of 1,582 were classified as pathogenetic SNVs. These involved chromatin modifiers, JAK-STAT, and T-cell receptor-associated genes (e.g., *TET2*, *DNMT3A*, *JAK1*, *STAT3*, *RHOA*, *TP53*, and *NOTCH1*)^{37,59-62}. Previously undescribed putative tumorigenic variants (e.g., *DIAPH1*, *FAT4*, *CRIPAK*, *SH3RF2*, and *BCLAF1*⁶³⁻⁶⁷) were detected (Figure 4C). Oncogenic drivers were enriched in AITL (*TET2* and *RHOA*)⁶⁸, ALK⁻ ALCL (*JAK1* and *STAT3*)⁶⁹, and MF (*PLCG1*)⁷⁰. Most mutations were faithfully shared between primary tumors and along PDX passages. Conversely, some were exclusive to either primary (e.g., *KMT2D*) or PDX (e.g., *CSF2*, *GATA3*, and *ASXL3*, Figure 4D) or emerged along serial PDX passages (*AUTS2* and *CSF2*, Figure S4F). Higher mutational burdens were observed in ALK⁻ ALCL, PTCL-NOS, and MF (Figure S4G). Lastly, we screened 104 normal/primary/PDX/PDX-Dline samples by deep sequencing and annotated 537 mutations in 450 pathogenetic genes (Table S2). When we compared WES and deep sequencing analyses (data not shown), we observed >90% concordance with an increased VAF of selected alterations in propagated PDX (Figure S4H).

To explore the evolutionary mutation trajectories, we built a tumor evolutionary directed graph (TEDG)^{71,72} showing that ancestor mutations usually occurred in *STAT3*, *TP53*, *IDH2*, and *KMT2C*, followed sequentially by those in *JAK1*, *CDK11B*, *TET2*, and *RHOA*. Mutations in *ACIN1*, *NOTCH1*, *DIAPH1*, and *CSF2* were mostly acquired along PDX propagation (Figure 4E). We then implemented a clonal evolution analysis on 29/49 models using cancer-cell fraction (CCF) estimation by ABSOLUTE⁷³. We classified a clonal mutation if the CCF was >0.85 with a probability >0.5, and subclonal otherwise. We identified 2,103 clonal and 1,544 subclonal mutations (Table S6) and constructed evolution models (e.g., T1-T3-T5 and, for selected cases, up to T15)⁷⁴. All models showed a major cluster of co-shared mutations among primaries and PDX (Figure 4F-H and S4I-K), with dominant clones preserved over propagations. Minor subclones branched and expanded along PDX propagations, with some clonal competition (Figure 4F-H). Finally, we computed Nei's genetic distances on 22/29 models to estimate clonal drifting along propagation (Figure 4I-J, and S4L)⁷⁵ and defined three subgroups based on low/medium/high evolution rate (average Nei's score): 14/22 (64%) low (<0.5), 7/22

(32%) median (>0.5 and <1), and only 1/22 (4%) high score (>1). This confirmed the overall stability of PDX compared to different systems (e.g., glioblastoma, Figure S4M). In sum, PDX maintain primary-matched pathogenetic drivers and degrees of lymphoma heterogeneity⁷⁶.

PTCL PDX recapitulate primary and host microenvironment interactions

To explore the nature of the PTCL TME, we took advantage of our methodology^{24,77} to extract functional signatures from the crosstalk of TME with cancer cells (FGES) from bulk RNA-seq. We first used 24 FGES to virtually reconstruct the TME of 845 PTCLs from 16 public datasets and our cohort. We separated them into four major clusters representing “lymphoma microenvironment” categories (Table S7, Figure 5A, Figure S5A-E): “B-cell rich” for the abundance of B cells and B-cell trafficking FGES; “Mesenchymal” (MS) for overrepresentation of FGES linked to stromal cells, extracellular matrix (ECM) and ECM remodeling; “Inflammatory” for the presence of FGES related to macrophages and NK cells; and “Depleted” that overall had the lowest representation of TME FGES. PTCL subgroups were distributed across the four TME without specific associations, although each group displayed distinct signatures and bore different genomic defects (Figure S5F). A survival analysis on two distinct PTCL patients’ cohorts ($n = 253$), showed that the “depleted” TME was associated with poorer prognosis (uncorrected $P=0.005$) (Figure 5B). Remarkably, the only FGES overrepresented in the “depleted” TME cases were related to “Th2-interleukins and GATA3-activation” and “proliferation rate” (Fig. 5A) and exhibited the highest proportion of tumor cells as determined by mutational load (Figure S5G, $P<0.01$ vs. the other categories). Similar data were recently described in an independent PTCL cohort⁷⁸. Next, we performed a multiplex imaging analysis of primary PTCL using antibodies recognizing different subtypes of T-cells, macrophages, and stromal elements, confirming the RNA deconvolution predictions (Figure 5C and S5H).

We extended this approach to PDX models, using converted mouse FGES (mFGES), and showed the same four TME categories of primary tumors (Figure 5D, Figure S5F-N). Using only human reads, we performed a clustering analysis of the PTCLs into 4 functional “intrinsic” T-cell phenotypes: Th1 (mostly AITLs and PTCL-NOS), Tfh (AITL), Th2 (PTCL-NOS carrying JAK-STAT mutations), and cytotoxic (mainly ALCL) (Figure S5F). The Th1 and Tfh group frequently displayed *TET2*, *RHOA* mutations, and detectable EBV transcripts. The cytotoxic group had the lowest TCR signaling rate and few normal T-cells (Figure S5K), in line with the ALCL low TCR signaling⁷⁹. Most samples with high TCR signaling displayed *TET2/DNMT* and/or *RHOA/PCLG1* defects⁸⁰; meanwhile, ~50% of those lacking them were EBV+. TCR-negative samples were conversely enriched in *JAK1/STAT3* mutants and/or clustered among ALCL^{2,79}. We next showed that TME cell populations were mostly conserved along PDX passages (Figure 5E), particularly in ALK⁺ ALCL, which maintained their cytotoxic phenotype, and for most Th2 PDX. Nevertheless, changes were observed, suggesting some plasticity (i.e., “mesenchymal” and “B-cell rich” TMEs, Figure 5E and S5I). A transition to a “mesenchymal” TME was seen in ALCLs whose tumor content rapidly increased after engraftment. Other PDX displayed a progression to a “B-cell rich” TME (e.g., NY-PTCL-CR, IL33, IL98), likely driven by an increased number of EBV-LCLs (Figure S5I-J)^{81,82}.

Additionally, we interrogated murine TAMs and CAFs, which increased along PDX passages (Figure S5M). Both M1-like and M2-like TAMs expanded in PDX, with an increased M2/M1 ratio (primary:1.53 vs PDX: 2.27; Figure 5F). Regarding CAFs, signatures corresponding to “myCAF” and “iCAF” (Table S7) were also enriched (Figure 5G-H and S5N).

As a functional validation, murine PDX stromal and tumor endothelial cells (TECs) improved the survival of co-cultured lymphoma cells (Figure 5I, S5O)^{83,84}. Co-cultured CAFs upregulated biogenesis, migration, cell mobility, and DNA replication pathways (Figure 5J), mimicking the phenotype of freshly isolated mesenchymal stromal cells (MSCs; Figure 5K), a phenotype partially lost when cultured alone. Remarkably, freshly isolated CAFs from matched tumors or in-vitro re-educated-CAFs more efficiently rescued PDX under serum deprivation (Figure 5L-M). Finally, PDX-CAFs improved the viability of 2 models (IL2 and IL142A) in co-culture drug screening platforms (Figure 5N-O), including compounds targeting PTCL driver pathways (Figure 5O). This effect was only seen with lymphoma-matched PDX-MSCs (Figure S5P), suggesting a lymphoma-specific education. We next identified putative pathways that mediated the host rescue, as depicted in Fig S5Q, where CAF rescue was partially abrogated with crizotinib (navitoclax/ABT263, belinostat, etc). Finally, we found that mouse mesenchymal cells (MS-5) protected ALCL cell lines from brentuximab-vedotin induced-death (Figure S5R).

Therapeutic responses are assessed in PTCL PDX.

We first examined the therapeutic prediction of six PDX (3 ALK⁺ ALCL, 1 PTCL-NOS, and 2 ALK⁻ ALCL) performing a high-throughput in-vitro drug screening (Figure S6A) targeting ~634 proteins (Table S8, Figure 6A), demonstrating a high reproducibility among replicates (Figure S6B), and along serial propagations (Figure 6A-C and S6C). Therapeutic responses differed according to the subtype (Figure 6B-C). Most compounds had little effect. However, a sub-group of 19 drugs showed higher efficacy across samples (Figure 6C). We then correlated the gene expression profiles with cell viability after drug exposure and identified predictive signatures to belinostat (Figure S6D-E) and ruxolitinib ($R=0.97$, $p=0.033$) (Figures 6D-G, S6D, and S6F). Next, we expanded the screening to PDX-Dlines with 53 drugs, including the 30 most active compounds within the 433-drug library and 23 drugs from clinical trials (Table S9, Figure 6H), establishing dose-response curves (Figure 6I and S6G). Also, PDX-Dlines displayed individual patterns of responses to ALKi crizotinib (TO-ALCL-DN03, ALK⁺ ALCL) and JAKi ruxolitinib, tofacitinib, and cerdulatinib (mutJAK1- IL2 model; Figure 6H), in line with their genetic alterations. Conversely, cytotoxic chemo-therapeutics (daunorubicin, SN38, vincristine), HDAC inhibitors (romidepsin, and panobinostat), a survivin inhibitor YM155, proteasome inhibitors (bortezomib and CEP18870), an aurora-kinase inhibitor (tozasertib) and a CDK9 inhibitor (AZD4573) were pan-active, even at low concentrations.

Seeking drug combination candidates, we developed a deep learning-based algorithm named DeepPTCL (see Methods). Having demonstrated a consensus between the TCGA cell lines and PTCL (see Methods, Figure S6H), we screened 8 of the most effective drugs for synergies (irinotecan, romidepsin, duvelisib, pralatrexate, AZD-4573, cedulatinib, azacytidine, crizotinib) on PDX-Dlines (IL2, IL89, IL142A, TO-ALCL-DN03, and TO-ALCL-Belli). DeepPTCL predicted 6 top synergy combinations with duvelisib (Figure 6J), some further validated in-vitro (duvelisib/cerdulatinib in *JAK1*^{mut} IL2 PDX-Dline, duvelisib/venetoclax in IL2 and IL142A PDX-Dlines, carrying *PTEN*, and *TP53* deletions) (Figure 6K and Figure S6I). Lastly, we linked responses of representative combinations to the mesenchymal TME within the FGES subtypes (Figure S6J).

PTCL PDX preclinical trials in-vivo

To assess responses to standard and innovative drugs/combinations, we selected 17 PTCL PDX (10 naïve and 7 refractory; Figure 7A, Table S9).

First, we tested whether PDX recapitulated patients' responses (Table S10; Figure 7B-C and S7A-C) to: i) CHOP, demonstrating that TO-ALCL-DN03 responded in line with the matched patient (partial response-PR, Figure S7D-F) while MT05 and TO-ALCL-Marc were refractory as the donor-patients; and ii) targeted agents. These latter experiments showed that *JAK1^{mut}* IL2 PDX was refractory to ruxolitinib and romidepsin, as its corresponding patient (Figure 7C); and the NPM-ALK+ IL69 - derived from a patient refractory to CHOP, brentuximab vedotin (BV) and crizotinib - did not also show significant responses (Figure 7B). Similar responses were documented in the IL79 ALK+ ALCL model (Figure S7G). Conversely, the ALKi-naïve TO-ALCL-DN03 was eradicated by crizotinib (Figure S7H), while NY-ALCL-SG showed little-to-no response to crizotinib and ceritinib (respectively) but was partially controlled by brentuximab vedotin (Figure 7D). For the ALKi-naïve NY-ALCL-SGC, we observed a significant response to crizotinib followed by a relapse; this latter phenotype was controlled by the duvelisib-crizotinib combination (Figure 7D)⁸⁵. As STAT3 powers some ALK- ALCL⁶⁹, we treated a naïve STAT3+ ALCL PDX with baricitinib, a *JAK1/JAK2* inhibitor, using two different dosing schedules. Growth inhibition was partially achieved in BID-treated mice, demonstrating that prolonged and significant suppression of pSTAT3 is required for improved clinical outputs (Figure S7I).

Afterward, we harnessed multiple PDX to design precision-medicine-driven pre-clinical trials by integrating phenotypic, genomic, and drug screening data. We chose a debulking approach using irinotecan, which was effective in the in-vitro screening (Figure 6C), followed by chemo-free approaches (Figure 7E and Figure S7J). Irinotecan has some activity in PTCL patients⁸⁶ and in relapsed/refractory non-Hodgkin patients⁸⁷⁻⁸⁹. In detail, CD30+ ALCL PDX (IL69, IL79, MT05, and DN03) were challenged with irinotecan and BV (Figure 7E), while the IL2 PTCL-NOS PDX was treated with irinotecan and ruxolitinib (Figure S7J). Combinations either eradicated and/or yielded improvement in survival. Finally, we tested effective in-vitro drugs (Figure 6H), either as single agents or in combinations (Figure 7F, Figure S7K-L). Pralatrexate proved to be the most effective, improving OS and, in some cases, leading to lymphoma eradication as a single agent (IL142A, Figure S7K), or in combination with romidepsin (IL2, Figure 7F) or duvelisib (IL107, Figure S7L). Conversely, azacitidine (Figure 7G, and S7M)^{90,91} decreased lymphoma growth (Figure 7G, S7M-P) and prolonged survival (Figure S7P). We next combined CDK9 inhibitor (AZD-4573)⁹² with cerdulatinib⁹³, following a 1 x 1 x 1 pre-clinical design²⁶, in 9 PDX (Figure 8A). As a single agent, cerdulatinib showed a modest effect in 3/9 models, and significant readouts in only 2/9 models. AZD-4573 was more potent, with a modest effect in 2/9, and superior response in 4/9 models (Figure 8A-C and Figure S8A). Their combination yielded improved responses in 5/9 models, extending survival (pairwise log-rank $p=0.019$) (Figure 8C and Figure S8A-B). By bulk RNAseq we observed that non-responders had an upregulation of TCR signaling, conversely, responders were enriched in genes regulating migration, cytoskeleton, and cell interactions (Figure 8D).

Lastly, we assessed the efficacy of CAR-T in PTCL PDX, a still largely unexplored field^{94,95}. We took advantage of two CART products specifically targeting CD30 or CD5 (CART30 and CART5, respectively), the latter engineered to lack endogenous CD5 expression, avoiding fratricide effects and with enhanced antitumor activity (see Methods⁹⁶). Both products were effective *in-vitro* (CART5 against IL2, a PTCL-NOS, CD5+/CD30-, and CART30 against TO-ALCL-DN03, an ALK+ALCL, CD30+/CD5-) (Figure 8E and Figure S8C-D). *In-vivo*, CART5 controlled lymphoma growth, especially in combination with nivolumab (Figure 8F). Meanwhile, CART30 or CART30/nivolumab combination showed a partial effect (Figure 8G). This was likely due to a defective intratumoral infiltration (Figure 8H and S8E) and disrupted crosstalk, as shown by multiplex imaging. Indeed, ALCL cells were strongly

PDL1+, largely excluding PD1+ and EOMES+ CART at lymphoma periphery (Figure 8I) and distant locations (i.e., spleen, Figure S8F).

Discussion

This study establishes the largest available patient-derived xenograft (PDX) biorepository for PTCL, offering a robust preclinical resource to study tumor evolution, drug resistance, and personalized therapies. PDX faithfully replicate primary tumor characteristics, including histopathology, clonality, genomic, transcriptomic, and drug susceptibility, making them an invaluable resource for understanding PTCL pathogenesis.

PDX fidelity and drifting along propagation is still a matter of debate^{30,33,97}. Here, we proved that PDX closely matched primary samples, displaying identical TCR rearrangements, and retaining the same driver mutations/CNV and gene-expression patterns. Nevertheless, distinct subclones were detectable with the acquisition of non-random defects in a stepwise fashion (i.e., loss of *TET2*, *DNMT3a*) and the acquisition of mutations (i.e., *RHOA*, *IDH2*, or *NOTCH1/4* in ALCL and AITL PDX, respectively). This supports the model of stepwise T-cell transformation, defining preferential trajectories/pathways driven by intrinsic defects. These findings feature the relevance of PTCL PDX to inform the potential evolutionary trajectory of human tumors. Along the same lines, we discovered genomic aberrations (e.g., *ACADVL-VAV1* and *MAZ-NF1*) converging on specific pathways and propelling T-cell transformation. These findings support the implementation of agents selectively targeting downstream effectors (*STAT3*, *IRF4* PROTACs, etc.). Strikingly, PTCL PDX and PDX-Dlines maintained a significant subclonal heterogeneity, a feature often lost by conventional cell lines, providing a better representation and higher predictive power^{17,98}. We took advantage of this predictive potential by comparing, via a deep-learning model, PTCL PDX transcriptional signatures with those of the Cancer Cell Line Encyclopedia, to in-silico predict and in-vitro validate drug combinations.

Personalized treatments require cancer genomic stratification^{99,100}, providing a more granular landscape and pinpointing the role of the microenvironment^{24,101}. Here, we proved that PTCL and matched-PDX can be stratified by microenvironment functional signatures (FGES) derived by lymphoma-host cognate interactions. This stratification is of prognostic relevance, with the “Th2” subgroup (so-called Th2/GATA3, over-activating the PI3K pathway) bearing the most unfavorable outcome. Similar data were recently presented in an independent cohort⁷⁸. Strikingly, despite the paucity of the PDX microenvironment, the host elements' compositions somehow recapitulated the PTCL-landscapes, supporting a model predicting the education of the host by lymphoma elements¹⁰²⁻¹⁰⁵. PDX cells could also instruct stromal-remodeling *in-vitro*, establishing prosurvival niches with drug-counteracting capabilities. This model allows the functional validation of host-mediated protumorigenic mechanisms and testing of *ad hoc* regimens strategies¹⁰⁶⁻¹⁰⁸. Considering the limited array of intrinsic druggable liabilities, we believe that targeting lymphoma microenvironment will become of pivotal importance in future studies.

Finally, PDX are emerging as a powerful tool in clinical oncology for investigating rare tumors and neoplasms¹⁰⁹⁻¹¹¹, such as PTCL^{12,17}. We believe that the future/systematic generation of PDX from patients enrolled in clinical trials will allow the direct comparison of PDX and patients' responses, faster PDX-based predictions, and the possibility to assign/switch patients to the most effective therapeutic arms^{32,111}. Here, we performed pre-clinical trials using experimental drugs (mostly derived from drug-screening approaches and/or in-silico predictions), and proved their efficacy as single agents or combinations. Also, we proved that immune-based CAR-T strategies (CD5KO-CART5 and CART30) can be explored and validated in PTCL PDX.

In summary, PDX provide a compelling opportunity to foster the translation of drug and immune-based strategies from the bench to the bedside^{24,112}. Our biorepository provides a resource for PTCL research and serves as a preclinical platform for testing novel therapies. By integrating genomic, transcriptomic, and drug response data, this study advances precision medicine for PTCL patients.

Limitations

Despite the significance of our findings, several limitations must be acknowledged.

Limited immune system representation: PDX models lack a functional immune system^{25,111}, limiting the evaluation of immunotherapies, including CAR-T and checkpoint inhibitors. Thus, studies should explore humanized mouse models to address this limitation.

Engraftment success varies: ~36% of PTCL successfully engrafted, with lower rates for rare subtypes. We believe that tissue availability, technical (tissue amount/appropriateness), and biological features of rare lymphomas (individual and heterogeneous genotypes, host requirements) partially explain these failures^{113,114}. To improve success, we employed b2/MCH-I-II knockout mice to lessen GVHD-like reactions, which can jeopardize engraftments¹¹⁵. Further optimization (e.g., IL15-NSG mice) did not improve NK/T PTCL engraftment, demonstrating that defined/multiple signals are required, hardly overcome by individual engineered models. We found liability in the emergence of EBV-transformed cells¹¹⁶ (especially in AITL), rarely controlled by anti-CD19 ADC or Rituximab in NSG Hc1 mice, in contrast to previous studies with solid cancers^{117,118}. This predicts that EBV+ and/or B-cells may not be simply bystander elements but can contribute to the early stage of transformation and/or sustain lymphoma growth/survival¹¹⁹. This model is in line with the EBV-peptide recognition (EBNA LMP1, etc.) by lymphoma/leukemia TCR/MHC-I complex and TCR triggering. These data extend the putative pathological role of B-cells in the genesis and maintenance of AITL¹²⁰.

Microenvironment changes over passages: while PDX retain key tumor features, some human host components diminish over serial passages, affecting tumor-host interactions. Nevertheless, as for other PDX^{24,121,122}, functional similarities between human and mouse TME, and the protumorigenic role of CAFs were observed. Future work taking advantage of co-culture systems and engineered microenvironments is required to dissect the mechanisms of action.

Deep-learning therapy prediction requires validation: the DeepPTCL algorithm successfully predicted effective drug combinations, fostering future (pre)clinical studies in patients before entering into clinics.

Clinical translation of PDX findings: while PDX drug responses nicely correlated with patient outcomes, the implementation of PDX in prospective clinical trials is needed for the translatability of our findings. We hope that new clinical trials will include the utilization of patients' samples for the generation of PDX and, thus, the future design and validation of broader PTCL therapeutic strategies.

Acknowledgments

We thank all staff members of the Immunopathology Laboratory at Weill Cornell Medicine for their support. We are grateful to the Epigenomics and Genomics Cores of Weill Cornell Medicine for next-generation sequencing. We thank the members of the Weill Cornell Cell Sorting Core and Edward Meyer Cancer Center PDX Shared Resource. We thank Drs. Lorenzo Galluzzi and Shahin Rafii for intellectual discussions, feedback and support. We thank the mouse facility operators and Drs. Kvin Lertpiriyapong and Rodolfo Ricart Arbona. We are grateful to Ani Arkur, Sofia Alayon, and Shefali B. Sha for their administrative support and financial management. G.I. is supported by CA229086,

CA229100, CA195568, LLS 7011-16; L.V.C and R.F.: Italian Association for Cancer Research (AIRC, Milan, Italy), Metastases 5x1000 Special Program, grant 21198; L.V.C and G.M.: American Italian Cancer Foundation (AICF) Post-Doctoral Research Fellowship (AICF 2021-22 and 2023-24); D.F.: the Rita-Levi Montalcini grant from Italian Ministry of University and Research (MIUR). V.F.: Italian Association for Cancer Research (AIRC, Milan, Italy), MFAG 2023 ID 28974; D.M.W. was supported by NCI R35 CA231958, NCI P01 CA233412, and Leukemia and Lymphoma Society Specialized Center of Research 7026-21. R.R., A.W., and Z.L. were supported by NCI R35 CA253126, U01CA243073, and Stand Up to Cancer Convergence Program. Z.L. was supported by the NSFC 32170565 and the CAS Hundred Talents Program. W.C.C. was supported by the COH Cancer Center Support Grant P30, CA033572, and 1PO1CA229100.

Author contributions

Conceptualization: D.F., L.V.C., R.P., E.M., S.Y.N., A.M., Z.E., A.I., D.A., P.M., J.R., F.B., R.F., J.B., D.B., J.C.C., W.T., D.M.W., L.C., R.R., S.H., G.I. - Methodology and Investigation: D.F., L.V.C., J.P., A.T., W.C., V.F., F.T., N.Z., C.K., G.M., R.P.P., M.G., R.M., G.A., M.T.C., C.P., R.A.E., S.P., R.W., N.D.S., I.K. - Software and Formal Analysis: L.Z., N.K., P.G., M.S., P.Z., L. Y., A.W., X.H., A.N., O.K., D.N., D.T., E.B., A.B., A.K., D.K., E.P., V.S., K.T., N.D.S., S.D., G.M., L.C., S.G., L.S., J.O., C.Z., L.Q., O.E., C.X. - Resources: D.N., M.P., E.T., B.F., A.M., F.Z., J.S., E.D.S., Z.E., D.A., P.M., J.R., J.D.B., W.C.C., W.T., M.R., D.W., S.H., G.I. - Writing original draft: D.F., L.V.C., W.T., L.C., and G.I. - Writing, reviewing, and editing: D.F., L.V.C., W.T., L.C., and G.I. - Funding Acquisition: D.F., S.H., D.W., R.F., G.I. - Project administration: G.I.

Declaration of interests

D.M.W. is an employee of Merck and has an equity interest in Ajax, Bantam and Travera.

F.B.: institutional research funds from ADC Therapeutics, Bayer AG, Cellectis, Helsinn, HTG Molecular Diagnostics, ImmunoGen, iOnctura, Menarini Ricerche, NEOMED Therapeutics 1, Nordic Nanovector ASA, Sepxis AG; advisory board fees from Novartis; consultancy fee from Helsinn, Menarini; expert statements provided to HTG Molecular Diagnostics; travel grants from Amgen, Astra Zeneca, iOnctura.

Figure titles and legends

Figure 1. Generation of PTCL PDX and PDX-derivates.

(A) Schematic representation of PDX generation and propagation strategies. Different primary sample sources and routes of implantation are annotated.

(B) Pie chart indicating the PTCL total and subtype-specific number of PDX generated.

(C) PTCL PDX subtype-specific percentage of engraftment.

(D) Number of PDX generated from naïve or refractory patients for different PTCL subtypes.

(E) Time of engraftment (in days) of PDX belonging to different PTCL subcategories along different rounds of propagation (T1 to T10). Error bars represent standard deviations.

(F) Representative MRI scanning of 4 different organs (lung, kidney, liver, spleen) of an NSG mouse implanted with the different PDX. Arrows indicate lymphoma infiltration.

(G) Representative H&E staining of 4 different organs (lung, kidney, liver, spleen) of NSG mice implanted with the AITL PDX model (magnification ×40).

- (H) Flow cytometric analysis of EBV+ AITL PDX IL129A prior (upper panels) and after CD19-ADC treatment (lower panels).
- (I) Schematic representation of PDX-Dlines generation strategies.

Figure 2. PDX faithfully mimic matched primary donor samples.

- (A) H&E staining of primary lymphomas (green frames) and matched PDX (yellow frames - magnification 40x).
- (B) EBV in-situ hybridization depicting EBV+ lymphoblastoid cells (EBER+) in AITL PDX.
- (C) Multiparametric In Situ Imaging (MISI) of representative AITL lesions derived from diagnostic (lymph node) and patient-matched PDX (lung).
- (D) Pie graph reporting the expression of 26 IHC markers in primary and PDX (T1 to T16) samples. Red: highly expressed, green: low expressed.
- (E) α/β TCR clonal representation of primary and PDX, along serial passages.
- (F) EBV positivity among PTCL.
- (G) TCR repertoire against EBV peptides and their mismatched sequences compare to known reference sequences.
- (H). Prediction binding of EBV peptides to MHC class II determinants.
- (I) In-vitro competitive binding assay of EBV tetramers to recombinant DRB1.

Figure 3. PDX maintain the inter- and intra-tumoral heterogeneity of matched lymphoma.

- (A) PCA of PDX and primary lymphoma matched samples (AITL, PTCL-NOS and ALCL) based on the bulk RNA expression levels excluding non-lymphoma reads in primary samples.
- (B) Heatmap and unsupervised hierarchical clustering based on 1000 top differentially expressed genes of PDX and primary lymphomas belonging to the main 4 PTCL subcategories (AITL, PTCL-NOS, ALK+ ALCL, ALK- ALCL).
- (C) Supervised hierarchical clustering of primary and PDX based on 12 known publicly available signatures stratifying different PTCL entities (A: PMC2817630_AITL, B: PMC2817630_ATLL, C: PMC4014836_TBX21/GATA3, D: PMC20159827_ALK+, E: PMC2817630_ALK+, F: PMC4014836_ALK+/-, G: PMC4014836_AITL, H: PMC4014836_ATLL, I: PMC4014836_ATLL, J: PMC2817630_CT_PTCL, K: PMC6161771_DUSP22 and L: PMC4014836_ENKTL).
- (D) UMAP clusters annotation based on single-cell RNASeq expression of PTCL-NOS and AITL (IL2 and IL138A) and ALCL (IL69, IL79 and IL89) PDX.
- (E) Dot plot representation of top gene transcripts in each UMAP cluster of the PDX models sequenced by single-cell RNA seq.
- (F) UMAP cluster annotation based on single-cell RNASeq expression (IL138A primary and T3 PDX model). Cell types have been annotated on the right part of the graph.
- (G) Hallmark analysis of selected differentially expressed pathways among three tumor clusters of IL138A primary and PDX, based on single-cell RNASeq expression data. Cluster 0 was present in both primary and PDX, while clusters 1&2 were enriched in IL138A PDX vs the correspondent primary.
- (H) Heatmap reporting fusions of primary and PDX samples belonging to different PTCL. Only chimeras with a pathogenetic score ≥ 0.7 are depicted.
- (I) Antitumoral effect of AZD6244 in TO-ALCL-Belli PDX model ($n= 8$ mice/group). Error bars represent standard deviations.

(J) Circle plot depicting fusion landscapes of IL2 and IL19 primary and PDX samples.

Figure 4. PTCL PDX models mutational landscape and clonal evolution

(A) Global Copy Number Variation (CNV) analysis of primary and PDX along propagation.

(B) Chromosome view of genes included in the recurrent deleted or amplified genomic regions in PTCL-NOS and ALCL (ALK⁺ and ALK⁻).

(C) Mutational landscape of PTCL primary and PDX samples assessed by WES. Variant sites with read depth lower than five are marked as NA. For the sample ID, 'P' stands for primary tumors.

(D) Ternary plot of mutation frequency in recurrently mutated genes, comparing primary tumor-specific (left, green), PDX-specific (right, red), and shared (top, blue) alterations. The size of each node represents the mutation frequency.

(E) PDX tumor evolutionary directed graph of gene mutations. Arrows show the order in which mutations occur. The size of each node corresponds to the frequency of mutations.

(F-G-H) Tumor evolution models of NY-ALCL-SG, NY-AI-AM, and TO-ALCL-BELLI PDX models. Fish plots (bottom panels) show dynamic changes in CCF of each mutation cluster along serial passages, as depicted in the inferred phylogenetic trees (top panels).

(I) Nei's genetic distance indicates the global evolution score of PDX models.

(J) Nei's genetic distance indicates the global evolution score of PDX derived from different PTCL entities.

Figure 5. The microenvironment of primary and PDX defines distinct subgroups of PTCLs.

(A) Heatmap of the activity scores of 20 FGES and 4 signaling pathways (x-axis) denoting four major TME clusters of primary PTCL (n=845). In each dataset, signatures were median scaled using median and MAD (median absolute deviation) calculated only for samples with AITL or PTCL-NOS. MFP (Microenvironment Functional Phenotypes) portraits were predicted by Louvain clustering (with a threshold of closest points 0.25) within 20 signatures. Samples were sorted by MFP and by diagnosis, and for each MFP and diagnosis by Proliferation rate increasing. The bottom four molecular pathways were calculated by Progeny.

(B) Kaplan–Meier models of OS according to the PTCL TME category.

(C) TME annotation by multiplex analysis of PDX.

(D) Heatmap of the activity scores of 20 FGES (x-axis) denoting four major TME clusters of PDX. Signature scores (calculated by ssGSEA algorithm) were median scaled for each biopsy site separately taking median and MAD only from AITL and PTCL NOS samples. Oncoplot below the heatmap depicts mutations, ALK, and EBV status. Color palettes on the top indicate MFP, biopsy site, T phenotype, and diagnosis for each sample.

(E) Left: Sankey plot showing changes in T differentiation throughout primary and three passages of PDX. Right: plot showing changes in MFP subtypes throughout primary and three passages of PDX.

(F) Proportion of macrophages M1 or M2 enriched in PDX by FGES.

(G) The proportion of myCAF enriched in selected PDX subtypes by FGES. Error bars represent standard deviations.

(H) The proportion of iCAF enriched in PDX by FGES. Error bars represent standard deviations.

(I) Barplot of apoptotic lymphoma cells cocultured with and without stromal cells (STCs). Data are representative of three replicates. Error bars represent standard deviations.

(J) Gene ontology analysis indicates the biological processes enriched in educated vs not educated SCTs.

(K) Unsupervised hierarchical clustering of the top 100 differentially expressed genes in not-educated (cultured in-vitro >3 days) and (re)educated (freshly isolated or co-cultured in-vitro with PTCL cells >3 days) STCs isolated from PDX.

(L) Percentage of viable IL2 PDX cells cultured in stress conditions alone (red bar) or cocultured with STCs isolated from different PDX. Data are representative of three replicates. Error bars represent standard deviations.

(M) Percentage of viable MT05 PDX cells cultured in stress conditions alone (red bar) or cocultured with STCs isolated from different PDX. Data are representative of three replicates. Error bars represent standard deviations.

(N) Bar plots reporting the delta of the specific cell death of PDX-Dlines (IL2 and IL142A) exposed to 40-drugs with or without STCs (72hrs at 1 μ M).

(O) Barplot showing viable PTCL PDX cells cocultured with STCs or cultured alone in the presence of targeting agents (72hr). Data are representative of three replicates. Error bars represent standard deviations.

Figure 6. Ex Vivo PDX Drug responses.

(A) Heatmap showing the magnitude of the cross-correlation of 6 PDX freshly isolated cells exposed to the drug library.

(B) Principal component analysis (PCA) of 19 PDX freshly isolated cells based on the responses to 433 drugs. Circled dotted lines group together samples of PTCL subtype.

(C) Heat map showing the responses of 6 PDX models (19 freshly isolated cell samples) to 433 drugs. Dendrograms on the left and bottom show unsupervised hierarchical clustering of drugs and PDX along the axis of maximum variation (ward) for the Euclidean distances. The dot plot denotes the average drug viabilities per PDX across 433 drugs (top). Dot plot shows the average sample viabilities per drug (right).

(D) Dot plots showing the correlation between the expression levels of JAK1 and JAK2 across PTCL subtypes with cell viability after ruxolitinib treatment (72hr, 1 μ M). The correlation coefficients and p-values are indicated.

(E) Heatmap and unsupervised clustering depicting the gene expression within the JAK-STAT pathway. Genes were selected based on the correlation between the expression and viability of samples treated with Ruxolitinib (1 μ M, 72hrs). The viability values are indicated in the upper color bars.

(F) Heatmap and unsupervised clustering depicting the gene expression from a regression analysis obtained by modeling the cell viabilities as a function of the PTCL subtypes plus each gene expression.

(G) Dot plot showing the predicted vs actual cell viabilities, with correlation and p-value across PTCL subtypes. The prediction derives from the regression analysis in Figure 5F.

(H) Heatmap displaying the response of five PDX-Dlines to 40 compounds. Specific cell death is reported in percentage.

(I) IC50 assessment in five PDX-Dlines treated in-vitro with increasing concentrations of compounds (day 3 and 6).

(J) Box plot indicating the predicted synergy score by DeepPTCL algorithm for the indicated drug combinations across PTCL.

(K) Percentage of viable IL2 and IL142A PDX-DLines cultured in the presence of the indicated concentrations of duvelisib and cerdulatinib (IL2), or duvelisib and venetoclax (IL142A) for 72hrs. Data are representative of three replicates. Error bars represent standard deviations.

Figure 7. The mouse hospital and pre-clinical trials.

(A) PTCL pre-clinical trials overview and Kaplan-Meier plots representative of the overall survival of PDX models.

(B) Comparison of IL69 patient and matched PDX responses to CHOP, brentuximab, and crizotinib ($n= 8 - 10$ mice/group). Top panel: IL69 patient clinical history. Error bars represent standard deviations. P-values were estimated with adjusted t-test (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). Kaplan-Meier curve of the OS (right panel, log-rank test, $p<0.0001$).

(C) Comparison of IL2 patient and matched PDX responses to ruxolitinib and romidepsin ($n= 8 - 10$ mice/group). Top panel: IL2 patient clinical history. Error bars represent standard deviations. Kaplan-Meier curve of the OS (right panel, log rank test, $p=ns: >0.05$).

(D) Left panel: antitumoral effect of crizotinib alone or in combination with duvelisib in NY-ALCL-SGC PDX ($n= 8-10$ mice/group). Right panel: antitumoral effect of crizotinib, brentuximab and ceritinib in NY-ALCL-SG PDX ($n= 8-10$ mice/group). Error bars represent standard deviations.

(E) Antitumoral effect of irinotecan, brentuximab or combination in ALCL PDX (MT05: cALCL, IL69, DN03, IL79: ALK⁺ ALCL, IL2: PTCL-NOS). Kaplan-Meier curves of the OS (right panel, log rank test, $p<0.0001$). Individual biological and technical replicates are depicted as single lines.

(F) Antitumoral effect of pralatrexate, duvelisib, and romidepsin or combinations in IL2 PTCL-NOS PDX ($n= 8-10$ mice/group). Error bars represent standard deviations (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). Kaplan-Meier curves of the OS (right panel, log rank test, $p<0.0001$).

(G) hCD45 IHC staining of IL129A PDX treated with vehicle or azacytidine. Left panels: mice organs (lungs, kidney, spleen, liver, heart). Right panels: lungs (40x).

Figure 8. PDX pre-clinical trials support the implementation of drug combinations and immune-based regimens.

(A) Swimmer plot of PDX models ($n=9$, 36 mice) treated with vehicle, cerdulatinib, AZD-4573 or combination.

(B) Barplot depicting PDX tumor size across time points (vehicle, cerdulatinib, AZD-4573, combination). p-values were calculated with one-way ANOVA with adjustment for multiple comparisons *: $p<0.05$.

(C) Kaplan-Meier plots of the global OS of PDX models ($n=9$, 36 mice; log-rank test, $p=0.017$).

(D) Heatmap depicting the top differentially expressed genes in PDX models responders and not-responders to AZD4573 *in-vivo* treatment.

(E) Flow cytometry analysis of TO-ALCL-DN03 (above panels) and IL2 (below panels) PDX-Dlines cocultured with CART30 cells at the indicated target (red dots) to effector (green dots) ratio.

(F) Antitumoral effect of CART5 cells alone or combinations with nivolumab in IL2 PTCL-NOS PDX ($n= 6-10$ xenograft/group). Error bars represent standard deviations.

(G) Antitumoral effect of CART30 cells alone or combinations with nivolumab in NY-ALCL-SG ALK+ALCL PDX ($n= 6-10$ xenograft/group). Error bars represent standard deviations.

(H) Detection of UTD and CART30 within the peri-tumor and tumor masses (CART30 are depicted in green and NY-ALCL-SG cells in red).

(I) Multiparametric analysis demonstrates the positive PDL1 expression of NY-ALCL-SG cells (red color) and CD2 (green), PD1 (low/partial white) staining of CART30.

Supplemental Tables titles and legends (Excel format)

Table S1: PDX & Clinical data TCL patients

A: PDX and PDX-Dlines list
B: Patient clinical annotation
C: Primary-PDX identity
D: All implanted samples source

Table S2: Sequencing metadata

A: WES
B: Bulk RNA Seq
C: scRNA Seq
D: DeepSeq
E: TCR_data
F: BCR_data
G: EBV status
H: TCR_EBV
I: EBV match TCR
J: MHC12_AITL

Table S3: Fusions detected in TCL PDX cohort

A: Fusions detected in the TCL PDX cohort

Table S4: CNV results

A: Copy number aberrations estimated from WES data in the TCL PDX cohort

Table S5: Somatic mutations detected in TCL PDX cohort

A: NY-AI-AM
B: NY-AI-CL
C: NY-AT-FC
D: TO-ALCL-BELLI
E: COH1
F: TO-ALCL-DN03
G: IL114A
H: IL2
I: IL6
J: IL17
K: IL19
L: IL33
M: IL34
N: IL35
O: IL36
P: IL38B
Q: IL40
R: IL41

S: IL49
 T: IL54
 U: IL56
 V: IL65
 W: IL69
 X: IL76
 Y: IL78
 Z: IL79
 AA: IL81
 AB: IL86
 AC: IL88
 AD: IL89
 AE: IL92
 AF: IL94
 AG: IL98
 AH: IL104
 AI: IL107
 AJ: IL122A
 AK: IL123
 AL: IL126A
 AM: IL126B
 AN: IL129A
 AO: IL135A
 AP: IL138A
 AQ: TO-ALCL-MARC
 AR: TO-ALCL-MARI
 AS: MT05
 AT: NY-NK-CD
 AU: NY-PTCL-RV
 AV: NY-ALCL-SG
 AW: NY-NK-VP

Table S6: Clonal evolution analysis

A: Clonal evolution analysis reporting cancer cell fraction estimates and mutation clonality

Table S7: Datasets for microenvironment signature

A: Datasets utilized to generate microenvironment signatures

B: TME subtype of 70 primary PTCL

Table S8: 433-HTS screening

A: List of 433 compounds utilized in the high throughput (HTS) drug screening

STAR Methods

Key resources table

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
anti-CD3e conjugated to FITC (clone 17A2)	BD Bioscience	349201

anti-CD57 conjugated to PE (clone B3GAT1)	BD Bioscience	560844
anti-CD5 conjugated to PerCP-Cy5.5 (clone L17F12)	BD Bioscience	341099
anti-CD4 conjugated to PE-Cy7 (clone SK3)	BD Bioscience	348799
anti-CD7 conjugated to APC (clone 124-1D1)	Invitrogen	17-0079-42
anti-CD8 conjugated to APC-H7 (clone SK1)	BD Bioscience	641409
anti-CD2 conjugated to BV421 (clone TS1/8)	Biologend	309216
anti-CD45 conjugated to V500C (clone 2D1)	BD Bioscience	647450
anti-TCRa/b conjugated to FITC (clone WT31)	BD Bioscience	340883
anti-TCRg/g conjugated to PE (clone 111F2)	BD Bioscience	347907
anti-CD56 conjugated to PerCP-Cy5.5 (clone B159)	BD Bioscience	560842
anti-CD3 conjugated to PE-Cy7 (clone SK7)	BD Bioscience	341101
anti-CD30 conjugated to APC (clone HRS4)	Beckman Coulter	A87939
anti-CD25 conjugated to APC-H7 (clone M-A251)	BD Bioscience	560244
anti-CD16 conjugated to BV421 (clone 3G8)	Biologend	302032
anti-CD7 conjugated to FITC (clone M-T701)	BD Bioscience	340699
anti-CD185 conjugated to PE (clone J252D4)	Biologend	356904
anti-CD278 conjugated to PerCP-Cy5.5 (clone C398.4A)	Biologend	313518
anti-CD10 conjugated to APC (clone HI10A)	BD Bioscience	340923
anti-CD279 conjugated to BV421 (clone MIH4)	BD Bioscience	565935
anti-CD5 conjugated to BV605 (clone UCHT2)	BD Bioscience	563945
anti-Kappa conjugated to FITC (Rabbit anti-Human)	Agilent	FO434
anti-Lambda conjugated to PE (rabbit anti-Human)	Agilent	RO437
anti-CD23 conjugated to PE-Cy7 (clone M-L233)	BD Bioscience	561167
anti-CD20 conjugated to APC-H7 (clone L27)	BD Bioscience	641405
anti-CD19 conjugated to BV421 (clone HIB19)	BD Bioscience	562440
anti-ALK-1	Leica Biosystems	PA0831
anti-CD30 (clone BerH2)	Dako	GA602
anti-CD3 (clone PS1)	Novocastra	NCL-CD3-PS1
anti-CD2 (clone AB75)	Novocastra	NCL-CD2-271
anti-CD4 (clone 4B12)	Leica Biosystems	PA0371
anti-CD7 (clone LP15)	Novocastra	NCL-L-CD7-580 P
anti-CD5 (clone 4C7)	Novocastra	NCL-L-CD5-4C7
anti- TIA1 (clone 2G9A10F5)	Immunotech	IM2550
anti-granzyme (clone GrB7)	Monosan	MON7029C
anti-perforin (clone 5B10)	thermoscientific	MS-1834-R7
anti- TCRa/b (clone IP26)	Biologend	306718
anti-CD20 (clone L26)	Dako	M0755
anti-PAX5 (clone 24/PAX5)	BD Transduction Lab	610863
anti-CD25 (clone 4C9)	Leica Biosystems	PA0306

anti-CLA (rabbit polyclonal)	Dako	N/A
anti-OCT2 (rabbit polyclonal)	Santa Cruz	sc-56822
anti-BOB1 (rabbit polyclonal)	Leica Biosystems	PA0558
anti-MIB (clona MIB-1)	Agilent	GE020
anti-GAS1 (clone C-17)	Santa Cruz	N/A
anti-pSTAT3 (clone M9C6)	Cell Signaling Technology	4113
anti-C/EBP (C19)	Santa Cruz	N/A
anti-NFATC2 (clone M20)	Santa Cruz	sc-1151
anti-pJAK2 (clone E132)	abcam	ab219728
anti-pJAK3 (rabbit polyclonal)	Santa Cruz	sc-16567
anti-P42/44	Cell Signaling Technology	9102s
anti-pP42/44	Cell Signaling Technology	9101s
anti-GAPDH	Cell Signaling Technology	5174s
anti-CD2	Leica	AB75
anti-CD30	Agilent	BERH2
anti-PDL1	Roche	SP263
anti-EOMES	eBioscience/Invitrogen/Thermo	WD1928
anti-CD3	Epredia/Thermo	SP7
anti-CD68	Agilent	KP1
anti-CD163	Leica	10D6
anti-SMA	Agilent	1A4
anti-CD20	Leica	L26
DAPI	Cell Signaling Technology	
Biological samples		
PTCL Patient Samples	Weill Cornell Medicine, New York Presbyterian Hospital (NY), Memorial Sloan Kettering Cancer Center (NY), City of Hope (CA), The Tisch Cancer Institute at Mount Sinai, University of Torino (IT), San Raffaele (IT).	WCM IRB: 1302013582, 0107004999, 1410015560; MSKCC IRB: 13-014, 09-141, 12-245, 06-107; University of Torino: 0081521
Healthy Peripheral blood mononuclear cells	New York Blood Bank	Custom Order
Tissue Blocks of human PTCL	as described in Crescenzo et al., 2015	10.1016/j.ccell.2015.03.006
Chemicals, peptides, and recombinant proteins		
17AAG	Selleckchem	S1141
ABT-199	Selleckchem	S8048

ABT263	Selleckchem	S1001
AUY922	Selleckchem	S1069
Azacytidine	Selleckchem	S1782
AZD4573	Selleckchem	S8719
Belinostat	Selleckchem	S1085
Bortezomib	Selleckchem	S1013
Brentuximab vedoton	Boc Science	914088-09-8
CC220	Selleckchem	S8760
CEP18870	Selleckchem	S1157
Cerdulatinib	Selleckchem	S3566
Ceritinib	Selleckchem	S4967
Chidamide	Selleckchem	S8567
CHIR124	Selleckchem	S2683
Crenolanib	Selleckchem	S2730
Crizotinib	Selleckchem	S1068
Cyclophosphamide	Selleckchem	S2057
Daunorubicin	Selleckchem	S3035
Decitabine	Selleckchem	S1200
Dexamethason	Selleckchem	S5956
Doxorubicin	Selleckchem	S1208
Duvelisib	Selleckchem	S7028
Enzastaurin	Selleckchem	S1055
Ganetespib	Selleckchem	S1159
GDC-0077	Selleckchem	S8668
Idelalisib	Selleckchem	S2226
Irinotecan	Selleckchem	S1198
KPT330	Selleckchem	S7252
Lenalidomide	Selleckchem	S1029
MK1775	Selleckchem	S1525
MLN2238	Selleckchem	S2180
NSC319726	Selleckchem	S7149
NVP742	Selleckchem	S1088
Ouabain	Selleckchem	S4016
Panobinostat	Selleckchem	S1030
PomalidomideS1567	Selleckchem	S1567
Prednisone	MedChemExpress	HY-B0214
Pralatrexate	Selleckchem	S1497
PU-H71	Selleckchem	S8039
RGFP-966	Selleckchem	S7229
RO4929097	Selleckchem	S1575
Romidepsin	Selleckchem	S3020

Ruxolitinib	Selleckchem	S1378
SC144	Selleckchem	S7124
Selumetinib	Selleckchem	S1008
Semagacestat	Selleckchem	S1594
SN38	Selleckchem	S4908
Stattic	Selleckchem	S7024
Tozasertib	Selleckchem	S1048
TGR1202	Selleckchem	S8194
Tofacitinib	Selleckchem	S2789
TSA	Selleckchem	S1045
Valemetostat	Selleckchem	S8926
Vincristine	Selleckchem	S9555
YKL-5-124	Selleckchem	S8863
YM155	Selleckchem	S1130
Ficoll-Paque PLUS	Cytiva	17144003
Trypan Blue	Sigma Aldrich	T10282
RPMI 1640 Medium	Gibco™	11875093
DMEM Medium	ThermoFisher Scientific	C11965092
Phosphate Buffered Saline (1X)	ThermoFisher Scientific	20021-027
Fetal Bovine Serum; Heat inactivated	Corning	35-011-CV
Ethylenediaminetetraacetic acid (EDTA) 0.5M	VWR	E522-100ML
Penicillin-Streptomycin-Glutamine (100X)	Gibco/Invitrogen	15140-122
Normocin	Invivogen	ant-nr-1
Gemcitabine	Selleck Chemicals	S1714
Mitomycin C	Sigma-Aldrich	M4287
0.25% Trypsin-EDTA	Gibco™	25200056
Collagenase Type IV	Sigma-Aldrich	C5138-5G
Accutase cell dissociation reagent	ThermoFisher Scientific	A1110501
Cell strainer, 100µm, filter	Corning	431742
Cell strainer, 70µm, filter	Corning	431751
Cell strainer, 40µm, filter	Falcon, Fisher Scientific	C352340
Recombinant Human IL-2	R&D systems	202-IL
Recombinant Human IL-7	R&D systems	207-IL-025
Recombinant Human IL-15	R&D systems	247-ILB
DNase I	Worthington Biochemical	LS002007
LB agar Lennox	Gibco	244520
Trizol	ThermoFisher	15596018
SYBR™ Select Master Mix	Applied Biosystems	4472897
EBER probes	Leica	ISH5687-A

CellTrace™ CFSE Cell Proliferation Kit	Invitrogen	C34554
CellTrace™ Violet	Invitrogen	C34557
Critical commercial assays		
SureSelect Strand-Specific RNA Library Agilent Preparation Kit	Agilent	G9691A
TruSeq® Stranded Total RNA Library Prep Human/Mouse/Rat	Illumina	20020597
SureSelectXT Human All Exon 50 Mb v4 Kit	Agilent	5190-4632
SureSelectXT Human All Exon 50 Mb v5 Kit	Agilent	5190-6209
DNeasy Blood & Tissue Kit	Qiagen	69504
RNeasy Mini kit	Qiagen	74106
Qubit dsDNA HS and BR Assay Kits	Thermo Fisher Scientific	Q32851
Bio-Rad protein assay kit	Bio-Rad Laboratories	5000001
PCR Mycoplasma Detection Kit - Quantity: 100 Reactions	Applied Biological material	G238
CD3 MicroBeads, human	Miltenyi Biotec	130-097-043
CD19 MicroBeads, human	Miltenyi Biotec	130-050-301
<i>TCRB</i> Gene Clonality Assay	Invivoscribe	12050011
<i>IGH</i> + <i>IGK</i> B-Cell Clonality Assay	Invivoscribe	11000031
Chromium™ Next GEM Single Cell 5' Library and Gel Bead Kit v1.1	10x Genomics	1000165
Chromium™ Single Cell 5' Library Construction Kit	10x Genomics	1000020
Deposited data		
Raw Data Files from RNA-seq	This paper - SRA	SRA: PRJNA1214670
Raw Data Files from WES	This paper - SRA	SRA: PRJNA1198080
Raw Data Files from scRNASeq	This paper - SRA	SRA: PRJNA1218277
WES data	Nat Genet Da Silva Almeida 2015	https://www.nature.com/articles/ng.3442#Sec17
WES data	Nat Genet Sakata-Yanagimoto 2014	https://www.nature.com/articles/ng.2872#Sec24
WES data	Nat Genet Choi 2015	https://www.nature.com/articles/ng.3356#Sec34
WES data	Mod Pathol 2020 Laginestra	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994417/
WES data	Nat Genet Kataoka 2015	https://www.nature.com/articles/ng.3415#Sec45
WES data	Frontiers in Oncology Mirza 2020	https://www.frontiersin.org/articles/10.3389/fonc.2020.00514/full

WES data	<i>Nat Genet Jiang 2015</i>	https://www.nature.com/articles/ng.3358
WES data	<i>Cancer cell Crescenzo 2015</i>	https://www.cell.com/cancer-cell/fulltext/S1535-6108(15)00094-X#secsectitle0015
WES data	Palomero, Nat Genet. 2014	https://www.nature.com/articles/ng.2873#Sec26
Targeted genomic	Schatz, Hortwitz, Weinstock Leukemia 2014	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286477/table/tbl1/?report=objectonly
Targeted genomic	Yoshida, Weinstock Blood 2020	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7180081/
Targeted genomic	<i>Nat Genet Sakata-Yanagimoto 2014</i>	https://www.nature.com/articles/ng.2872#Sec24
Targeted genomic	<i>Kataoka, Nat Genet. 2015</i>	https://www.nature.com/articles/ng.3415#Sec44
Targeted genomic	<i>Nat Genet Jiang 2015</i>	https://www.nature.com/articles/ng.3358
Targeted genomic	<i>Cancer cell Crescenzo 2015</i>	https://www.cell.com/cancer-cell/fulltext/S1535-6108(15)00094-X#secsectitle0015
RNA_Sequencing data	EGA	EGAS00001001296
RNA_Sequencing data	phs000689	phs000689
RNA_Sequencing data	SRP049695	SRP049695
RNA_Sequencing data	SRP029591	SRP029591
RNA_Sequencing data	SRP099016	SRP099016
RNA_Targeted data	GSE58445	GSE58445
RNA_Targeted data	GSE45712	GSE45712
RNA_Targeted data	GSE19069	GSE19069
RNA_Targeted data	GSE90597	GSE90597
RNA_Targeted data	GSE6338	GSE6338
RNA_Targeted data	GSE36172	GSE36172
RNA_Targeted data	E-TABM-783	E-TABM-783
RNA_Targeted data	GSE65823	GSE65823
RNA_Targeted data	GSE118623	GSE118623
RNA_Targeted data	E-TABM-702	E-TABM-702
RNA_Targeted data	GSE78513	GSE78513

RNA_Targeted data	GSE51521	GSE51521
RNA_Targeted data	GSE14317	GSE14317
RNA_Targeted data	GSE80631	GSE80631
RNA_Targeted data	GSE19067	GSE19067
RNA_Targeted data	GSE20874	GSE20874
Experimental models: Cell lines		
TO-ALCL-Belli PDX-Dline	This paper	N/A
TO-ALCL-DN03 PDX-Dline	This paper	N/A
TO-ALCL-MARI PDX-Dline	This paper	N/A
IL2 PDX-Dline	This paper	N/A
IL69 PDX-Dline	This paper	N/A
IL79 PDX-Dline	This paper	N/A
IL86 PDX-Dline	This paper	N/A
IL89 PDX-Dline	<i>Fiore, Cappelli, et al Cancers 2020</i> ¹²³	https://pub-med.ncbi.nlm.nih.gov/32560455/
IL104 PDX-Dline	This paper	N/A
IL135A PDX-Dline	This paper	N/A
IL142A PDX-Dline	This paper	N/A
IL 223B PDX-Dline	This paper	N/A
IL 228 PDX-Dline	This paper	N/A
COH1 PDX-Dline	This paper	N/A
MS-5 cell line	DSMZ	ACC 441
SUPM2 cell line	DSMZ	ACC 509
L82 cell line	DSMZ	ACC 597
MAC1 cell line	Expasy	CVCL_H631
TLBR1 cell line	DSMZ	ACC 904
Experimental models: Organisms/strains		
NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ	The Jackson Laboratory	5557
NOD.Cg-B2mtm1Unc Prkdcscid Il2rgtm1Wjl/SzJ	The Jackson Laboratory	10636
NOD.Cg-Prkdcscid H2-K1b-tm1Bpe H2-Ab1g7-em1Mvw H2-D1b-tm1Bpe Il2rgtm1Wjl/SzJ	The Jackson Laboratory	025216
NOD.Cg-Hc1 Prkdcscid Il2rgtm1Wjl/SzJ	The Jackson Laboratory	030511
Patient-derived xenografts (PDX)	This paper	Table S1
Oligonucleotides		
Primers for RTqPCR	This paper	Table S12
Software and algorithms		
Excel 2016	Microsoft	https://www.office.com/

GSEA (4.1.0)	Subramanian et al. 2005	https://www.gsea-msigdb.org/gsea/index.jsp
Halo	Indica labs	https://www.indicalab.com
STARTRAC	Zhang et al., 2018b	https://github.com/Jaaprin/STARTRAC
STAR aligner v2.6.1	Dobin et al., 2013	https://github.com/alexdobin/STAR
DiVa V8.0.1	BD Biosciences	https://www.bdbiosciences.com/en-us/products/software/instrument-software/bd-facsdiva-software
FlowJo v10.7.1	FlowJo, LLC	N/A
R v4.3.1	R Core Team, 2014 ¹²⁴	https://www.r-project.org
CIBERSORT	Newman et al., 2015	https://cibersort.stanford.edu/
Seurat v.4.0.3	Stuart et al., 2019	https://satijalab.org/seurat/
BLAST	Altschul (1990)	ftp.ncbi.nlm.nih.gov/blast/executables/blast=/LATEST
ImageJ Software	Open source	N/A
GraphPad Prism software version 9.3.1	GraphPad Software, Inc.	https://www.graphpad.com/
IGV	Robinson et al., 2011	http://software.broadinstitute.org/software/igv/
Kassandra code	Zaitsev A. et al Cancer Cell. 2022 Aug 8;40(8):879-894.e16. doi: 10.1016/j.ccell.2022.07.006.	https://github.com/BostonGene/Kassandra
Shiny v1.7.4	R Studio Partners, R Core Team 2019 ¹²⁵	https://www.r-project.org/nosvn/pandoc/shiny.html
Tidyverse v1.3.9	vignettes/paper.Rmd ¹²⁶	https://www.tidyverse.org/packages/
Bioconductor v3.17	Huber et al. 2015 ¹²⁷	https://www.bioconductor.org
Paper code #1	This paper	https://github.com/marchionniLab/ing-2023 - https://doi.org/10.5281/zenodo.14847458

Paper code #2	This paper	https://github.com/Mew233/DeepPTCL - https://doi.org/10.5281/zenodo.14845644
Other		
Clinical Annotations	This paper	Table S1
BD FACSCanto™ II	BD Biosciences	N/A
BD LSR Fortessa	BD Biosciences	N/A
LSRII	BD Biosciences	N/A
BD FACSARIA™ III Cell Sorter	BD Biosciences	N/A
BD FACSCelesta™ Cell Analyzer	BD Biosciences	N/A
NovaSeq 6000	Illumina	N/A
TissueLyser II	Qiagen	85300
Leica Bond-III	Leica instruments	N/A
Leica Bond-RX	Leica instruments	N/A
Rodent diet	PicoLab Rodent Diet 20	5053
Ventilated cages	N/A	N/A
Mouse hair removal kit	3 M	9667L
Gauze Sponges	Thermo Fisher Scientific	13-761-52
VWR® Dissecting Scissors, Sharp Tip, 41/2"	VWR	82027-578
VWR Dissecting Forceps	VWR	89259-944
Isoflurane chamber with nose cone	N/A	N/A
Wound Clip Complete Kit	Thermo Fisher Scientific	BD427638
1 ml syringe	VWR	76124-644
5 ml syringe	VWR	76163-596
Animal Ear Punch, Plier-Style	VWR	N 10806-290
Freezing container	VWR	55710-200
50ml Falcon Tubes	VWR	CA21008-940
Sterile Petri Dish	VWR	25384-342
Scalpel with blade no. 10	VWR-Miltex	21909-654
Sterile razor	VWR	55411-050
2ml Serological Pipette	Thermo Fisher Scientific	170365
5ml Serological Pipette	Thermo Fisher Scientific	170355
10ml Serological Pipette	Thermo Fisher Scientific	170367
25ml Serological Pipette	Thermo Fisher Scientific	170357
Alcohol pad	VWR	720-2586

Puralube® Ophthalmic Ointment	Patterson veterinary	211-38
Sutures: Dermalon Suture, Blue, Size 5/0, 18", CE-4 Needle	Medline	D-G175621
Insulin Syringes	VWR	BD328438
RAM Scientific Safe-T-Fill™ Capillary Blood Collection Systems: Lithium Heparin	ThermoFisher	14-915-65
Lab animal scale	N/A	N/A
Digital caliper	VWR	36934-152
Carbon Dioxide (CO2)	N/A	N/A
Isoflurane	N/A	N/A
Feeding gavage needles	braintreescientific	N-VP 22G-15S
Mouse Tail Illuminator Restrainer	braintreescientific	MSPP-MTISTD
Matrigel	Corning	354234
Trocar for mouse surgery	braintreescientific	TRO 14MS
Surgical Scrub Betadine	Purdue Products LP	6904214-40890
Betadine Iodine Solution	Purdue Products LP	158348
Meloxicam	Boeringer Ingelheim	L20805A-42
Tear gel	Optixcare Eye Lube	BP231-1
Ethyl Alcohol Anhydrous	Commercial Alcohols	PO16EAAN

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Giorgio Inghirami (ggi9001@med.cornell.edu).

Materials availability

Biobanked PDX are cataloged by the Center for Technology Licensing (<https://innovation.weill.cornell.edu>) and can be requested. Distribution of PDX and derived cell lines to third (academic or commercial) parties requires completion of a material transfer agreement and must be authorized by the medical ethical committee of WCM at request of the HUB to ensure the compliance with Institutional Review Board-Research at the Weill Cornell Medicine research involving human subjects' act. Use of PDX is subjected to patient consent; upon consent withdrawal, distributed PDX and any derived material will have to be promptly disposed of.

Data and code availability

- Raw sequencing data have been deposited to the Sequence Read Archive (SRA - <https://www.ncbi.nlm.nih.gov/sra>) and are publicly available. Accession numbers are listed in the key resources table (WES: PRJNA1198080; RNASeq: PRJNA1214670; scRNASeq:

PRJNA1218277). Also, this paper analyzes existing, publicly available data, whose accession numbers are listed in the key resources table.

- Codes used in this study are deposited at <https://github.com/marchionniLab/ing-2023> (<https://doi.org/10.5281/zenodo.14847458>) and <https://github.com/Mew233/DeepPTCL> (<https://doi.org/10.5281/zenodo.14845644>) and listed in the key resources table.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

EXPERIMENTAL MODEL AND STUDY PARTICIPANT DETAILS

Human study

The collection of PTCL patient data and tissue for the generation and distribution of PDX and derivatives were performed according to the guidelines of the Institutional Review Board-Research at the Weill Cornell Medicine, Memorial Sloan Kettering's Institutional Review Board (IRB)/Privacy Board and the Comitato Etico Interaziendale, AOU San Giovanni Battista di Torino and CTO Maria Adelaide di Torino. All patients participating in the study signed informed consent forms approved by the authority responsible (see above). In all cases, patients can withdraw their consent at any time, leading to the prompt disposal of their tissue and any derived material. Biobanked Patient-Derived models can be requested at <https://innovation.weill.cornell.edu>. Clinical information is available in Table S1. Additional data i.e. age, gender, genetics, therapy, etc. of subjects can be inquired through <https://innovation.weill.cornell.edu>.

Pathological samples most frequently from diagnostic tissue samples (76/88), and some from bone marrow (3/88), pleural effusions (2/88), or peripheral blood (7/88) were collected at the Weill Cornell Medicine (WCM) of New York, University of Torino, and Memorial Sloan Kettering Cancer Center (MSKCC). Both fresh (n=54) and viably cryopreserved tissue samples were implanted (n=34). Diagnoses were assigned according to the WHO classification by expert pathologists. De-identified patients' samples (323) were obtained with informed consent under WCM (78), Torino (6), MSKCC (234), S. Raffaele at Milan (1), City of Hope (3), and Mount Sinai (1) Institutional Review Boards (IRB)-approved protocols, according to the Declaration of Helsinki.

Mice models

NOD Cg-*Prkdc*^{scid} *Il2rg*^{tm1Wjl}/SzJ (NSG), NOD.Cg-B2m^{tm1Unc} *Prkdc*^{scid} *Il2rg*^{tm1Wjl}/SzJ (NSG B2m), NOD.Cg-*Prkdc*^{scid} H2-K1b-tm1Bpe H2-Ab1g7-em1Mvw H2-D1b-tm1Bpe *Il2rg*^{tm1Wjl}/SzJ (NSG-MHC I/II DKO), and NOD.Cg-Hc1 *Prkdc*^{scid} *Il2rg*^{tm1Wjl}/SzJ (NSG-Hc1) mice were originally purchased from Jackson Laboratories and then bred in-house and handled according to WCM Institutional Animal Care and Use Committee (protocol #2014-24).

Primary PTCL samples were implanted subcutaneous (sc, 2 fragments, 1mm³ each) or via intravenous (iv; 1 × 10⁶ cells, 150 µL of DPBS) or intra bone (ib; 1 × 10⁶ cells, 10-20 µL of DPBS) routes, in 4-6-week-old (male/female ratio: 1:1) NSG B2m/NSG-MHC I/II DKO mice¹²⁸. PDX-Dlines were s.c. implanted in Matrigel (25%, 1x10⁶ cells, 150 µL of DPBS). Engraftment was monitored every week by visual inspection (s.c.) and/or multicolor flow cytometry on peripheral blood. Mice were sacrificed at the earlier sign of distress. All tissues were collected for histology, immunohistochemistry, and

additional ancillary studies. Viable and dry samples were cryopreserved for PDX transplantation/biobanking and genomic/functional studies. Tumors were then propagated along multiple generations corresponding to serial passages (T).

Cell culture

PDX-Dlines, PDX derived stromal cells, PTCL continuous cell lines (SUPM2, L82, MAC1 and TLBR1), and MS-5 stromal cell line were cultured in RPMI (Sigma) supplemented with 20% FBS (Corning), 100 U/ml glutamine (Sigma), Normocin 1:500 (InvivoGen) and 100µg/ml streptomycin (Sigma) and maintained at 37°C in a humidified 5% CO₂ atmosphere. IL2 and TO-ALCL-BELLI PDX-Dlines were supplemented with exogenous interleukin2 (50U/ml) and interleukin15 (10ug/ml) (R&D). Cells were analyzed by flow cytometry using a panel of monoclonal antibodies against human T-Cell surface markers twice per year.

METHOD DETAILS

Isolation of viable PDX-derived tumor cells

Tumor tissue was finely dry minced using sterile blades and digested for 30-45 minutes at 37°C. Digestion media was composed of RPMI1640 (Sigma) and digestion buffer (4:1). The digestion buffer was prepared according to the following: 140nM NaCl (Sigma), 5mM KCl (Sigma), 2.5mM Phosphate buffer pH7.4 (prepared by solving 3.1g of NaH₂PO₄-H₂O and 10.9g of Na₂HPO₄ anhydrous in 1 liter of sterile cell culture grade water), 10mM Hepes (Sigma), 2mM CaCl₂ (Sigma), 1.3mM MgCl₂ (Sigma), 25mg/ml of Collagenase A (Roche), 25mg/ml Dispase II (Sigma), 250mg/ml DNAase (Roche). The digested tissue was then passed through 70µm nylon filters (Corning) and the resulting cell suspension was washed twice with PBS (Sigma). Cells were resuspended in RPMI1640 (Sigma) plus 20% FBS (Gibco) and seeded at 1 million/ml in T150 flasks (Corning) overnight. The day after, floating T-Cells were separated from stromal cells attached to the flasks and centrifuged on a Ficoll Paque (Sigma) gradient to remove dead cells, red blood cells, and debris, to isolate a pure (>95%) and viable (>95%) T-Cell population. Stromal adherent cells were cultured (RPMI1640 20%FBS - Sigma) and used for experimental purposes if needed. T-cell suspensions were cultured (RPMI1640 20%FBS – Sigma/Corning) and analyzed by flow cytometry using a panel of monoclonal antibodies against human T-Cell surface markers.

Histopathological analyses

Tissues were recovered within 0.5-1hr after mouse sacrifice, fixed in 10% neutral buffered formalin (Sigma), and processed for histology and immunohistochemistry. Immunohistochemistry was performed on 4µm Formalin Fixed Paraffin Embedded (FFPE) sections of multiple organs (lungs, spleen, liver, heart, kidney, and tumor mass). Deparaffinization, rehydration, and antigen retrieval were performed by BERS2 (prediluted; pH 9.0) antigen retrieval solution performed on the Bond-III Leica automated slide stainer for 20 minutes at 100°C. Specimens were incubated with primary antibodies (Table S11 and Key resources table) followed by visualization with the Leica Bond detection kit (BOND Polymer Refine Detection) for 15 minutes at room temperature. For dual optical staining, sections were then incubated with a second primary antibody and developed using a BOND Polymer Refine Red Detection, as described above. The specimens were then counterstained with hematoxylin and the cover slipped. Each IHC run contained external positive controls.

All the antibodies used (Table S11 and Key resources table) were diluted in PBS (Sigma).

Multicolor flow cytometry

Flow cytometry was performed by staining lymphoma cells with a mix of antibodies diluted 1:100 in PBS and recognizing T- and B-cell restricted markers. The antibodies used are summarized in the supplementary material and were purchased from BD Biosciences. Briefly, lymphoma cells were identified after gating on human CD45⁺ cells, and the selected markers were analyzed inside the human CD45-positive cell population. At least 10000 events were acquired. Samples were run on the BD FACSCanto™ and analyzed with the BD FACSDiva software.

Dual-color fluorescence in situ hybridization (FISH)

BAC clones spanning the gene loci were obtained from BACPAC Resources at <http://bacpac.chori.org>. Commercial FITC centromeric probes were used as well (Abbott Park, Illinois, U.S.A). DNA was labeled by nick-translation using spectrum green or Spectrum red-dUTP fluorochromes (Abbott). FISH was performed by standard methods and at least 20 metaphase spreads or 200 inter-phase nuclei on DAPI-stained slides were scored.

Multiplex Immunofluorescence Tissue Staining

Multiplexed immunofluorescence (mIF) was performed using the Opal system (Akoya Biosciences) and SignalStar™ by staining 4 micron-thick Bouin-fixed, paraffin-embedded whole-tissue sections from diagnostic biopsy specimens in a Bond RX automated tissue stainer (Leica Biosystems, Buffalo Grove, IL)¹²⁹. Alternatively, we used a combination of oligonucleotides and fluorophores to amplify the antibody signal, allowing for the detection of targets, at low expression levels (<https://www.cellsignal.com/applications/signalstar-multiplex-ihc-overview>). Whole slide scans were subsequently obtained at 20X magnification using the Vectra Polaris Automated Quantitative Pathology Imaging System (Akoya Biosciences) to generate a collection of tiled images, which were subsequently spectrally unmixed in InForm (v2.4.8, Akoya Biosciences). Unmixed tiles were finally fused in HALO (v3.3.2541.231, Indica Labs) to generate a single multi-layered TIFF image file for each sample, which was used in downstream analyses. The analysis was performed using QuPath 0.5.1 (<https://qupath.github.io>) where we identified each phenotype based on the median intensity of independent marker histograms.

The main phenotypes of the TME validation were classified as T cells (CD3 marker), Macrophages (CD68 and CD163), Fibroblast (SMA), B cells (CD20), and Others (DAPI without any other marker).

DNA and RNA extraction

Total RNA extraction from (dry frozen) tissues or cells was performed using TRIZOL (Invitrogen) according to the manufacturer's protocols. RNA quality was checked on an Agilent Bioanalyzer (Agilent Technologies). Samples with an RNA integrity number (RIN) >7 were selected for further analysis. RTqPCR was executed using the iQ SYBR Green Real-Time PCR Supermix (BioRad). The list of primers is reported in the Supplemental Table S12. Genomic DNA was extracted from (dry frozen) tissues or cells using phenol/chloroform (Sigma). Quality and quantity were checked using the Agilent TapeStation (Agilent) and Qubit (Invitrogen).

Identification of clonal antigen receptor gene rearrangements

Clonal rearrangements of BCR (IgH and IgK) and TCR genes were determined using the Invivoscribe kit based on the BIOMED-2 assay¹³⁰ on extracted DNA. PCR products are analyzed by capillary electrophoresis (CE) using the ABI 3500 Genetic Analyzer.

Total RNA and Whole-Exome sequencing

Total RNA was used for cDNA library preparation using the TruSeq-Stranded Total RNA sample preparation (HS protocol) following the manufacturer's instructions (Illumina). DNA1000 Kit (Agilent) was used to size and quantify the library preparation on an Agilent 2100 Bioanalyzer. Sequencing data were aligned to the human reference genome (hg38) using the STAR v2.3.5 aligner (Dobin, Davis et al. 2013) after human-mouse read disambiguation via BBsplit v37.76. Gene counts were calculated by using featureCounts (Liao, Smyth et al. 2014) v1.4.6 concerning Gencode v19 annotations. TCR signaling activity was determined from RNA-sequencing using validated signatures available at MSigDB (<https://www.gsea-msigdb.org/gsea/msigdb/index.jsp>).

For whole-exome sequencing, genomic DNA was used to prepare the libraries using the SureSelect 6.0 kit (Agilent), according to the manufacturer's protocol. Whole exome sequencing data were aligned to the human reference genome (hg38) using mem from BWA v-0.7.12 (Li 2013). Duplicate reads were removed using the MarkDuplicates command from Picard v1.124 (<http://broadinstitute.github.io/picard/>), and local realignment around indels was performed using ABRA v0.92 (Mose, Wilkerson et al. 2014). Somatic mutations were called with MuTect v1.1.5. FACETS v0.9.7-13 was employed for copy number analysis (Shen and Seshan 2016), and the segmentation was visualized in R with the plotAberration function from the copy number package (Nilsen, Liestol et al. 2012). Both RNA and DNA libraries were sequenced on an Illumina HiSeq 4000 (paired-end, 100bp or 50bp).

RNAseq data filtering and surrogate variable analysis

To analyze RNAseq data on PDX samples, mouse reads were filtered out using bbsplit.sh from the BBMap v37.76 package (<https://github.com/BioInfoTools/BBMap/tree/master>). We then only focused on human reads to perform subsequent expression analyses.

To overcome the heterogeneity in gene expression of different samples (e.g. primary and PDX) we constructed "surrogate variables" to assess so-called latent co-variables (variables that are not related to the factor of interest) using the svaseq package^{131,132}. This method provides a sample-wise matrix of numeric vectors representing surrogate variables which capture sources of variation in the data that are not of primary interest. When incorporated into downstream analyses, e.g., differential expression analysis, these variables are accounted for in the determination of differentially expressed genes. These adjustments resulted in a PCA plot (Figure 3A) defining the separation by subtype and intermingling between primary and PDX samples.

Binding affinity prediction

NetMHCIIpan-4.1 algorithm was used to Predict Binding Affinity of EBV Peptides¹³³. Each peptide's binding affinity was predicted for MHCII alleles found in PTCL primary and patient-derived models. To improve binding affinity, the original peptide sequences were extended followed by performing predictions for the prevalent MHCII alleles, which are common in over 90% of the population¹³⁴. For the synthesis, peptides with a predicted binding affinity of < 1000 nM for the haplotypes found in the patient-derived models were chosen. The peptides were synthesized by Genscript Biotech, NJ, USA.

Single-cell RNA-seq and data analyses

The 10x Genomics Chromium v.2 protocol was carried out according to the manufacturer's recommendations (10x Genomics, Pleasanton, CA). A total of 2000–5000 cells per sample were processed using Cell Ranger version 2.1.0 with default parameters. Reads were aligned to the human reference sequence hg38. Reads from the PDX tissues were additionally aligned to the mouse reference sequence mm10. Downstream analysis was performed using the Seurat package (version 3.2.2) in R (Butler et al., 2018). Low-quality cells (e.g., cells with >200 or <5000 unique molecular identifiers (UMIs) per cell and cells with >10% mitochondrial gene percentage) were removed. Doublets were identified using DoubletFinder¹³⁵ and removed. Normalization, variance stabilization, and integration were performed using SCTransform workflow¹³⁶. Uniform manifold approximation and projection (UMAP) dimensionality reduction was used to visualize cell clusters. Cells were then annotated using the SingleR package¹³⁷, which performs reference-based cell annotation. Two cell-type reference datasets from the celldex package¹³⁷ were utilized for cell annotation: the human primary cell atlas¹³⁸ and the Blueprint/ENCODE reference¹³⁹.

Targeted deep sequencing and mutation calling

A targeted sequencing gene panel including coding exons and splice sites of 538 genes (target region: ~3.2 Mb) that are recurrently mutated (>2) in mature T-cell neoplasms as well as genomic regions corresponding to recurrent translocations were designed to investigate the genomic profile of the primary and PDX tumors. Using an input of genomic DNA of at least 100 ng isolated from frozen tissues, the next-generation sequencing (NGS) libraries were constructed using the KAPA Hyperplus Kit (Roche), and hybrid selection was performed with the Twist Library Prep Kit (Twist Biosciences), according to manufacturer's protocols. Multiplexed libraries were sequenced using 150-bp paired end on HiSeq4000 sequencers (Illumina).

Paired sequencing fastq files were aligned to the human genome assembly (hg19) using the Burrows–Wheeler Aligner (version 0.7.1)¹⁴⁰. SAMtools (version 1.2)¹⁴¹ were used to sort, index the reads. Then, duplicated reads were marked with Picard (version 1). Somatic mutations were called by the variance calling software SAVI2, which is based on the empirical Bayesian method¹⁴². Somatic mutations that annotated as a synonymous variant, intragenic variant, or intron variant; annotated as a common SNP (dbSnp138); with variant allele frequency $\leq 5\%$ in the tumor sample; with altered reads ≥ 2 in the matched normal control; with overall mismatch rate > 0.02 (<https://github.com/genome/bam-readcount>) were removed. For PDX samples, reads originated from the mouse genome were removed by filtering out reads with 2 or less unmatched bases compared to the mouse reference genome (GRCm38). For those tumors without normal control, somatic mutations detected in any normal samples in the cohort were additionally filtered out. To annotate and predict the putative pathogenicity of the variants, we used the Annovar dbNSFP variants annotation and set a threshold of at least 3 concordant entries⁵⁹. Mutation signature analysis was performed using R package SomaticSignatures¹⁴³. Next, we used R package to generate the Ternary plot¹⁴⁴. To infer the mutation order of somatic variants in PTCL, we followed the strategy in Wang et al.⁷¹ for the reconstruction of tumor evolutionary directed graph. We selected the recurrently mutated genes to build patient specific evolutionary networks. A mutation observed in both the primary tumor and the PDX was defined as clonal events, whereas subclonal events were mutations only observed in one of these samples. Then, we pooled multiple sequential networks from different patients to construct the mutation order during tumor progression.

Copy Number Calling, Tumor Purity Estimation, CCF Estimation and Phylogenetic Tree Reconstruction

CNVkit¹⁴⁵ was used to generate estimated copy number variations (CNV) in a tumor specimen compared with its matching normal. GISTIC 2.0 was used to detect recurrent copy number variations (CNV)¹⁴⁶. ABSOLUTE was used to infer tumor purity and cancer cell fraction (CCF) for each WES sample by integrating variant allele frequencies (VAF) and copy number variations (CNV). Then, the ABSOLUTE-annotated MAF files were utilized by PhylogicNDT¹⁴⁷ to infer the clonal structure, phylogenetic relationship between clones and evolution among different time points. Fish plots were generated by R package fishplot¹⁴⁸.

TCR clonality and prediction of antigen binding

We used MiXCR (<http://mixcr.milaboratory.com/> and <https://github.com/milaboratory/mixcr/>), a universal framework that processes big immunome data from raw sequences to quantitated clonotypes¹⁴⁹. We defined explicit clones, populations expressing defined TCRs with a read coverage greater than 20, and the most abundant clone(s) with a significantly higher coverage compared to a second-most covered clonotype. We next interrogated the predicted amino acid sequences of the CDR3 using a curated database of T-cell receptor (TCR) sequences with known antigen specificities (<https://vdjdb.cdr3.net/search>)¹⁵⁰. Both TCR alpha and beta chains were evaluated, and mismatched were scored. We then correlated putative binding peptides and their corresponding aminoacidic sequences with HLA-A or HLA-B alleles. T Cell Receptor Gamma Gene Rearrangement was performed using a commercial Kit (Gamma TCR clonality was determined by Assay 2.0 - ABI Fluorescence).

Functional experiments

Cell number and viability were assessed by Trypan blue exclusion count (Invitrogen). Cell metabolism was evaluated using luminescence of CTG-tagged ATP kit (cell titer glo Promega kit), the plates were analyzed on a plate reader (Synergy 4, Biotek). Apoptosis was detected using Annexin V-7AAD Apoptosis Detection Kit I (BD Pharmingen), while cell death with propidium iodide staining (PI). Cells were analyzed by flow cytometry (BD LSR-II).

Protein isolation and Western blotting

Cells were lysed in JST buffer (Tris-HCl 20mM pH7.5, 150 mM NaCl, 1% Triton X-100, 5 mM EDTA, 1mM Na3VO4, 1mM PMSF, 10mM NaF, and 1X protease inhibitor cocktail, Sigma). Protein concentration was determined with the DC protein assay (BioRad) using bovine serum albumin (Sigma) as the standard, and equal amounts of protein were analyzed by SDS-PAGE (12% acrylamide). Gels were electroblotted into nitrocellulose membranes (G & E Healthcare). Membranes were blocked for 1 h with 5% non-fat dry milk (Sigma) in PBS plus 0.1% Tween-20 and incubated at 4°C overnight with the primary antibody. Detection was performed with peroxidase-conjugated secondary antibodies, using the enhanced chemiluminescence system (Thermo Scientific). Primary antibodies used were anti-phospho-p44/42 (Cell Signaling #9101, 1:10 dilution), anti-p44/42 (Cell Signaling #9102, 1:10 dilution) and anti-GAPDH (Cell Signaling #5174, 1:100 dilution).

DeepPTCL

DeepPTCL, a deep learning model designed to predict drug synergy on cell lines from the Cancer Genome Atlas. Drugs represented as SMILES were converted using RDKit into a PyG graph, with atoms represented as nodes and bonds represented as edges. The features of the cell line were gathered from the Genomics of Drug Sensitivity in Cancer. From the normalized expression levels of 17,737 genes, we selected 908 landmark genes. To develop the model, we used DrugComb (the largest database of high-throughput combination screening data) as a training dataset with 2,174 drugs on 164 cell lines, altogether a total of 16,3816 drug-drug-cell triplets. We then trained the model with a 5-fold cross-validation (each colored line represents a run). We designed two challenging tasks for training to improve model generalizability. In the leave-drug-out setup, we excluded drugs seen from training from the test set. For the leave-combination-out setup, the drug pairs from training were removed from the test set, although the same individual drugs might appear in both datasets. The performance of the model was evaluated using AUROC and PRAUC metrics. The higher AUROC and PRAUC value quantifies the better performance of the model. We show DeepPTCL, achieved an AUROC score of 0.806 (CI = 0.801-0.819) and a PRAUC score of 0.54 (CI = 0.518-0.576) on the held-out test data of 32,000 drug combinations.

Drug screenings and response prediction

The HTS drug-screening library, composed of 433 targeted-compounds, was purchased from SelleckChem, and consists of a subset of SelleckChem's 'Targeted Selective inhibitory Library'. Drugs were selected based on current clinical applications (FDA approved), selectivity (target of canonical signaling pathways [JAK/STAT, Ras/ERK, PI3K/ATK, β -catenin, chromatin-modifiers, anti-apoptotic etc.]) and redundancy (multiple drugs targeting the same pathways). Collectively, a total of 634 proteins were targeted. Drug screening plates were prepared at a concentration of 1 μ M spanning 2x 384 well plates using the Tecan Freedom EVO 150 (Tecan, CH) in the High throughput and Spectroscopy facility at Rockefeller University. ~33,000 PTCL cells were added per well, having 150 μ L of total volume (drug solution + cells), and incubated at 37°C for 72 hours. After drug incubation, cell viability was evaluated based on luminescence of CTG-tagged ATP (cell titer glo Promega kit), and assessed using a plate reader (Synergy 4, Biotek), and the data was processed, analyzed, and plotted using Matlab (Mathworks, MA). To determine compound activity, each data point was normalized to its corresponding in-plate vehicle control (16 wells of vehicle controls per plate), and then linearized to transform the response-matrix (16x33) into a 433x1 drug-response vector. To assess the degree of concordance, sample-replicates were plotted analyzed using principle component analysis (PCA). For the flow cytometry-based 53 drugs screening, the following conditions were applied: PTCL cells were labelled with Cell Tracer Violet (1 μ M, Invitrogen), washed and plated (83,000 cells/well) in 96-well plates and challenged with the drug library (1 μ M) in duplicate/triplicate. After 72 hours, all cells were collected and stained with propidium iodide (Sigma). In selected cases, 10000 stromal cells stained with CFSE (1 μ M, Invitrogen) were previously added and allowed to attach to the plate overnight. Cell viability was assessed by HTS flow cytometry (BD Celesta, Fortessa and Symphony). At least 10,000 events were recorded per well. Flow data were analyzed by FCSEXPRESS 7 (DeNovo Software) and Prism 9 (GraphPad Software, Inc.). When two drugs were screened in combination, compounds were delivered simultaneously at the indicated concentrations on PTCL cells plated as above. Readouts were collected and analyzed as described for the flow cytometry-based 53 drugs screening.

To perform prediction models using viability data and RNAseq data, we used the R caret (Classification And REgression Training) package as previously described, adopting a splitting data procedure with 70% training to 30% test ratio as validation¹¹.

For each drug, we explored gene signatures included in the drug-related KEGG pathway database and focused on gene sets predicting cell viability (“feature selection”) using recursive feature elimination or Gam scoring^{151,152}.

TME FGES

We previously developed a method for TME cell deconvolution and machine learning algorithm to reconstruct the TME using bulk expression data²⁴. This method is based on the presence and association of Functional Gene Expression Signatures (FGES) covering distinct cellular subtypes. Twenty FGES relevant to TME (e.g., cancer-associated fibroblasts and tumor-infiltrating lymphocytes), non-cellular components of the tumor microenvironment (e.g., immune-suppressive cytokines and extracellular matrix), biological processes (e.g., secretion and proliferation) were curated from the original FGES publication²⁴ and four canonical pathways activation were calculated using PROGENy (Pathway RespOnsive GENes¹⁵³). Twenty-four FGES (including four signaling pathways) were developed (Table S7). Selected cellular FGES were also validated using publicly available single-cell RNA-seq data²⁴.

TME clustering

FGES signatures were used to identify microenvironmental patterns among PTCL samples by unsupervised dense clustering using the Louvain method for community detection (63). FGES intensities were median-transformed within each cohort. Non-PTCL samples were also transformed using PTCL samples’ median and MAD values. Inter sample similarity was calculated using Pearson correlation. The resulting distance matrix was converted into a graph where each sample formed a node, and two nodes formed an edge with weight equal to the pair’s Pearson correlation. Edges with weight lower than specified thresholds were removed and the Louvain community detection algorithm was applied to calculate graph partitioning into clusters. To mathematically determine the optimum threshold for observed clusters, we used minimum David Bolduin, maximum Calinski Harabasz and Silhouette scores excluding separations with low-populated clusters (<5% of samples).

TME Heterogeneity and Pseudotime Analysis

Shannon diversity indexes were calculated from the TME cell deconvolution profiles. To calculate the TME heterogeneity index for each tumor, we performed cell deconvolution on the bulk RNA-seq samples from tumor tissue. From this prediction, we calculated the estimated proportion (p) of cells that belong to each distinct cell type. The subpopulation diversity index was then calculated as Shannon Index: $DI = -\sum_i (p_i \times \ln p_i)$, with larger values representing higher TME heterogeneity within the lymphoma. The monocle 2.0 R package¹⁵⁴ was implemented for dimensionality reduction and the construction of pseudotime.

Tumor Clonality

To process immunome data from RNA sequences into quantitated clonotypes, we applied MiXCR v2.1.7^{149,155}. Single clonotypes were grouped into clones with specific VDJ combination and identical CDR3 nucleotide sequences. For T cells, the clones were further aggregated into clone groups if the

VDJ combination was the same and CDR3 nucleotide sequences differed no more than 1 nucleotide. The biggest clone group was assigned as tumor if the absolute clonotype counts > 20; the relative clonotype counts > 5%; the ratio of the second biggest group to the first < 0.6 and the group contains an enriched clone > 25%. The TCRa/b chains were called if there was an enriched clonotype in one of the TCR chains. In cases with an enriched clone in both chains, the biggest by absolute counts was selected.

Viral reads identification

Viral reads identification was based on GATK Pathseq software kit ¹⁴², quantitative assessment expressed in VRM (viral read per million human reads). Viral status and serotype verification were performed using the VIRTUS pipeline ¹⁴³. Threshold for determining viral status as "positive" was chosen at 2 VRM (viral reads per million host reads). At this threshold, the number of raw reads makes it possible to evaluate the expression of viral transcripts. Mapping, score, and quantification of viral transcripts was also analyzed by ViGEN ¹⁴⁴.

Analysis of Murine TME Signatures

We used Kallisto v.0.42.4¹⁵⁶ to align RNA-sequencing reads to the transcriptome reference GRCm38.p6. Transcript annotation (protein coding and noncoding), transcript to gene mapping, and annotation to human homologs for murine genes were retrieved from the Ensembl database¹⁵⁷. For the PDX sample xengsort algorithm ¹⁴⁶ was used to split reads into human, mouse or neither origin. Gene expression was calculated by combining host and graft raw Kallisto output and refactoring TPM values. Only protein-coding genes with human homologs were used in subsequent analysis. To measure the similarity between the human lymphoma sample microenvironment and a particular murine lymphoma phenotype, we developed the microenvironment similarity (MES) metric, which is a reversed Euclidean distance between estimated percentages of different cell types in murine and human samples as follows: $MES(P, s) = 1/(p_{humani} - p_{mousei})^2$, where P is a murine lymphoma phenotype, s is a human lymphoma sample, p_{humani} is the estimated cell percentage of cell type i in the sample s , p_{mousei} is the median estimated cell percentage of cell type i among murine samples with phenotype P .

Kassandra deconvolution

To get more quantitative insights into the human and PDX TME we utilized previously developed algorithm Kassandra. It allows to estimate percentages of the major populations of cells using bulk RNA-sequencing⁷⁷.

CART generation and production

Human T cells obtained from the University of Pennsylvania Human Immunology Core were combined in a 1:1 ratio of CD4+ and CD8+ cells. For cells subjected to electroporation (CD5 KO CART5 cells), a mixture of 5 µg sgRNA and 10 µg of TrueCut Cas9 Protein v2 (Invitrogen; Cat# A36499) was prepared and incubated at room temperature for 10 minutes to form a ribonucleoprotein (RNP) complex before electroporation. The CRISPR-Cas9 sgRNA was chemically synthesized (Integrated DNA Technologies). A total of 10×10^6 T cells in 100 µL of the buffer provided with P3 Primary Cell 4D-Nucleofector X Kit L (Lonza; Cat# V4XP-3024) were mixed with the RNP complex and electroporated using the pulse code EO-115 in a 4D-Nucleofector (Lonza; Cat# AAF-1002B). Mock KO UTD cells

underwent the same electroporation procedure described above without the presence of an RNP complex. Following electroporation, T cells were incubated at 37°C for 24 hours and subsequently activated using CD3/CD28 Dynabeads (Gibco; Cat# 40203D) at a ratio of 3 beads per cell. For cells not subjected to electroporation (UTD and CART30), the expansion process began at the CD3/CD28 Dynabead activation step. The following day, CAR lentiviral vectors (CAR5 or CAR30) were introduced to the stimulated cultures at a multiplicity of infections ranging between 1 and 3. Beads were removed between days 6-8 post-stimulation, and cell counting was performed every other day using a Moxi GO II (Orflo) until growth kinetics and cell size indicated they had rested from stimulation. Initially, all electroporated T cells were cultured with 20 ng/mL of supplemental cytokines IL-7 and IL-15, which were gradually reduced to 0 ng/mL by the end of the expansion process.

For the *in-vitro* cytotoxic assays, PDX-Dline cells (5×10^5 /well) were cocultured with CAR T cells at the indicated E:T ratios in 96 well round bottom for 24-48-72 hours. Cells were harvested, washed and stained with an amine-reactive viability dye for dead cell detection and surface T-cell associated/restricted antigens. The samples were analyzed by flow-cytometry (FCM). Percent of viable cells, and target cells (PDX-Dline cells of CART) were enumerated. Specific lysis was calculated using the following formula: % specific lysis = [(experimental lysis – spontaneous lysis)/(maximum lysis – spontaneous lysis)] $\times$ 100.

For the *in-vivo* CART adoptive therapies 6–10-week-old NOD-SCID- γ c $^{-/-}$ (NSG) mice were injected on day 7-14 after s.c. tumor delivery, 1×10^6 T cells (control or CAR engineered) were injected via tail vein in 0.2mL sterile PBS. Animals were monitored for signs of disease progression and overt toxicity, such as xenogeneic graft-versus-host disease, as evidenced by >10% loss in body weight, loss of fur, diarrhea, conjunctivitis, and disease-related hind limb paralysis.

Preclinical in-vivo studies

For *in-vivo* experiments, xenografts were surgically implanted in 4-8 weeks old adult NSG mice and numbers, age, and gender of the mice were equally distributed among arms. Compounds were administered according to Table S10. Mice were closely followed for symptoms of tumor progression until moribund. Tumor burden was evaluated by digital caliper twice a week on s.c. masses or MRI where specified. Bodyweight was used as a surrogate for drug toxicity. Statistics and graphic representation were generated using Prism 9 (GraphPad Software, Inc.).

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistics and Software

Statistical significance was calculated by two-tailed Student's *t* test and Mantel–Cox test with GraphPad Prism software. GraphPad Prism software was used to calculate the IC₅₀ values. Statistically significant differences are indicated with asterisks in the figures, accompanied by *P* values in the figure legends. Error bars indicate standard error of the mean (SEM) for the number of replicates, as indicated in the figure legends. Data visualization and plots were generated in R. Schematic visualizations were produced at <https://biorender.com>.

References

1. Swerdlow, S.H., Campo, E., Arber, D.A., Cazzola, M., Cook, J.R., Dohner, H., Dreyling, M., Hasslerjian, R.P., Jaffe, E.S., Orazi, A., et al. (2022). Response to "The WHO classification of haematolymphoid tumours" (Editorial). *Leukemia* 36, 2748-2749. 10.1038/s41375-022-01689-9.
2. Fiore, D., Cappelli, L.V., Broccoli, A., Zinzani, P.L., Chan, W.C., and Inghirami, G. (2020). Peripheral T cell lymphomas: from the bench to the clinic. *Nat Rev Cancer* 20, 323-342. 10.1038/s41568-020-0247-0.
3. Vose, J., Armitage, J., and Weisenburger, D. (2008). International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol* 26, 4124-4130. JCO.2008.16.4558 [pii]
10.1200/JCO.2008.16.4558.
4. Mak, V., Hamm, J., Chhanabhai, M., Shenkier, T., Klasa, R., Sehn, L.H., Villa, D., Gascoyne, R.D., Connors, J.M., and Savage, K.J. (2013). Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. *J Clin Oncol* 31, 1970-1976. 10.1200/JCO.2012.44.7524.
5. Khan, N., and Cheson, B.D. (2013). PTCL therapies: a review of treatment and outline of novel therapies. *Am J Ther* 20, 524-533. 10.1097/MJT.0b013e31828232a3.
6. Moskowitz, A.J., Stuver, R.N., and Horwitz, S.M. (2024). Current and upcoming treatment approaches to common subtypes of PTCL (PTCL NOS, ALCL, TFHs). *Blood*. 10.1182/blood.2023021789.
7. Broccoli, A., Argnani, L., and Zinzani, P.L. (2017). Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease. *Cancer Treat Rev* 60, 120-129. 10.1016/j.ctrv.2017.09.002.
8. Ma, H., Marchi, E., and O'Connor, O.A. (2020). The peripheral T-cell lymphomas: an unusual path to cure. *Lancet Haematol* 7, e765-e771. 10.1016/S2352-3026(20)30207-6.
9. Jack, J., Rotroff, D., and Motsinger-Reif, A. (2014). Lymphoblastoid cell lines models of drug response: successes and lessons from this pharmacogenomic model. *Curr Mol Med* 14, 833-840. 10.2174/1566524014666140811113946.
10. Yuan, R., Chen, S., and Wang, Y. (2020). Computational Prediction of Drug Responses in Cancer Cell Lines From Cancer Omics and Detection of Drug Effectiveness Related Methylation Sites. *Front Genet* 11, 917. 10.3389/fgene.2020.00917.
11. Kurilov, R., Haibe-Kains, B., and Brors, B. (2020). Assessment of modelling strategies for drug response prediction in cell lines and xenografts. *Sci Rep* 10, 2849. 10.1038/s41598-020-59656-2.
12. Cutucache, C.E., and Herek, T.A. (2016). Burrowing through the Heterogeneity: Review of Mouse Models of PTCL-NOS. *Front Oncol* 6, 206. 10.3389/fonc.2016.00206.
13. Chiarle, R., Gong, J.Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W.J., Dhall, G., Howes, J., Piva, R., and Inghirami, G. (2003). NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. *Blood* 101, 1919-1927. 10.1182/blood-2002-05-1343
2002-05-1343 [pii].
14. Dierks, C., Adrian, F., Fisch, P., Ma, H., Maurer, H., Herchenbach, D., Forster, C.U., Sprissler, C., Liu, G., Rottmann, S., et al. (2010). The ITK-SYK fusion oncogene induces a

- T-cell lymphoproliferative disease in mice mimicking human disease. *Cancer Res* 70, 6193-6204. 10.1158/0008-5472.CAN-08-3719.
15. Mhaidly, R., Krug, A., Gaulard, P., Lemonnier, F., Ricci, J.E., and Verhoeyen, E. (2020). New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. *Oncogenesis* 9, 73. 10.1038/s41389-020-00259-x.
 16. Debackere, K., Marcelis, L., Demeyer, S., Vanden Bempt, M., Mentens, N., Gielen, O., Jacobs, K., Broux, M., Verhoef, G., Michaux, L., et al. (2021). Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified. *Nat Commun* 12, 3705. 10.1038/s41467-021-24037-4.
 17. Ng, S.Y., Yoshida, N., Christie, A.L., Ghandi, M., Dharia, N.V., Dempster, J., Murakami, M., Shigemori, K., Morrow, S.N., Van Scoyk, A., et al. (2018). Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. *Nat Commun* 9, 2024. 10.1038/s41467-018-04356-9.
 18. Mer, A.S., Ba-Alawi, W., Smirnov, P., Wang, Y.X., Brew, B., Ortmann, J., Tsao, M.S., Cescon, D.W., Goldenberg, A., and Haibe-Kains, B. (2019). Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. *Cancer Res* 79, 4539-4550. 10.1158/0008-5472.CAN-19-0349.
 19. Ireson, C.R., Alavijeh, M.S., Palmer, A.M., Fowler, E.R., and Jones, H.J. (2019). The role of mouse tumour models in the discovery and development of anticancer drugs. *Br J Cancer* 121, 101-108. 10.1038/s41416-019-0495-5.
 20. Garcia-Tunon, I., Hernandez-Sanchez, M., Ordonez, J.L., Alonso-Perez, V., Alamo-Quijada, M., Benito, R., Guerrero, C., Hernandez-Rivas, J.M., and Sanchez-Martin, M. (2017). The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia. *Oncotarget* 8, 26027-26040. 10.18632/oncotarget.15215.
 21. Wei, X., Yang, J., Adair, S.J., Ozturk, H., Kescu, C., Lee, K.Y., Kane, W.J., O'Hara, P.E., Liu, D., Demirlenk, Y.M., et al. (2020). Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cells. *Proc Natl Acad Sci U S A* 117, 28068-28079. 10.1073/pnas.2009899117.
 22. Szlachta, K., Kescu, C., Tufan, T., Adair, S.J., Shang, S., Michaels, A.D., Mullen, M.G., Fischer, N.L., Yang, J., Liu, L., et al. (2018). CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response. *Nat Commun* 9, 4275. 10.1038/s41467-018-06676-2.
 23. Maykel, J., Liu, J.H., Li, H., Shultz, L.D., Greiner, D.L., and Houghton, J. (2014). NOD-scidIl2rg (tm1Wjl) and NOD-Rag1 (null) Il2rg (tm1Wjl) : a model for stromal cell-tumor cell interaction for human colon cancer. *Dig Dis Sci* 59, 1169-1179. 10.1007/s10620-014-3168-5.
 24. Kotlov, N., Bagaev, A., Revuelta, M.V., Phillip, J.M., Cacciapuoti, M.T., Antysheva, Z., Svekolkina, V., Tikhonova, E., Mihecheva, N., Kuzkina, N., et al. (2021). Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. *Cancer Discov* 11, 1468-1489. 10.1158/2159-8290.CD-20-0839.
 25. Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Saleh, M., Asadzadeh Aghdaei, H., and Baghaei, K. (2022). Patient-derived xenograft (PDX) models, applications and challenges in cancer research. *J Transl Med* 20, 206. 10.1186/s12967-022-03405-8.
 26. Gao, H., Korn, J.M., Ferretti, S., Monahan, J.E., Wang, Y., Singh, M., Zhang, C., Schnell, C., Yang, G., Zhang, Y., et al. (2015). High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. *Nat Med* 21, 1318-1325. 10.1038/nm.3954.

27. Sun, H., Cao, S., Mashl, R.J., Mo, C.K., Zaccaria, S., Wendl, M.C., Davies, S.R., Bailey, M.H., Primeau, T.M., Hoog, J., et al. (2022). Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. *Nat Commun* 13, 294. 10.1038/s41467-021-27678-7.
28. Aparicio, S., Hidalgo, M., and Kung, A.L. (2015). Examining the utility of patient-derived xenograft mouse models. *Nat Rev Cancer* 15, 311-316. 10.1038/nrc3944.
29. Klco, J.M., Spencer, D.H., Miller, C.A., Griffith, M., Lamprecht, T.L., O'Laughlin, M., Fronick, C., Magrini, V., Demeter, R.T., Fulton, R.S., et al. (2014). Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. *Cancer Cell* 25, 379-392. 10.1016/j.ccr.2014.01.031.
30. Ben-David, U., Ha, G., Tseng, Y.Y., Greenwald, N.F., Oh, C., Shih, J., McFarland, J.M., Wong, B., Boehm, J.S., Beroukhi, R., and Golub, T.R. (2017). Patient-derived xenografts undergo mouse-specific tumor evolution. *Nat Genet* 49, 1567-1575. 10.1038/ng.3967.
31. Willyard, C. (2018). The mice with human tumours: Growing pains for a popular cancer model. *Nature* 560, 156-157. 10.1038/d41586-018-05890-8.
32. Hidalgo, M., Amant, F., Biankin, A.V., Budinska, E., Byrne, A.T., Caldas, C., Clarke, R.B., de Jong, S., Jonkers, J., Maeldensmo, G.M., et al. (2014). Patient-derived xenograft models: an emerging platform for translational cancer research. *Cancer Discov* 4, 998-1013. 10.1158/2159-8290.CD-14-0001.
33. Woo, X.Y., Giordano, J., Srivastava, A., Zhao, Z.M., Lloyd, M.W., de Bruijn, R., Suh, Y.S., Patidar, R., Chen, L., Scherer, S., et al. (2021). Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. *Nat Genet* 53, 86-99. 10.1038/s41588-020-00750-6.
34. Chapuy, B., Cheng, H., Watahiki, A., Ducar, M.D., Tan, Y., Chen, L., Roemer, M.G., Ouyang, J., Christie, A.L., Zhang, L., et al. (2016). Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biologic heterogeneity of the disease. *Blood*. 10.1182/blood-2015-09-672352.
35. Townsend, E.C., Murakami, M.A., Christodoulou, A., Christie, A.L., Koster, J., DeSouza, T.A., Morgan, E.A., Kallgren, S.P., Liu, H., Wu, S.C., et al. (2016). The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. *Cancer Cell* 29, 574-586. 10.1016/j.ccell.2016.03.008.
36. Zhang, L., Nomie, K., Zhang, H., Bell, T., Pham, L., Kadri, S., Segal, J., Li, S., Zhou, S., Santos, D., et al. (2017). B-Cell Lymphoma Patient-Derived Xenograft Models Enable Drug Discovery and Are a Platform for Personalized Therapy. *Clin Cancer Res* 23, 4212-4223. 10.1158/1078-0432.CCR-16-2703.
37. Ng, S.Y., Brown, L., Stevenson, K., deSouza, T., Aster, J.C., Louissaint, A., Jr., and Weinstock, D.M. (2018). RhoA G17V is sufficient to induce autoimmunity and promotes T-cell lymphomagenesis in mice. *Blood* 132, 935-947. 10.1182/blood-2017-11-818617.
38. Zammarchi, F., Corbett, S., Adams, L., Tyrer, P.C., Kiakos, K., Janghra, N., Marafioti, T., Britten, C.E., Havenith, C.E.G., Chivers, S., et al. (2018). ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies. *Blood* 131, 1094-1105. 10.1182/blood-2017-10-813493.
39. Wang, T., Lu, Y., Polk, A., Chowdhury, P., Murga-Zamalloa, C., Fujiwara, H., Suemori, K., Beyersdorf, N., Hristov, A.C., Lim, M.S., et al. (2017). T-cell Receptor Signaling Activates an ITK/NF-kappaB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. *Clin Cancer Res* 23, 2506-2515. 10.1158/1078-0432.CCR-16-1996.

40. Nakhoul, H., Lin, Z., Wang, X., Roberts, C., Dong, Y., and Flemington, E. (2019). High-Throughput Sequence Analysis of Peripheral T-Cell Lymphomas Indicates Subtype-Specific Viral Gene Expression Patterns and Immune Cell Microenvironments. *mSphere* 4, 10.1128/mSphere.00248-19.
41. Iqbal, J., Wright, G., Wang, C., Rosenwald, A., Gascoyne, R.D., Weisenburger, D.D., Greiner, T.C., Smith, L., Guo, S., Wilcox, R.A., et al. (2014). Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. *Blood* 123, 2915-2923. 10.1182/blood-2013-11-536359.
42. Amador, C., Greiner, T.C., Heavican, T.B., Smith, L.M., Galvis, K.T., Lone, W., Bouska, A., D'Amore, F., Pedersen, M.B., Pileri, S., et al. (2019). Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry. *Blood* 134, 2159-2170. 10.1182/blood.2019000779.
43. Scott, D.W., Mungall, K.L., Ben-Neriah, S., Rogic, S., Morin, R.D., Slack, G.W., Tan, K.L., Chan, F.C., Lim, R.S., Connors, J.M., et al. (2012). TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma. *Blood* 119, 4949-4952. 10.1182/blood-2012-02-414441.
44. Della-Valle, V., Roos-Weil, D., Scourzic, L., Mouly, E., Aid, Z., Darwiche, W., Lecluse, Y., Damm, F., Memet, S., Mercher, T., et al. (2020). Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice. *Blood Cancer J* 10, 38. 10.1038/s41408-020-0305-6.
45. Ramis-Zaldivar, J.E., Gonzalez-Farre, B., Balague, O., Celis, V., Nadeu, F., Salmeron-Villalobos, J., Andres, M., Martin-Guerrero, I., Garrido-Pontnou, M., Gaafar, A., et al. (2020). Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. *Blood* 135, 274-286. 10.1182/blood.2019002699.
46. Abate, F., da Silva-Almeida, A.C., Zairis, S., Robles-Valero, J., Couronne, L., Khiabani, H., Quinn, S.A., Kim, M.Y., Laginestra, M.A., Kim, C., et al. (2017). Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. *Proc Natl Acad Sci U S A* 114, 764-769. 10.1073/pnas.1608839114.
47. Fujisawa, M., Sakata-Yanagimoto, M., Nishizawa, S., Komori, D., Gershon, P., Kiryu, M., Tanzima, S., Fukumoto, K., Enami, T., Muratani, M., et al. (2018). Activation of RHOA-VAV1 signaling in angioimmunoblastic T-cell lymphoma. *Leukemia* 32, 694-702. 10.1038/leu.2017.273.
48. Turner, S.D., Yeung, D., Hadfield, K., Cook, S.J., and Alexander, D.R. (2007). The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms. *Cell Signal* 19, 740-747. 10.1016/j.cellsig.2006.09.007.
49. Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., D'Escamard, V., Forni, G., and Inghirami, G. (2008). The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. *Nat Med* 14, 676-680. nm1769 [pii] 10.1038/nm1769.
50. Nicolae, A., Xi, L., Pham, T.H., Pham, T.A., Navarro, W., Meeker, H.G., Pittaluga, S., Jaffe, E.S., and Raffeld, M. (2016). Mutations in the JAK/STAT and RAS signaling pathways are common in intestinal T-cell lymphomas. *Leukemia* 30, 2245-2247. 10.1038/leu.2016.178.
51. Boddicker, R.L., Razidlo, G.L., and Feldman, A.L. (2019). Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas. *Small GTPases* 10, 33-39. 10.1080/21541248.2016.1263718.

52. Stengel, A., Shahswar, R., Haferlach, T., Walter, W., Hutter, S., Meggendorfer, M., Kern, W., and Haferlach, C. (2020). Whole transcriptome sequencing detects a large number of novel fusion transcripts in patients with AML and MDS. *Blood Adv* 4, 5393-5401. 10.1182/bloodadvances.2020003007.
53. Foltz, S.M., Gao, Q., Yoon, C.J., Sun, H., Yao, L., Li, Y., Jayasinghe, R.G., Cao, S., King, J., Kohnen, D.R., et al. (2020). Evolution and structure of clinically relevant gene fusions in multiple myeloma. *Nat Commun* 11, 2666. 10.1038/s41467-020-16434-y.
54. Boi, M., Rinaldi, A., Kwee, I., Bonetti, P., Todaro, M., Tabbo, F., Piva, R., Rancoita, P.M., Matolcsy, A., Timar, B., et al. (2013). PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. *Blood* 122, 2683-2693. 10.1182/blood-2013-04-497933.
55. de Mel, S., Soon, G.S., Mok, Y., Chung, T.H., Jeyasekharan, A.D., Chng, W.J., and Ng, S.B. (2018). The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation. *Int J Mol Sci* 19. 10.3390/ijms19071931.
56. Lone, W., Bouska, A., Sharma, S., Amador, C., Saumyaranjan, M., Herek, T.A., Heavican, T.B., Yu, J., Lim, S.T., Ong, C.K., et al. (2021). Genome-Wide miRNA Expression Profiling of Molecular Subgroups of Peripheral T-cell Lymphoma. *Clin Cancer Res* 27, 6039-6053. 10.1158/1078-0432.CCR-21-0573.
57. Gasparini, P., Cascione, L., Landi, L., Carasi, S., Lovat, F., Tibaldi, C., Ali, G., D'Incecco, A., Minuti, G., Chella, A., et al. (2015). microRNA classifiers are powerful diagnostic/prognostic tools in ALK-, EGFR-, and KRAS-driven lung cancers. *Proc Natl Acad Sci U S A* 112, 14924-14929. 10.1073/pnas.1520329112.
58. Bagot, M., Porcu, P., Marie-Cardine, A., Battistella, M., William, B.M., Vermeer, M., Whittaker, S., Rotolo, F., Ram-Wolff, C., Khodadoust, M.S., et al. (2019). IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody, in patients with relapsed or refractory cutaneous T-cell lymphoma: an international, first-in-human, open-label, phase 1 trial. *Lancet Oncol* 20, 1160-1170. 10.1016/S1470-2045(19)30320-1.
59. Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 38, e164. 10.1093/nar/gkq603.
60. Vallois, D., Dobay, M.P., Morin, R.D., Lemonnier, F., Missiaglia, E., Juilland, M., Iwaszkiewicz, J., Fataccioli, V., Bisig, B., Roberti, A., et al. (2016). Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. *Blood* 128, 1490-1502. 10.1182/blood-2016-02-698977.
61. Lemonnier, F., Couronne, L., Parrens, M., Jais, J.P., Travert, M., Lamant, L., Tournillac, O., Rousset, T., Fabiani, B., Cairns, R.A., et al. (2012). Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood* 120, 1466-1469. 10.1182/blood-2012-02-408542.
62. Waldmann, T.A., and Chen, J. (2017). Disorders of the JAK/STAT Pathway in T Cell Lymphoma Pathogenesis: Implications for Immunotherapy. *Annu Rev Immunol*. 10.1146/annurev-immunol-110416-120628.
63. Kaustio, M., Nayeibzadeh, N., Hinttala, R., Tapiainen, T., Astrom, P., Mamia, K., Pernaa, N., Lehtonen, J., Glumoff, V., Rahikkala, E., et al. (2021). Loss of DIAPH1 causes SCBMS, combined immunodeficiency, and mitochondrial dysfunction. *J Allergy Clin Immunol* 148, 599-611. 10.1016/j.jaci.2020.12.656.

64. Dobashi, A., Tsuyama, N., Asaka, R., Togashi, Y., Ueda, K., Sakata, S., Baba, S., Sakamoto, K., Hatake, K., and Takeuchi, K. (2016). Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type. *Genes Chromosomes Cancer* 55, 460-471. 10.1002/gcc.22348.
65. Li, D.Q., Nair, S.S., Ohshiro, K., Kumar, A., Nair, V.S., Pakala, S.B., Reddy, S.D., Gajula, R.P., Eswaran, J., Aravind, L., and Kumar, R. (2012). MORC2 signaling integrates phosphorylation-dependent, ATPase-coupled chromatin remodeling during the DNA damage response. *Cell Rep* 2, 1657-1669. 10.1016/j.celrep.2012.11.018.
66. Kim, T.W., Kang, Y.K., Park, Z.Y., Kim, Y.H., Hong, S.W., Oh, S.J., Sohn, H.A., Yang, S.J., Jang, Y.J., Lee, D.C., et al. (2014). SH3RF2 functions as an oncogene by mediating PAK4 protein stability. *Carcinogenesis* 35, 624-634. 10.1093/carcin/bgt338.
67. Zhou, X., Wen, Y., Tian, Y., He, M., Ke, X., Huang, Z., He, Y., Liu, L., Scharf, A., Lu, M., et al. (2019). Heat Shock Protein 90alpha-Dependent B-Cell-2-Associated Transcription Factor 1 Promotes Hepatocellular Carcinoma Proliferation by Regulating MYC Proto-Oncogene c-MYC mRNA Stability. *Hepatology* 69, 1564-1581. 10.1002/hep.30172.
68. Sakata-Yanagimoto, M., Enami, T., Yoshida, K., Shiraishi, Y., Ishii, R., Miyake, Y., Muto, H., Tsuyama, N., Sato-Otsubo, A., Okuno, Y., et al. (2014). Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat Genet* 46, 171-175. 10.1038/ng.2872.
69. Crescenzo, R., Abate, F., Lasorsa, E., Tabbo, F., Gaudiano, M., Chiesa, N., Di Giacomo, F., Spaccarotella, E., Barbarossa, L., Ercole, E., et al. (2015). Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. *Cancer Cell* 27, 516-532. 10.1016/j.ccell.2015.03.006.
70. Perez, C., Mondejar, R., Garcia-Diaz, N., Cereceda, L., Leon, A., Montes, S., Duran Vian, C., Perez Paredes, M.G., Gonzalez-Moran, A., Alegre de Miguel, V., et al. (2020). Advanced-stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor-kappaB and nuclear factor of activated T cells pathways. *Br J Dermatol* 182, 147-155. 10.1111/bjd.18098.
71. Wang, J., Khiabani, H., Rossi, D., Fabbri, G., Gattei, V., Forconi, F., Laurenti, L., Marasca, R., Del Poeta, G., Foa, R., et al. (2014). Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. *Elife* 3. 10.7554/eLife.02869.
72. Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D.I., Zairis, S., Abate, F., Liu, Z., Elliott, O., Shin, Y.J., et al. (2016). Clonal evolution of glioblastoma under therapy. *Nat Genet* 48, 768-776. 10.1038/ng.3590.
73. Carter, S.L., Cibulskis, K., Helman, E., McKenna, A., Shen, H., Zack, T., Laird, P.W., Onofrio, R.C., Winckler, W., Weir, B.A., et al. (2012). Absolute quantification of somatic DNA alterations in human cancer. *Nat Biotechnol* 30, 413-421. 10.1038/nbt.2203.
74. Brastianos, P.K., Carter, S.L., Santagata, S., Cahill, D.P., Taylor-Weiner, A., Jones, R.T., Van Allen, E.M., Lawrence, M.S., Horowitz, P.M., Cibulskis, K., et al. (2015). Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. *Cancer Discov* 5, 1164-1177. 10.1158/2159-8290.CD-15-0369.
75. Lee, J.K., Wang, J., Sa, J.K., Ladewig, E., Lee, H.O., Lee, I.H., Kang, H.J., Rosenbloom, D.S., Camara, P.G., Liu, Z., et al. (2017). Spatiotemporal genomic architecture informs precision oncology in glioblastoma. *Nat Genet* 49, 594-599. 10.1038/ng.3806.
76. Schurch, C.M., Federmann, B., Quintanilla-Martinez, L., and Fend, F. (2018). Tumor Heterogeneity in Lymphomas: A Different Breed. *Pathobiology* 85, 130-145. 10.1159/000475530.

77. Zaitsev, A., Chelushkin, M., Dyikanov, D., Cheremushkin, I., Shpak, B., Nomie, K., Zyrin, V., Nuzhdina, E., Lozinsky, Y., Zotova, A., et al. (2022). Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. *Cancer Cell* 40, 879-894 e816. 10.1016/j.ccell.2022.07.006.
78. Huang, Y.H., Qiu, Y.R., Zhang, Q.L., Cai, M.C., Yu, H., Zhang, J.M., Jiang, L., Ji, M.M., Xu, P.P., Wang, L., et al. (2024). Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. *Cell Rep Med* 5, 101416. 10.1016/j.xcrm.2024.101416.
79. Ambrogio, C., Martinengo, C., Voena, C., Tondat, F., Riera, L., di Celle, P.F., Inghirami, G., and Chiarle, R. (2009). NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells. *Cancer Res* 69, 8611-8619. 0008-5472.CAN-09-2655 [pii] 10.1158/0008-5472.CAN-09-2655.
80. Vallois, D., Dupuy, A., Lemonnier, F., Allen, G., Missiaglia, E., Fataccioli, V., Ortonne, N., Clavert, A., Delarue, R., Rousselet, M.C., et al. (2018). RNA fusions involving CD28 are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. *Haematologica* 103, e360-e363. 10.3324/haematol.2017.186767.
81. Zhou, Y., Attygalle, A.D., Chuang, S.S., Diss, T., Ye, H., Liu, H., Hamoudi, R.A., Munson, P., Bacon, C.M., Dogan, A., and Du, M.Q. (2007). Angioimmunoblastic T-cell lymphoma: histological progression associates with EBV and HHV6B viral load. *Br J Haematol* 138, 44-53. 10.1111/j.1365-2141.2007.06620.x.
82. Chiba, S., and Sakata-Yanagimoto, M. (2020). Advances in understanding of angioimmunoblastic T-cell lymphoma. *Leukemia* 34, 2592-2606. 10.1038/s41375-020-0990-y.
83. Lwin, T., Hazlehurst, L.A., Li, Z., Dessureault, S., Sotomayor, E., Moscinski, L.C., Dalton, W.S., and Tao, J. (2007). Bone marrow stromal cells prevent apoptosis of lymphoma cells by upregulation of anti-apoptotic proteins associated with activation of NF-kappaB (RelB/p52) in non-Hodgkin's lymphoma cells. *Leukemia* 21, 1521-1531. 10.1038/sj.leu.2404723.
84. Blonska, M., Agarwal, N.K., and Vega, F. (2015). Shaping of the tumor microenvironment: Stromal cells and vessels. *Semin Cancer Biol* 34, 3-13. 10.1016/j.semcancer.2015.03.002.
85. Mastini, C., Campisi, M., Patrucco, E., Mura, G., Ferreira, A., Costa, C., Ambrogio, C., Germina, G., Martinengo, C., Peola, S., et al. (2023). Targeting CCR7-PI3Kgamma overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. *Sci Transl Med* 15, eabo3826. 10.1126/scitranslmed.abo3826.
86. Niitsu, N., Kohori, M., Higashihara, M., and Bessho, M. (2007). Phase II study of the irinotecan (CPT-11), mitoxantrone and dexamethasone regimen in elderly patients with relapsed or refractory peripheral T-cell lymphoma. *Cancer Sci* 98, 109-112. 10.1111/j.1349-7006.2006.00349.x.
87. Saotome, T., Takagi, T., Sakai, C., Kumagai, K., and Tamaru, J. (2000). Combination chemotherapy with irinotecan and adriamycin for refractory and relapsed non-Hodgkin's lymphoma. *Ann Oncol* 11, 115-116. 10.1023/a:1008368905546.
88. Kang, H.J., Kim, W.S., Suh, C., Park, Y.H., Kim, B.S., Yuh, Y.J., and Ryoo, B.Y. (2008). Irinotecan plus cisplatin and dexamethasone (ICD) combination chemotherapy for patients with diffuse large B-cell lymphoma previously treated with Rituximab plus CHOP. *Cancer Chemother Pharmacol* 62, 299-304. 10.1007/s00280-007-0607-4.

89. Sharkey, R.M., Govindan, S.V., Cardillo, T.M., and Goldenberg, D.M. (2012). Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies. *Mol Cancer Ther* 11, 224-234. 10.1158/1535-7163.MCT-11-0632.
90. Lemonnier, F., Dupuis, J., Sujobert, P., Tournilhac, O., Cheminant, M., Sarkozy, C., Pelletier, L., Marcais, A., Robe, C., Fataccioli, V., et al. (2018). Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. *Blood* 132, 2305-2309. 10.1182/blood-2018-04-840538.
91. Ruan, J., Moskowitz, A., Mehta-Shah, N., Sokol, L., Chen, Z., Kotlov, N., Nos, G., Sorokina, M., Maksimov, V., Sboner, A., et al. (2023). Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. *Blood* 141, 2194-2205. 10.1182/blood.2022018254.
92. Cidado, J., Boiko, S., Proia, T., Ferguson, D., Criscione, S.W., San Martin, M., Pop-Damkov, P., Su, N., Roamio Franklin, V.N., Sekhar Reddy Chilamakuri, C., et al. (2020). AZD4573 Is a Highly Selective CDK9 Inhibitor That Suppresses MCL-1 and Induces Apoptosis in Hematologic Cancer Cells. *Clin Cancer Res* 26, 922-934. 10.1158/1078-0432.CCR-19-1853.
93. Hamlin, P.A., Flinn, I.W., Wagner-Johnston, N., Burger, J.A., Coffey, G.P., Conley, P.B., Michelson, G., Leeds, J.M., Der, K., Kim, Y., et al. (2019). Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. *Am J Hematol* 94, E90-E93. 10.1002/ajh.25387.
94. Shaw, L.C., Poussin, M., Rodriguez-Garcia, A., Eggold, J., Minutolo, N.G., Wang, J., Rook, A.H., Schuster, S.J., and Powell, D.J. (2023). TCR β -CART therapy mediates high-precision targeting of malignant T-cell clones. *Blood Adv* 7, 1885-1898. 10.1182/bloodadvances.2022008798.
95. Wu, Y., Chen, D., Lu, Y., Dong, S.C., Ma, R., Tang, W.Y., Wu, J.Q., Feng, J.F., and Wu, J.Z. (2022). A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb. *Cancer Gene Ther* 29, 167-177. 10.1038/s41417-021-00295-8.
96. Patel, R.P., Ghilardi, G., Zhang, Y., Chiang, Y.H., Xie, W., Guruprasad, P., Kim, K.H., Chun, I., Angelos, M.G., Pajarillo, R., et al. (2024). CD5 deletion enhances the antitumor activity of adoptive T cell therapies. *Sci Immunol* 9, eadn6509. 10.1126/sciimmunol.adn6509.
97. Villacorta-Martin, C., Craig, A.J., and Villanueva, A. (2017). Divergent evolutionary trajectories in transplanted tumor models. *Nat Genet* 49, 1565-1566. 10.1038/ng.3983.
98. Chen, J., Zhang, Y., Petrus, M.N., Xiao, W., Nicolae, A., Raffeld, M., Pittaluga, S., Bamford, R.N., Nakagawa, M., Ouyang, S.T., et al. (2017). Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations. *Proc Natl Acad Sci U S A* 114, 3975-3980. 10.1073/pnas.1700682114.
99. Ramsdale, E., van Besien, K., and Smith, S.M. (2011). Personalized treatment of lymphoma: promise and reality. *Semin Oncol* 38, 225-235. 10.1053/j.seminoncol.2011.01.008.
100. Intlekofer, A.M., and Younes, A. (2014). Precision therapy for lymphoma--current state and future directions. *Nat Rev Clin Oncol* 11, 585-596. 10.1038/nrclinonc.2014.137.
101. Sugio, T., Miyawaki, K., Kato, K., Sasaki, K., Yamada, K., Iqbal, J., Miyamoto, T., Ohshima, K., Maeda, T., Miyoshi, H., and Akashi, K. (2018). Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS. *Blood Adv* 2, 2242-2252. 10.1182/bloodadvances.2018018754.


102. Liu, T., Guo, S., Ji, Y., and Zhu, W. (2023). Role of cancer-educated mesenchymal stromal cells on tumor progression. *Biomed Pharmacother* 166, 115405. 10.1016/j.biopha.2023.115405.
103. Le Naour, A., Prat, M., Thibault, B., Mevel, R., Lemaitre, L., Leray, H., Joubert, M.V., Coulson, K., Golzio, M., Lefevre, L., et al. (2020). Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors. *J Mol Cell Biol* 12, 202-215. 10.1093/jmcb/mjz090.
104. Hill, B.S., Sarnella, A., D'Avino, G., and Zannetti, A. (2020). Recruitment of stromal cells into tumour microenvironment promote the metastatic spread of breast cancer. *Semin Cancer Biol* 60, 202-213. 10.1016/j.semcancer.2019.07.028.
105. Zheng, Z., Li, P., Shen, F., Shi, Y., and Shao, C. (2022). Mesenchymal Stem/Stromal Cells in Cancer: from Initiation to Metastasis. *Arch Med Res* 53, 785-793. 10.1016/j.arcmed.2022.11.001.
106. Valkenburg, K.C., de Groot, A.E., and Pienta, K.J. (2018). Targeting the tumour stroma to improve cancer therapy. *Nat Rev Clin Oncol* 15, 366-381. 10.1038/s41571-018-0007-1.
107. Shojaei, F., and Ferrara, N. (2008). Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. *Drug Resist Updat* 11, 219-230. 10.1016/j.drug.2008.09.001.
108. Tarin, D. (2013). Role of the host stroma in cancer and its therapeutic significance. *Cancer Metastasis Rev* 32, 553-566. 10.1007/s10555-013-9438-4.
109. Siolas, D., and Hannon, G.J. (2013). Patient-derived tumor xenografts: transforming clinical samples into mouse models. *Cancer Res* 73, 5315-5319. 10.1158/0008-5472.CAN-13-1069.
110. Kopetz, S., Lemos, R., and Powis, G. (2012). The promise of patient-derived xenografts: the best laid plans of mice and men. *Clin Cancer Res* 18, 5160-5162. 10.1158/1078-0432.CCR-12-2408.
111. Liu, Y., Wu, W., Cai, C., Zhang, H., Shen, H., and Han, Y. (2023). Patient-derived xenograft models in cancer therapy: technologies and applications. *Signal Transduct Target Ther* 8, 160. 10.1038/s41392-023-01419-2.
112. Vennin, C., Chin, V.T., Warren, S.C., Lucas, M.C., Herrmann, D., Magenau, A., Melenec, P., Walters, S.N., Del Monte-Nieto, G., Conway, J.R., et al. (2017). Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. *Sci Transl Med* 9. 10.1126/scitranslmed.aai8504.
113. Landis, M.D., Lehmann, B.D., Pietenpol, J.A., and Chang, J.C. (2013). Patient-derived breast tumor xenografts facilitating personalized cancer therapy. *Breast Cancer Res* 15, 201. 10.1186/bcr3355.
114. Na, Y.S., Ryu, M.H., Park, Y.S., Lee, C.W., Lee, J.K., Park, Y., Park, J.M., Ma, J., and Kang, Y.K. (2020). Establishment of patient-derived xenografts from patients with gastrointestinal stromal tumors: analysis of clinicopathological characteristics related to engraftment success. *Sci Rep* 10, 7996. 10.1038/s41598-020-64552-w.
115. Brehm, M.A., Kenney, L.L., Wiles, M.V., Low, B.E., Tisch, R.M., Burzenski, L., Mueller, C., Greiner, D.L., and Shultz, L.D. (2019). Lack of acute xenogeneic graft- versus-host disease, but retention of T-cell function following engraftment of human peripheral blood mononuclear cells in NSG mice deficient in MHC class I and II expression. *FASEB J* 33, 3137-3151. 10.1096/fj.201800636R.
116. Bondarenko, G., Ugolkov, A., Rohan, S., Kulesza, P., Dubrovskiy, O., Gursel, D., Mathews, J., O'Halloran, T.V., Wei, J.J., and Mazar, A.P. (2015). Patient-Derived Tumor Xenografts

- Are Susceptible to Formation of Human Lymphocytic Tumors. *Neoplasia* 17, 735-741. 10.1016/j.neo.2015.09.004.
117. Butler, K.A., Hou, X., Becker, M.A., Zanfagnin, V., Enderica-Gonzalez, S., Visscher, D., Kalli, K.R., Tienchaianada, P., Haluska, P., and Weroha, S.J. (2017). Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts. *Neoplasia* 19, 628-636. 10.1016/j.neo.2017.04.007.
 118. Leiting, J.L., Hernandez, M.C., Yang, L., Bergquist, J.R., Ivanics, T., Graham, R.P., and Truty, M.J. (2019). Rituximab Decreases Lymphoproliferative Tumor Formation in Hepatopancreaticobiliary and Gastrointestinal Cancer Patient-Derived Xenografts. *Sci Rep* 9, 5901. 10.1038/s41598-019-42470-w.
 119. Bayda, N., Tilloy, V., Chaunavel, A., Bahri, R., Halabi, M.A., Feuillard, J., Jaccard, A., and Ranger-Rogez, S. (2021). Comprehensive Epstein-Barr Virus Transcriptome by RNA-Sequencing in Angioimmunoblastic T Cell Lymphoma (AITL) and Other Lymphomas. *Cancers (Basel)* 13. 10.3390/cancers13040610.
 120. Fujisawa, M., Nguyen, T.B., Abe, Y., Suehara, Y., Fukumoto, K., Suma, S., Makishima, K., Kaneko, C., Nguyen, Y.T.M., Usuki, K., et al. (2022). Clonal germinal center B cells function as a niche for T-cell lymphoma. *Blood* 140, 1937-1950. 10.1182/blood.2022015451.
 121. Sueyoshi, K., Komura, D., Katoh, H., Yamamoto, A., Onoyama, T., Chijiwa, T., Isagawa, T., Tanaka, M., Suemizu, H., Nakamura, M., et al. (2021). Multi-tumor analysis of cancer-stroma interactomes of patient-derived xenografts unveils the unique homeostatic process in renal cell carcinomas. *iScience* 24, 103322. 10.1016/j.isci.2021.103322.
 122. Cappelli, L.V., Fiore, D., Phillip, J.M., Yoffe, L., Di Giacomo, F., Chiu, W., Hu, Y., Kayembe, C., Ginsberg, M., Consolino, L., et al. (2023). Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities. *Blood* 141, 503-518. 10.1182/blood.2022015414.
 123. Fiore, D., Cappelli, L.V., Zumbo, P., Phillips, J.M., Liu, Z., Cheng, S., Yoffe, L., Ghione, P., Di Maggio, F., Dogan, A., et al. (2020). A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. *Cancers (Basel)* 12. 10.3390/cancers12061603.
 124. RC, T. (2014). A language and environment for statistical computing. *MSOR connections* 1.
 125. Chang, W., Cheng, J., and Allaire, J. (2023). Web Application Framework.
 126. Wickham, H., Averick, M., and Bryan, J. (2019). Welcome to the Tidyverse. *vignettes/paperRmd*.
 127. Huber, W., Carey, V.J., Gentleman, R., Anders, S., Carlson, M., Carvalho, B.S., Bravo, H.C., Davis, S., Gatto, L., Girke, T., et al. (2015). Orchestrating high-throughput genomic analysis with Bioconductor. *Nat Methods* 12, 115-121. 10.1038/nmeth.3252.
 128. Cacciapuoti, M.T., Cappelli, L.V., Fiore, D., Toruno, P., Kayembe, C., Tam, W., and Inghirami, G. (2021). In Vivo and Ex Vivo Patient-Derived Tumor Xenograft Models of Lymphoma for Drug Discovery. *Curr Protoc* 1, e96. 10.1002/cpz1.96.
 129. Sarachakov, A., Varlamova, A., Svekolkina, V., Polyakova, M., Valencia, I., Unkenholz, C., Pannellini, T., Galkin, I., Ovcharov, P., Tabakov, D., et al. (2023). Spatial mapping of human hematopoiesis at single-cell resolution reveals aging-associated topographic remodeling. *Blood* 142, 2282-2295. 10.1182/blood.2023021280.
 130. van Dongen, J.J., Langerak, A.W., Bruggemann, M., Evans, P.A., Hummel, M., Lavender, F.L., Delabesse, E., Davi, F., Schuurink, E., Garcia-Sanz, R., et al. (2003). Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-


- cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. *Leukemia* 17, 2257-2317. 10.1038/sj.leu.2403202.
131. Leek, J.T., and Storey, J.D. (2007). Capturing heterogeneity in gene expression studies by surrogate variable analysis. *PLoS Genet* 3, 1724-1735. 10.1371/journal.pgen.0030161.
 132. Leek, J.T., Johnson, W.E., Parker, H.S., Jaffe, A.E., and Storey, J.D. (2012). The sva package for removing batch effects and other unwanted variation in high-throughput experiments. *Bioinformatics* 28, 882-883. 10.1093/bioinformatics/bts034.
 133. Reynisson, B., Barra, C., Kaabinejadian, S., Hildebrand, W.H., Peters, B., and Nielsen, M. (2020). Improved Prediction of MHC II Antigen Presentation through Integration and Motif Deconvolution of Mass Spectrometry MHC Eluted Ligand Data. *J Proteome Res* 19, 2304-2315. 10.1021/acs.jproteome.9b00874.
 134. Greenbaum, J., Sidney, J., Chung, J., Brander, C., Peters, B., and Sette, A. (2011). Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes. *Immunogenetics* 63, 325-335. 10.1007/s00251-011-0513-0.
 135. McGinnis, C.S., Murrow, L.M., and Gartner, Z.J. (2019). DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst* 8, 329-337 e324. 10.1016/j.cels.2019.03.003.
 136. Hafemeister, C., and Satija, R. (2019). Normalization and variance stabilization of single-cell RNA-seq data using regularized negative binomial regression. *Genome Biol* 20, 296. 10.1186/s13059-019-1874-1.
 137. Aran, D., Looney, A.P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R.P., Wolters, P.J., Abate, A.R., et al. (2019). Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat Immunol* 20, 163-172. 10.1038/s41590-018-0276-y.
 138. Mabbott, N.A., Baillie, J.K., Brown, H., Freeman, T.C., and Hume, D.A. (2013). An expression atlas of human primary cells: inference of gene function from coexpression networks. *BMC Genomics* 14, 632. 10.1186/1471-2164-14-632.
 139. Consortium, E.P. (2012). An integrated encyclopedia of DNA elements in the human genome. *Nature* 489, 57-74. 10.1038/nature11247.
 140. Li, H. (2013). Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. *arXivorg*.
 141. Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., and Genome Project Data Processing, S. (2009). The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25, 2078-2079. 10.1093/bioinformatics/btp352.
 142. Trifonov, V., Pasqualucci, L., Tiacci, E., Falini, B., and Rabadan, R. (2013). SAVI: a statistical algorithm for variant frequency identification. *BMC Syst Biol* 7 Suppl 2, S2. 10.1186/1752-0509-7-S2-S2.
 143. Gehring, J.S., Fischer, B., Lawrence, M., and Huber, W. (2015). SomaticSignatures: inferring mutational signatures from single-nucleotide variants. *Bioinformatics* 31, 3673-3675. 10.1093/bioinformatics/btv408.
 144. Hamilton, N., and Ferry, A. (2018). Ternary Diagrams Using ggplot2. *Journal of Statistical Software*.

145. Talevich, E., Shain, A.H., Botton, T., and Bastian, B.C. (2016). CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing. *PLoS Comput Biol* 12, e1004873. 10.1371/journal.pcbi.1004873.
146. Mermel, C.H., Schumacher, S.E., Hill, B., Meyerson, M.L., Beroukhi, R., and Getz, G. (2011). GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol* 12, R41. 10.1186/gb-2011-12-4-r41.
147. Leshchiner, I., Livitz, D., Gainor, J., Rosebrock, D., Spiro, O., Martinez, A., Mroz, E., Lin, J.J., Stewart, C., Kinm, J., et al. (2018). Comprehensive analysis of tumour initiation, spatial and temporal progression under multiple lines of treatment. *bioRxiv*
148. Miller, C.A., McMichael, J., Dang, H.X., Maher, C.A., Ding, L., Ley, T.J., Mardis, E.R., and Wilson, R.K. (2016). Visualizing tumor evolution with the fishplot package for R. *BMC Genomics* 17, 880. 10.1186/s12864-016-3195-z.
149. Bolotin, D.A., Poslavsky, S., Davydov, A.N., Frenkel, F.E., Fanchi, L., Zolotareva, O.I., Hemmers, S., Putintseva, E.V., Obratsova, A.S., Shugay, M., et al. (2017). Antigen receptor repertoire profiling from RNA-seq data. *Nat Biotechnol* 35, 908-911. 10.1038/nbt.3979.
150. Goncharov, M., Bagaev, D., Shcherbinin, D., Zvyagin, I., Bolotin, D., Thomas, P.G., Minervina, A.A., Pogorelyy, M.V., Ladell, K., McLaren, J.E., et al. (2022). VDJdb in the pandemic era: a compendium of T cell receptors specific for SARS-CoV-2. *Nat Methods* 19, 1017-1019. 10.1038/s41592-022-01578-0.
151. Chen, Q., Meng, Z., and Su, R. (2020). WERFE: A Gene Selection Algorithm Based on Recursive Feature Elimination and Ensemble Strategy. *Front Bioeng Biotechnol* 8, 496. 10.3389/fbioe.2020.00496.
152. Melamed, R.D., Wang, J., Iavarone, A., and Rabadan, R. (2015). An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. *J Mol Cell Biol* 7, 203-213. 10.1093/jmcb/mjv026.
153. Schubert, M., Klinger, B., Klunemann, M., Sieber, A., Uhlitz, F., Sauer, S., Garnett, M.J., Bluthgen, N., and Saez-Rodriguez, J. (2018). Perturbation-response genes reveal signaling footprints in cancer gene expression. *Nat Commun* 9, 20. 10.1038/s41467-017-02391-6.
154. Trapnell, C., Cacchiarelli, D., Grimsby, J., Pokharel, P., Li, S., Morse, M., Lennon, N.J., Livak, K.J., Mikkelsen, T.S., and Rinn, J.L. (2014). The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. *Nat Biotechnol* 32, 381-386. 10.1038/nbt.2859.
155. Redmond, D., Poran, A., and Elemento, O. (2016). Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq. *Genome Med* 8, 80. 10.1186/s13073-016-0335-7.
156. Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-seq quantification. *Nat Biotechnol* 34, 525-527. 10.1038/nbt.3519.
157. Zerbino, D.R., Achuthan, P., Akanni, W., Amode, M.R., Barrell, D., Bhai, J., Billis, K., Cummins, C., Gall, A., Giron, C.G., et al. (2018). Ensembl 2018. *Nucleic Acids Res* 46, D754-D761. 10.1093/nar/gkx1098.


A




B




C



D




E




F




G




H



I










Figure 4


A




B




D




E




H



C



I



J





Figure 55









Figure 7


A




B




C







D



E



F



G






Figure 8


A




B




C




D




E




F




G



H



I



SUPPLEMENTAL INFORMATION

A patient-derived T-cell lymphoma biorepository uncovers pathogenetic mechanisms and host-related therapeutic vulnerabilities.

Authors:

Danilo Fiore^{1,2,3,44}, Luca Vincenzo Cappelli^{1,4,44}, Liu Zhaoqi^{5,6,7}, Nikita Kotlov⁸, Maria Sorokina⁸, Jude Phillip^{9,10}, Paul Zumbo^{11,12}, Liron Yoffe^{1,13}, Paola Ghione¹⁴, Anqi Wang⁵, Xueshuai Han^{5,6,7}, Abigail Taylor¹, William Chiu¹, Valentina Fragliasso^{1,15}, Fabrizio Tabbo^{1,16}, Nahuel Zamponi⁹, Nicolás Di Siervi⁹, Clarisse Kayembe¹, Giovanni Medico¹, Ruchi P Patel^{17,18}, Marcello Gaudiano¹, Rodolfo Machiorlatti¹⁹, Giuseppina Astone¹, Maria Teresa Cacciapuoti¹, Giorgia Zanetti¹, Claudia Pignataro², Ruiz Arvin Eric¹, Sanjay Patel¹, Francesca Zammarchi²⁰, Claudio Zanettini¹, Lucio Queiroz¹, Anastasia Nikitina⁸, Olga Kudryashova⁸, Anton Karelin⁸, Daniil Nikitin⁸, Dmitry Tychinin⁸, Ekaterina Postovalova⁸, Alexander Bagaev⁸, Viktor Svekolkina⁸, Ekaterina Belova⁸, Katerina Tikhonova⁸, Sandrine Degryse⁸, Chengqi Xu¹³, Domenico Novero²¹, Maurilio Ponzoni²², Enrico Tiacci²³, Brunangelo Falini²³, Joo Song²⁴, Inna Khodos²⁵, Elisa De Stanchina²⁵, Gabriele Macari²⁶, Luciana Cafforio²⁶, Simone Gardini²⁶, Roberto Piva^{27,28}, Enzo Medico²⁹, Samuel Y Ng^{30,31}, Allison Moskowitz¹⁴, Zachary Epstein¹⁴, Andrew Intlekofer¹⁴, Dogan Ahmed³³, Wing C. Chan²⁴, Peter Martin³³, Jia Ruan³³, Francesco Bertoni^{34,35}, Robin Foà⁴, Joshua D. Brody^{36,37,38,39}, David M. Weinstock⁴⁰, Jaspreet Osan⁴¹, Laura Santambrogio⁴¹, Oliver Elemento¹³, Doron Betel^{9,11,12}, Wayne Tam^{1,42}, Marco Ruella^{17,18,43}, Leandro Cerchietti⁹, Raul Rabadan⁵, Steven Horwitz¹⁴, Giorgio Inghirami^{1*}

Affiliations:

¹Pathology and Laboratory Medicine, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY 10065, USA.

²Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, 80131 Naples, Italy.

³Institute for Experimental Endocrinology and Oncology, "G.Salvatore" IEOS, Consiglio Nazionale delle Ricerche (CNR), 80131 Naples, Italy.

⁴Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.

⁵Program for Mathematical Genomics, Department of Systems Biology, Department of Biomedical Informatics, Columbia University, New York, NY 10027 USA.

⁶Chinese Academy of Sciences Key Laboratory of Genomic and Precision Medicine, Beijing Institute of Genomics, Chinese Academy of Sciences and China National Center for Bioinformation, Beijing 100101, China.

⁷University of Chinese Academy of Sciences, Beijing 100049, China.

⁸BostonGene Corporation, Waltham, Massachusetts, 02453, USA.

⁹Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, NY, 10065 US.

¹⁰Chemical and Biomolecular Engineering, Oncology, Sidney Kimmel Comprehensive Cancer Center, Core Member, Institute for Nanobiotechnology (INBT), Whiting School of Engineering, Johns Hopkins University, MD 21218, USA.

¹¹Applied Bioinformatics Core, Weill Cornell Medicine, New York, NY, 10065, USA.

¹²Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, 10065, US.

¹³Englander Institute for Precision Medicine, Institute for Computational Biomedicine, Weill Cornell Medicine, New York, NY 10065, USA.

¹⁴Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.

¹⁵Laboratory of translational research, Azienda USL – IRCCS di Reggio Emilia, 42122 Reggio Emilia, Italy.

¹⁶SC Oncologia ASL CN2 Alba Bra Ospedale Michele e Pietro Ferrero - 12060 Verduno (CN), Italy.

¹⁷Center for Cellular Immunotherapies, Perelman School of Medicine at the University of Pennsylvania, 3400 Civic Center Boulevard, Perelman Center for Advanced Medicine, SPE 8-112, Philadelphia, PA 19104, USA.

¹⁸Division of Hematology-Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

¹⁹Department of Pathology, Center for Experimental Research and Medical Studies, University of Torino, 10126 Torino, Italy.

²⁰ADC Therapeutics (UK) Limited, London, W12 0BZ United Kingdom.

- ²¹Division of Pathological Anatomy, Quality and Safety of Diagnosis and Treatment, Città della Salute e della Scienza, 10126 Turin, Italy.
- ²²Pathology Unit, San Raffaele Scientific Institute, Milan, Italy; Unit of Lymphoid Malignancies, San Raffaele Scientific Institute, 20132, Milan, Italy.
- ²³Institute of Hematology, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea delle Fratte, Perugia, 06156 Italy.
- ²⁴Department of Pathology, City of Hope Medical Center, Duarte CA, 91010, US.
- ²⁵Antitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY 10065, US.
- ²⁶GenomeUp S.r.l., 00144 Rome RM, Italy.
- ²⁷Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy.
- ²⁸Medical Genetics Unit, Città della Salute e della Scienza University Hospital, 10126 Turin, Italy.
- ²⁹Department of Oncology, University of Torino, Candiolo, TO, Italy; Candiolo Cancer Institute, FPO-IRCCS, 10060 Candiolo, TO, Italy.
- ³⁰Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA.
- ³¹National Cancer Institute, Bethesda, MD 20892, USA.
- ³²Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
- ³³Lymphoma Service, Weill Cornell Medical Center, New York, NY 10065, USA.
- ³⁴Lymphoma Genomics, Institute of Oncology Research, Faculty of Biomedical Sciences, USI, 6500 Bellinzona, Switzerland.
- ³⁵Oncology Institute of Southern Switzerland, EOC, 6500 Bellinzona, Switzerland.
- ³⁶Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, US.
- ³⁷Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- ³⁸Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- ³⁹Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- ⁴⁰Merck Research Laboratories, Boston, MA 02115, USA.
- ⁴¹Department of Radiation Oncology, Weill Cornell Medicine, New York, NY 10065, USA.
- ⁴²Division of Hematopathology, Northwell Health, New York, NY 11740, USA.
- ⁴³Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104, USA.
- ⁴⁴D. Fiore and L.V. Cappelli contributed equally to this article.

*Corresponding Author: ggi9001@med.cornell.edu

Inventory of Supplemental Material

- Supplemental Tables [Uploaded separately as Excel spreadsheets (Table S1-S8) and PDF files (Table S9-S12)]
- Supplemental Figure and Legends (Figure S1-S8)

Supplemental Tables Titles (PDF format)

Supplemental Table 9. 53 drugs – HTS screening list.

Table S9. List of the 53 drugs selected for the co-culture drug screening

Compounds	Targets
17AAG	HSP90
ABT-199	BCL2
ABT263	BCL2, BCL2L1, BCL2L2
AUY922	HSP90A, HSP90B
Azacytidine	DNA methyltransferase
AZD4573	CDK9
Belinostat	HDAC
Bortezomib	PSMC1
CC220	cereblon
CEP18870	PSMC1
Cerdulatinib	JAK1/JAK2/JAK3/TYK2/Syk
Ceritinib	ALK, InsR, IGF-1R, STK22D
CFT-13778	IKZF1
Chidamide	HDAC1, 2, 3, and 10
CHIR124	CHEK1
Crenolanib	PDGFRA, PDGFRB, FLT3 (D842V)
Crizotinib	c-Met and ALK
Cyclophosphamide	alkylating agent
Daunorubicin	inhibits DNA synthesis
Decitabine	DNA methyltransferase
Dexamethason	glucocorticoid
Duvelisib	PI3K δ/γ
Enzastaurin	PRKCB, PRKCA, PRKCG, PRKCE
Ganetespib	HSP90
GDC-0077	PI3K α
Idelalisib	p110 δ
KPT330	XPO1
MK1775	WEE1
MLN2238	PSMC1
NSC319726	TP53 (R175)
NVP742	IGF1R
Ouabain	ATP1B
Panobinostat	HDAC
Pomalidomide	CRBN, TNF- α
Pralatrexate	antifolate

PU-H71	HSP90
RGFP-966	HDAC3
RO4929097	γ secretase (NOTCH)
Romidepsin	HDAC1 and HDAC2
Ruxolitinib	JAK1, JAK2
SC144	IL6ST
Selumetinib	MAP2K1, MAPK3, MAPK1
Semagacestat	APP, NOTCH
SN38	TOP1
Stattic	STAT3
Tozasertib	Aurora A, Aurora C, Aurora B, FLT3, Bcr-Abl
TGR1202	PI3K δ
Tofacitinib	JAK3
TSA	ALL HDACS (Except HDAC8)
Valemetostat	EZH1/2
Vincristin	inhibitor of polymerization of microtubules
YKL-5-124	CDK7
YM155	BIRC5

Supplemental Table 10. In-vivo mice treatments.

Table S10. List of PDX and PDX-Dlines models included in pre-clinical trials and respective therapeutic schemes and readouts matched with patient's responses.							
Model id	Subtype	Naive/refractory	Treatment regimen	Treatment algorithm	Patient response	Readout	
IL2 (PDX and PDX-Dlines)	PTCL-NOS	Refractory	Combo Irinotecan plus Ruixotinib	Irinotecan: IP - 20mg/kg - QD ; Ruixotinib ab libitum in chow	/	TGI - OS	
			Combo Romidepsin/pralatrexate/duvelisib	Romidepsin: IP - 2/4mg/kg - QW; Pralatrexate: IP - 15mg/kg - BW; Duvelisib: PO - 10mg/kg - QD	Romidepsin: SD	TGI - OS	
			Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
			CAR-T cells anti CD5/nivolumab	CART: IV - 1x10 ⁶ % CART cells (single injection); nivolumab: IP - 0.5mg/kg - QD	/	TGI	
IL59	ALK+ ALCL	Refractory	CHOP	CHO: IV - C: 30mg/kg (single injection); H: 2,475 mg/kg (single injection); O: 0,375 mg/kg (single injection); P: IM - 0,02 mg/kg (QD)	CHOP: PD	TGI - OS	
			Critoxinib	PO - 50mg/kg - QD	Critoxinib: POD, death	TGI - OS	
			Combo Irinotecan plus brentuximab vedotin	Irinotecan: IP - 20mg/kg - QD; brentuximab: IV - 4mg/kg - BW	Brentuximab: POD	TGI - OS	
			Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
IL79	ALK+ ALCL	Refractory	Critoxinib	PO - 50mg/kg - QD	/	TGI - OS	
			Combo Irinotecan plus brentuximab vedotin	Irinotecan: IP - 20mg/kg - QD; brentuximab: IV - 4mg/kg - QD	Brentuximab: POD	TGI - OS	
			Ruixotinib	ab libitum in chow	/	TGI - OS	
			Cerdulatinib	PO - 30mg/kg - QD	/	TGI - OS	
IL89 (PDX and PDX-Dline)	BIA-ALCL	Naive	Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
			Pralatrexate	IP - 15mg/kg - BW; Duvelisib: PO - 10mg/kg - QD	/	TGI - OS	
			Azacitidine	IP - 25mg/m ² - QD	/	TGI - OS	
			ADCT402	IV - 15mg/kg - (single injection)	/	TGI - OS	
IL135A PDX-Dline	PTCL-NOS	Refractory	Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
			Combo Romidepsin/pralatrexate	Romidepsin: IP - 2mg/kg - QW; Pralatrexate: IP - 15mg/kg - BW	/	TGI - OS	
			Cerdulatinib	PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
			Cerdulatinib	PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
IL142A (PDX and PDX-Dline)	ALK- ALCL	Refractory	Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
			Ruixotinib	PO - 100mg/kg - QD	/	TGI	
			AZD5344	PO - 50mg/kg - QD	/	TGI	
			Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
TO-ALCL-BELL (PDX and PDX-Dline)	ALK- ALCL	Naive	CHOP	CHO: IV - C: 30mg/kg (single injection); H: 2,475 mg/kg (single injection); O: 0,375 mg/kg (single injection); P: IM - 0,02 mg/kg (QD)	CHOP: PR	TGI	
			CHOP - 2 rounds	CHO: IV - C: 30mg/kg (single injection); H: 2,475 mg/kg (single injection); O: 0,375 mg/kg (single injection); P: IM - 0,02 mg/kg (QD)	CHOP: PR	TGI	
			CEP-28122	PO - 30mg/kg - QD	/	TGI - OS	
			Combo Irinotecan plus brentuximab vedotin	Irinotecan: IP - 20mg/kg - QD; brentuximab: IV - 4mg/kg - BW	/	TGI - OS	
TO-ALCL-MARC	ALK- ALCL	Naive	Combo Cerdulatinib/AZD4573	Cerdulatinib: PO - 30mg/kg - QD; AZD4573: IP - 15mg/kg - BW	/	TGI - OS	
			CHOP	CHO: IV - C: 30mg/kg (single injection); H: 2,475 mg/kg (single injection); O: 0,375 mg/kg (single injection); P: IM - 0,02 mg/kg (QD)	CHOP: PD	TGI	
			Ruixotinib	PO - 100mg/kg - QD	/	TGI	
			Combo Irinotecan plus brentuximab vedotin	Irinotecan: IP - 20mg/kg - QD; brentuximab: IV - 4mg/kg - BW	/	TGI - OS	
MT05	ALK- ALCL	Naive	CHOP	CHO: IV - C: 30mg/kg (single injection); H: 2,475 mg/kg (single injection); O: 0,375 mg/kg (single injection); P: IM - 0,02 mg/kg (QD)	CHOP: PR	TGI	
			brentuximab vedotin	IV - 4mg/kg - BW	/	TGI	
			critoxinib	PO - 50mg/kg - QD	/	TGI	
			CAR-T cells anti CD30/nivolumab	CART: IV - 1x10 ⁶ % CART cells (single injection); nivolumab: IP - 0.5mg/kg - QD	/	TGI	
NY-ALCL-SG	ALK+ ALCL	Naive	baricitinib	PO - 10-50mg/kg - QD	/	TGI	
			critoxinib	PO - 50mg/kg - QD	/	TGI	
			CAR-T cells anti CD30/nivolumab	CART: IV - 1x10 ⁶ % CART cells (single injection); nivolumab: IP - 0.5mg/kg - QD	/	TGI	
			Critoxinib	PO - 50mg/kg - QD; Duvelisib: PO - 10mg/kg - QD	/	TGI	
NY-ALCL-SA	ALK- ALCL	Naive	baricitinib	PO - 10-50mg/kg - QD	/	TGI	
			Critoxinib	PO - 50mg/kg - QD; Duvelisib: PO - 10mg/kg - QD	/	TGI	
			CAR-T cells anti CD30/nivolumab	CART: IV - 1x10 ⁶ % CART cells (single injection); nivolumab: IP - 0.5mg/kg - QD	/	TGI	
			Critoxinib	PO - 50mg/kg - QD; Duvelisib: PO - 10mg/kg - QD	/	TGI	
IL6	AITL	Naive	Combo CHOP/azacitidine	CHO: IV - C: 30mg/kg (single injection); H: 2,475 mg/kg (single injection); O: 0,375 mg/kg (single injection); P: IM - 0,02 mg/kg (QD); Azacitidine: IP - 25mg/m ² - QD	/	TGI	

Supplemental Table 11. Antibodies for IHC list.

ANTIGEN	BRAND	CLONE	ANTIGEN RETRIVAL	DILUTION
CD3	Novocastra	PS1	Sodium Citrate pH6.0 - 30'	1:50
CD2	Novocastra	AB75	Sodium Citrate pH6.0 - 30'	1:50
CD4	Novocastra	4B12	EDTA pH8.0 - 30'	1:200
CD7	Novocastra	LP15	Sodium Citrate pH6.0 - 30'	1:80
CD5	Novocastra	4C7	Sodium Citrate pH6.0 - 30'	1:100
CD8	DAKO	C8114B	Sodium Citrate pH6.0 - 30'	1:50
CD20	DAKO	226	Sodium Citrate pH6.0 - 30'	1:200
PAX5	BD Transduc- tion Lab	24/PAX5	Sodium Citrate pH6.0 - 30'	1:50
CLA	DAKO	NA	Sodium Citrate pH6.0 - 30'	1:50
CD30	DAKO	BERH2	Sodium Citrate pH6.0 - 30'	1:40
ALK	ZYMED	Polyclonal	Sodium Citrate pH6.0 - 30'	1:2000
TIA 1	Immunotech	2G9A10F5	Sodium Citrate pH6.0 - 30'	1:50
GRANZYME B	Monosan	GrB7	Sodium Citrate pH6.0 - 30'	1:50
PERFORIN	Novocastra	5B10	EDTA pH8.0 - 30'	1:40
TCR α/β	Serotech	IP26	ENZYME - 5'	1:100
EBER	Leica Bond	EBER Probe	ENZYME - 5'	NA
CD25	Novocastra	4C9	Sodium Citrate pH6.0 - 30'	1:50
OCT2	Santa Cruz	Polyclonal	Sodium Citrate pH6.0 - 30'	1:100
BOB1	Santa Cruz	Polyclonal	Sodium Citrate pH6.0 - 30'	1:100
Ki-67	DAKO	MIB-1	EDTA pH8.0 - 30'	1:100
GAS1	Santa Cruz	C-17	Sodium Citrate pH6.0 - 30'	1:40
STAT3P	Cell Signaling	M9C6	Sodium Citrate pH6.0 - 30'	1:100
C/EBP β	Santa Cruz	C-19	Sodium Citrate pH6.0 - 30'	1:50
NFATC2	Santa Cruz	M20	Sodium Citrate pH6.0 - 30'	1:150
JAK2P	Santa Cruz	E132	Sodium Citrate pH6.0 - 30'	1:100
JAK3P	Santa Cruz	Polyclonal	Sodium Citrate pH6.0 - 30'	1:100
CD2	Leica	AB75	EDTA pH8.0 - 30'	1:150
CD30	Agilent	BERH2	EDTA pH8.0 - 30'	1:50
PDL1	Roche	SP263	EDTA pH8.0 - 30'	NA
EOMES	eBiosci- ence/Invitro- gen/Thermo	WD1928	EDTA pH8.0 - 30'	1:400
CD3	Epre- dia/Thermo	SP7	EDTA pH8.0 - 30'	1:100
CD68	Agilent	KP1	EDTA pH8.0 - 30'	1:4000
CD163	Leica	10D6	EDTA pH8.0 - 30'	NA

SMA	Agilent	1A4	EDTA pH8.0 - 30'	1:1600
CD20	Leica	L26	EDTA pH8.0 - 30'	1:200
DAPI	Cell Signaling Technology			1:1000

Supplemental Table 12. Primers for RTqPCR.

Supplemental Table S12 - Primers for RTqPCR	
RTqPCR SLC9A8-MTMR fusion FW: CTTGCCAGAGAGTGTTGCTG	
RTqPCR SLC9A8-MTMR fusion Rv: CTCGAAGGTCTTTGCAGTGG	
RTqPCR WRN-IL17RA fusion FW: GACAGCGGACTTCAACCTTC	
RTqPCR WRN-IL17RA fusion Rv: GGTCAGGTTTCGAGGGTGAA	
RTqPCR PSIP-PHC fusion FW: ATCAAGGGAAGAAAGGGCCA	
RTqPCR PSIP-PHC fusion Rv: TTTGGGGTTTCACAATGGCC	
RTqPCR SULT1A2-SULT1A1 fusion FW: TCATCAGCACCTACCCCAAG	
RTqPCR SULT1A2-SULT1A1 fusion Rv: GTGCCGGACTTGGGGTAG	
RTqPCR KANSL1-LRRC37A3 fusion FW: AGAAAGGGATAGATGGAATGAGT	
RTqPCR KANSL1-LRRC37A3 fusion Rv: ACAGTTGTCAGAGGATTGTGA	
RTqPCR EEF1DP3-FRY fusion FW: GGATCCCATTCACCTGAGGC	
RTqPCR EEF1DP3-FRY fusion Rv: AGAAGCAGGTGGAACCGGAG	
RTqPCR RP11-123010.4-GRIP1 fusion FW: CTGGAAGAAGAATATCCCTA	
RTqPCR RP11-123010.4-GRIP1 fusion Rv: TCCATCAGGCGGCTTTGTCT	
RTqPCR NUSAP1-GLYATL3 fusion FW: TGAGTCATCCAAACCTGGAA	
RTqPCR NUSAP1-GLYATL3 fusion Rv: TCCTTTTGAAAGGGGTTCCC	
RTqPCR PFKFB3-RP11-563J2.2 fusion FW: CCCTGCCCAGCTGCCTGCCC	
RTqPCR PFKFB3-RP11-563J2.2 fusion Rv: CGGAGCAGGGAGGAGAGTCA	

Supplemental Figure 1 (related to Figure 1).

(A-H) Time of engraftment and fitness along passages (T1, T3 and T5) of representative PDX models belonging to different PTCL/NK lymphomas subcategories.


(I) Representative ALCL-PDX dissemination in mouse (TO-ALCL-Belli).

(J) Pie chart showing the outcome of the PTCL samples implanted but not engrafted.

(K) TCR gamma and IGK rearrangement analysis using capillary electrophoresis of the EBV+ AITL IL129A PDX (T1 - and T3, after loncastuximab tesirine [ADCT-402] treatment).

(L) Vertical phylogenetic propagation of IL129A PDX after ADCT-402 treatment (T3, TR1235 m3952) along seven rounds of propagation (T7).





Figure S1














Supplemental Figure 2 (related to Figure 2).

- (A) Light microscopy of primary (A&B: upper panels) and matched PDX (bottom panels) (x20). B'' Insert representing anti-ALK immunohistochemical stain (IHC).
- (B) H&E of primary and matched T3-PDX (10x). Representative immunohistochemical stains for membrane/cytoplasmic antigens (CD30, ALK, ×10).
- (C) TCR rearrangement analysis in representative primary and PDX samples along different round of propagation.
- (D) Representative GeneScan analyses showing the TCR rearrangement in IL86 and NY-NK-VP primary and PDX samples.
- (E) Frequency of clonal TCR in PDX samples. Inserts correspond to sample with no explicit TCR clones (upper panel) and with detectable clones (lower panel).
- (F) Percentage of PDX with evident and non-explicit TCR clones
- (G) Pie chart showing the TCR clonal representation of primary and PDX samples.
- (H) Pie chart showing the TCR representation of specific TCR family segments.
- (I) Z-scored viral reads.
- (J) Expression of HTLV-1 and HHV6 transcripts in PDX samples.
- (K) Heatmap correlating EBV genes expression and TCR rearrangements predicted to recognize EBV peptides in 28 primary AITL samples.
- (L) Schematic representation of EBV peptide and predicted TCR usage and their selected antigen recognition.
- (M) BCR clonal representation of primary and PDX (low reads <50) samples.
- (N) BCR reconstruction of minor intra-lymphoma B-cells in IL36 primary and PDX matched samples.

A


ALCL-1	ALCL-2
Primary	
	
ALCL-PDX	
	
	



Supplemental Figure 3 (related to Figure 3).

- (A) PCA of PDX and primary lymphoma samples based on the bulk RNA expression levels.
- (B) ESTIMATE score indicating the average amount of tumor reads in primary PTCL and PDX models.
- (C) Bar plots indicating the percentages of reads mapping to human (green) or mouse (light blue) genomes in primary PTCL and PDX models samples. Ambiguous reads (red) are reported.
- (D) Dot plot correlating the VAFs of the variants in primary vs matched PDX (TO-ALCL-DN03).
- (E) Gene ontology analysis indicating the biological processes enriched in PDX versus primary samples.
- (F) Unsupervised hierarchical clustering of PDX and primary lymphoma samples based on bulk RNA expression levels with exclusion of non-lymphoma related reads of primary samples.
- (G) Heatmap and unsupervised hierarchical clustering based on differentially expressed genes in PDX and primary samples (PTCL-NOS and AITL).
- (H) Heatmap reporting the expression of canonical genes distinguishing GATA3 vs TBX21 PTCL.
- (I) Biological processes enriched in PTCL-NOS vs AITL primary samples and PDXs.
- (J) Dot plot graphs showing the relative contribution of genes defining different PTCL entities.
- (K) PCA of 4 PDX models and their corresponding PDX-Dlines based on the bulk RNA expression levels.
- (L) Expression of selected genes in each cluster from the scRNAseq analysis of IL138A primary and PDX.
- (M) Schematic representation of the ACADVL and VAV1 genes and their domains.
- (N) Schematic representation of the NF-1 and MAZ genes, and gene-view plot depicting the breakpoints for the NF1-MAZ fusion (TO-ALCL-BELLI PDX).
- (O) qRT-PCR identifies the NF1-MAZ fusion transcripts in primary, relapsed and serial TO-ALCL-Belli PDXs.
- (P) FISH test analysis demonstrating the loss of the NF1 locus (TO-ALCL-Belli PDX).
- (Q) Western blot analysis of TO-ALCL-BELLI PDX-Dline treated with AZD-6244 (4, 8 and 24 hr).
- (R) Selumetinib treatment of representative PDX-Dlines.
- (S) Schematics depicting the IL2/IL19 patient clinical history. Timepoints of collection of samples implanted are reported.
- (T) Venn diagram showing the individual and shared fusion transcripts (IL2 and IL19 primaries and PDXs).
- (U) (Left panels) RTqPCR validating the expression of three selected fusion transcripts in IL2 and IL19 PDX samples. NY-ALCL-SG-T6 sample represents a negative control (ALK⁺ ALCL). (Right panels) Sanger sequencing for selected cases.
- (V) RTqPCR validating the expression of selected fusion transcripts in IL2 and IL19 primary, PDX, and PDX-Dline (IL2 only) samples. Data are representative of three replicates. Error bars represent standard deviations.


Figure S3



Supplemental Figure 4 (related to Figure 4).

- (A) Comparisons of the percentage of mapped human reads in PDX sequencings between different PTCL tumor types.
- (B) Landscape of inferred copy number aberrations derived from primary tumors and matched PDX by CopywriteR algorithm.
- (C) Distribution of SNVs and indels commonly shared by primary tumor-specific or PDX-specific for each model.
- (D) Mutation signature analysis of primary tumors and matched PDX. Nucleotide changes were highly enriched for C>T transitions.
- (E) Comparison of variant allele frequency (VAF) of all somatic variants shared between primaries and matched PDXs. *P*-value was derived from paired t-test.
- (F) Ternary plot of mutation frequency in driver genes, comparing primary tumor-specific (left, green), early PDX (top, red), and late PDX (right, blue). Each node represents a cluster of mutated genes. The size of each node represents their overall frequency in our cohort.
- (G) Comparisons of mutation burden (total number of SNVs + indels) among different PTCL tumor types.
- (H) Deep targeted DNA sequencing of primary and PDX models IL2, IL19, NY-AI-AM and IL49.
- (I-K) IL54 (I), TO-ALCL-MARC (J) and TO-ALCL-MARI (K). Fish plots (right panel) show the dynamic changes in CCF of each mutation clusters (marked with different colors) along serial passages as depicted in the inferred phylogenetic trees (left panel).
- (L) Line-dot plots by PTCL subtypes, depicting Nei's genetic scores of individual models along propagation from primary to PDX spanning multiple passages.
- (M) Dotplot depicting Nei's genetic score of the entire PTCL PDX cohort compared to a reference glioblastoma cohort ⁸⁰


Figure S4



Supplemental Figure 5 (related to Figure 5).

- (A) TME cellular composition. Non-Normalized data: Percentage of mouse reads are depicted in blue. Columns represent percentage of total TME cells.
- (B) Percentage of stromal TME cells. Non-normalized data. Percentage of mouse reads are depicted in blue. Columns represent the percentage of stromal TME cells.
- (C) Global TME. Percentage of human and mouse TME cells combined.
- (D) TME cellular composition. Columns represent the percentage of total TME cells. Data normalized on mouse reads.
- (E) Percentage of stromal TME cells. Normalized data on mouse reads. Columns represent the percentage of stromal TME cells.
- (F) T-cell immunophenotype. Association between gene expression on the y-axis with PDX diagnosis on the x-axis where different colors represent different PTCL entities. The expression levels are represented with red intensities with light blue indicating no expression.
- (G) Tumor “purity” comparison between TH2-like category vs. other. **:p-value by Anova test <0.01. Error bars represent standard deviations.
- (H) Multiplex analysis of 4 PDXs representative of the different PTCL TME categories (IL2: Inflammatory, IL56: B-cell rich, IL98: Mesenchymal, IL17: Depleted).
- (I) Sankey plot showing changes in T differentiation throughout primary and three passages of PDX.
- (J) Schematic representation of host and lymphoma cells in primary and matched PDX. Mouse and human PDX cells are depicted in different grey scale colors.
- (K) TCR signaling. Association between gene expression on the y-axis with PDX diagnosis on the x-axis where different colors represent different PTCL entities. The expression levels are represented with red intensities with light blue indicating no expression.
- (L) TCR signaling in the 4 TME categories in primary and PDX PTCL samples.
- (M) Percentage and distribution of lymphoid and stromal cells in primary and serial passages of representative PDX models.
- (N) CAF expression profiling and stratification. Association between gene expression on the y-axis with PDX diagnosis on the x-axis where different colors represent different PTCL entities. The expression levels are represented with red intensities with light blue indicating no expression.
- (O) Barplot showing the differential percentage of apoptotic cells between IL2, MT05, IL69, and NY-NK-VP PDX samples cocultured with E4-EC vs cultured alone. Data are representative of three replicates. Error bars represent standard deviations.
- (P) Barplot showing the differential percentage of apoptotic cells in MT05 samples cultured alone or cocultured with E4-EC or with different stromal cells from different models. Data are representative of three replicates. Error bars represent standard deviations.
- (Q) Upper panel. Dotplot showing normalized viability of PDX-derived cells from ALK+ ALCL TO-ALCL-DN03 model cultured on fibroblasts, without or with crizotinib. The fibroblasts were harvested from the same tumor masses using enzymatic digestion (see Methods) and cultured ex-vivo; tumor cells were layered on top of them. The effect of each compound is expressed as a ratio of the viability under that drug/viability of the controls. Each compound was administered at 1uM final concentration; crizotinib, when present, was administered at 150nM or 250nM concentration. For some drugs (e.g. navitoclax/ABT263, belinostat, ponatinib, selumetinib) we observed a synergistic effect when adding crizotinib: those combinations produced inferior viability rates compared to the compounds alone. Bottom panel: raw viability of TO-ALCL-DN03 cells cultured without fibroblasts upon exposure to the same compounds. Data are representative of three replicates. Error bars represent standard deviations.
- (R) Barplots showing the sensitivity to brentuximab vedotin of ALK+ ALCL and ALK- ALCL cell lines cultured alone (black bars) or co-cultured with MS5 stromal cells (grey bars). Data are representative of three replicates. Error bars represent standard deviations.

Figure S5



Supplemental Figure 6 (related to Figure 6).

(A) Schematic representation of the high-throughput screening (HTS) strategy used to screen 433 drugs in PTCL PDX derived cells.

(B) Dot plot showing the HTS reproducibility across 2 replicates for a representative ALCL PDX model (IL79, T3. $P=0.61$, $p\text{-value}<0.001$).

(C) Bar plot showing the number of active compounds in the PDX models tested. Error bars represent standard deviations.

(D) Dot plot showing the correlation between the expression levels of HDAC4, HDAC11, and JAK2 across different PTCL subtypes with cell viabilities after belinostat or ruxolitinib treatment (72 hrs, 1 μ M).

(E) Heatmap and unsupervised clustering depicting the expression of a set of genes selected based on a significant correlation between their expression and the viability of the samples treated with belinostat (1 μ M, 72hrs).


(F) Dot plot depicting actual viability vs predicted by regression model based on the drug screening data (see Methods).

(G) Heatmap showing the dose responses (from 15nM to 10000nM) of five PTCL PDX models challenged with increasing concentrations of 16 compounds Pano= panobinostat; Cp24= compound 24; Cp50: compound 50¹⁷⁹; valemet= valemetostat; poma= pomalidomide; everoli: everolimus; tofa: tofacitinib.

(H) Comparison of the genomic signals in the training dataset (TCGA cell lines) and external testing datasets (PDX tumors). Gene expression patterns shared between preclinical 164 TCGA cell lines and 207 PDX tumors in a consensus space are reported.

(I) Percentage of viable IL2 PDX-DLines cultured in presence of the indicated concentrations of duvelisib and venetoclax for 72hrs. Data are representative of three replicates. Error bars represent standard deviations.

(J) Heatmap indicating the predicted synergy score assessed by DeepPTCL algorithm for the indicated drug combinations across distinct TME categories of PTCL samples.



Supplemental Figure 7 (related to Figure 7).

(A-C) Line-dot plot showing antitumoral effect of CHOP in TO-ALCL-MARC (A), MT05 (B), and TO-ALCL-DN03 (C) PDX tumors ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$).

(D) Schematic representation of the multi-CHOP treatment strategy tested in TO-ALCL-DN03 PDX model.

(E) Line-dot plot showing antitumoral effect of CHOP in TO-ALCL-DN03 PDX model ($n=8-10$ mice/group). Each line is representative of one mouse.

(F) Line-dot plot showing antitumoral effect of CHOP in TO-ALCL-DN03 PDX model following the second cycle of treatment ($n=8-10$ mice/group). Each line is representative of one mouse.

(G) (Left) Line-dot plot showing antitumoral effect of crizotinib in IL79 PDX model ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). (Right) Kaplan-Meier plot representative of the overall survival of mice under the two conditions, log-rank p -value=0.008.

(H) Line-dot plot showing antitumoral effect of CEP28122 in TO-ALCL-DN03 PDX model ($n=2-20$ mice/group). Treatment started when the tumors reached the volume of 0.5 – 1 – 1.5 – 2 mm³ (light blue, blue, purple, and magenta lines, respectively). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$).

(I) (Left) Line-dot plot showing antitumoral effect of baricitinib 200mg/kg QD or BID NY-ALCL-SA PDX model ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). (Right) Kaplan-Meier plot representative of the overall survival of mice under the different conditions, log-rank p -value<0.0001.

(J) (Left) Line-dot plot showing antitumoral effect of ruxolitinib, irinotecan or combination in IL2 PDX model ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). (Right) Kaplan-Meier plot representative of the overall survival of mice under the different conditions, log-rank p -value<0.0001.

(K) (Left) Line-dot plot showing antitumoral effect pralatrexate (prala), romidepsin (romi) or their combination in IL142A PDX model ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). (Right) Kaplan-Meier plot representative of the overall survival of mice under the different conditions, log-rank p -value=0.0096.

(L) (Left) Line-dot plot showing antitumoral effect pralatrexate (prala), duvelisib (duv) or their combination in IL107 PDX model ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). (Right) Kaplan-Meier plot representative of the overall survival of mice under the different conditions, log-rank p -value=0.036.


(M) Representative IHC stains for the CD45 in IL129A mice treated with azacitidine or vehicle. The upper panels show the CD2+ cell infiltration in several mice organs (lungs, kidney, spleen, liver, heart). The medium and bottom panels specifically magnify the lung infiltrations (10x and 40x, respectively).

(N) Barplot showing percentages of human CD45 (hCD45+) cell infiltration in the kidney of mice treated with azacitidine or vehicle.

(O) Representative pictures of lymphoma kidney infiltration in IL129A mice treated with vehicle (control - #1-2-3) or azacitidine (#4).

(P) (Left) Line-dot plot showing antitumoral effect of azacitidine in IL129A PDX model ($n=8-10$ mice/group). P-values were estimated with t-test adjusted for multiple comparisons (* $p<0.05$; ** $p<0.001$; *** $p<0.0001$). (Right) Kaplan-Meier plot representative of the overall survival of IL129A mice treated with vehicle or azacitidine, log-rank p -value=0.02.

Figure S7




Supplemental Figure 8 (related to Figure 8).


- (A) Line-dot plots showing tumor sizes (mm³) of mice belonging to 9 different PDX models (n=36 mice total) treated with vehicle, cerdulatinib, AZD-4573 or combination. Each tumor is reported individually.
- (B) Heatmap showing measures of effect of cerdulatinib, AZD-4573 or combination across the 9 PDX models tested.
- (C) In vitro efficacy of CD5KO-CART cells on IL2 and TO-ALCL-DN03 PDX-Dlines. Different Effector-to-Target (ET) ratio and timepoints are reported. Data are representative of three replicates.
- (D) In vitro efficacy of CD30-CART cells on IL2 and TO-ALCL-DN03 PDX-Dlines. Different Effector-to-Target (ET) ratio are reported.
- (E) Representative H&E staining of NY-ALCL-SG PDX tumor (upper panels), lung, and spleen (lower left and right panels, respectively) stained with the indicated antibodies (magnification $\times 15$).
- (F) Multiparametric analysis of NY-ALCL-SG spleen after CART30 injection stained with the indicated antibodies.

Figure S8


A




B




C




D




E




F





[Click here to access/download](#)


Supplemental Videos and Spreadsheets
Table S1_PDX & Clinical data TCL patients.xlsx






[Click here to access/download](#)

Supplemental Videos and Spreadsheets
Table S2_Sequencing metadata.xlsx







[Click here to access/download](#)

Supplemental Videos and Spreadsheets


Table S3_Fusions detected in TCL PDX cohort.xlsx






[Click here to access/download](#)

Supplemental Videos and Spreadsheets
Table S4_CNV results.xlsx







[Click here to access/download](#)

Supplemental Videos and Spreadsheets


Table S5_Somatic mutations detected in TCL PDX
cohort.xlsx






[Click here to access/download](#)

Supplemental Videos and Spreadsheets
Table S6_Clonal evolution analysis.xlsx







[Click here to access/download](#)

Supplemental Videos and Spreadsheets


Table S7_Datasets for microenvironment signature.xlsx





[Click here to access/download](#)

Supplemental Videos and Spreadsheets
Table S8_433-HTS screening.xlsx



CELL PRESS DECLARATION OF INTERESTS POLICY

Transparency is essential for a reader's trust in the scientific process and for the credibility of published articles. At Cell Press, we feel that disclosure of competing interests is a critical aspect of transparency. Therefore, we require a "declaration of interests" section in which all authors disclose any financial or other interests related to the submitted work that (1) could affect or have the perception of affecting the author's objectivity or (2) could influence or have the perception of influencing the content of the article.

What types of articles does this apply to?

We require that you disclose competing interests for all submitted content by completing and submitting the form below. We also require that you include a "declaration of interests" section in the text of all articles even if there are no interests to declare.

What should I disclose?

We require that you and all authors disclose any personal financial interests (e.g., stocks or shares in companies with interests related to the submitted work or consulting fees from companies that could have interests related to the work), professional affiliations, advisory positions, board memberships (including membership on a journal's advisory board when publishing in that journal), or patent applications and/or registrations that are related to the subject matter of the contribution. As a guideline, you need to declare an interest for (1) any affiliation associated with a payment or financial benefit exceeding \$10,000 p.a. or 5% ownership of a company or (2) research funding by a company with related interests. You do not need to disclose diversified mutual funds, 401ks, or investment trusts.

Authors should also disclose relevant financial interests of immediate family members. Cell Press uses the Public Health Service definition of "immediate family member," which includes spouse and dependent children.

Where do I declare competing interests?

Competing interests should be disclosed on this form as well as in a "declaration of interests" section in the manuscript. This section should include financial or other competing interests as well as affiliations that are not included in the author list. Examples of "declaration of interests" language include:

"AUTHOR is an employee and shareholder of COMPANY."

"AUTHOR is a founder of COMPANY and a member of its scientific advisory board."

NOTE: Primary affiliations should be included with the author list and do not need to be included in the "declaration of interests" section. Funding sources should be included in the "acknowledgments" section and also do not need to be included in the "declaration of interests" section. (A small number of front-matter article types do not include an "acknowledgments" section. For these articles, reporting of funding sources is not required.)

What if there are no competing interests to declare?

If you have no competing interests to declare, please note that in the "declaration of interests" section with the following wording:

"The authors declare no competing interests."

CELL PRESS DECLARATION OF INTERESTS FORM

If submitting materials via Editorial Manager, please complete this form and upload with your initial submission. Otherwise, please email as an attachment to the editor handling your manuscript.

Please complete each section of the form and insert any necessary “declaration of interests” statement in the text box at the end of the form. A matching statement should be included in a “declaration of interests” section in the manuscript.

Institutional affiliations

We require that you list the current institutional affiliations of all authors, including academic, corporate, and industrial, on the title page of the manuscript. ***Please select one of the following:***

- ☒ All affiliations are listed on the title page of the manuscript.
- ☐ I or other authors have additional affiliations that we have noted in the “declaration of interests” section of the manuscript and on this form below.

Funding sources

We require that you disclose all funding sources for the research described in this work. ***Please confirm the following:***

- ☒ All funding sources for this study are listed in the “acknowledgments” section of the manuscript.*

*A small number of front-matter article types do not include an “acknowledgments” section. For these, reporting funding sources is not required.

Competing financial interests

We require that authors disclose any financial interests and any such interests of immediate family members, including financial holdings, professional affiliations, advisory positions, board memberships, receipt of consulting fees, etc., that:

- (1) could affect or have the perception of affecting the author’s objectivity, *or*
- (2) could influence or have the perception of influencing the content of the article.

Please select one of the following:

- ☐ We, the authors and our immediate family members, have no financial interests to declare.
- ☒ We, the authors, have noted any financial interests in the “declaration of interests” section of the manuscript and on this form below, and we have noted interests of our immediate family members.

Advisory/management and consulting positions

We require that authors disclose any position, be it a member of a board or advisory committee or a paid consultant, that they have been involved with that is related to this study. We also require that members of our journal advisory boards disclose their position when publishing in that journal. **Please select one of the following:**

- ☐ We, the authors and our immediate family members, have no positions to declare and are not members of the journal's advisory board.
- ☒ The authors and/or their immediate family members have management/advisory or consulting relationships noted in the "declaration of interests" section of the manuscript and on this form below.

Patents

We require that you disclose any patent applications and/or registrations related to this work by any of the authors or their institutions. **Please select one of the following:**

- ☒ We, the authors and our immediate family members, have no related patent applications or registrations to declare.
- ☐ We, the authors, have a patent application and/or registration related to this work, which is noted in the "declaration of interests" section of the manuscript and on this form below, and we have noted the patents of immediate family members.

Please insert any "declaration of interests" statements in this space. This exact text should also be included in the "declaration of interests" section of the manuscript. If no authors have a competing interest, please insert the text, "The authors declare no competing interests."

D.M.W. is an employee of Merck and has an equity interest in Ajax, Bantam and Travera.

F.B.: institutional research funds from ADC Therapeutics, Bayer AG, Cellestia, Helsinn, HTG Molecular Diagnostics, ImmunoGen, iOnctura, Menarini Ricerche, NEOMED Therapeutics 1, Nordic Nano-vector ASA, Sepxis AG; advisory board fees from Novartis; consultancy fee from Helsinn, Menarini; expert statements provided to HTG Molecular Diagnostics; travel grants from Amgen, Astra Zeneca, iOnctura.

- ☒ On behalf of all authors, I declare that I have disclosed all competing interests related to this work. If any exist, they have been included in the "declaration of interests" section of the manuscript.